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ABSTRACT 
High-density lipoproteins and their major protein, apolipoprotein A-I (apoA-
I), remove excess cellular cholesterol and protect against atherosclerosis. 
However, in acquired amyloidosis, non-variant full-length apoA-I deposits as 
fibrils in arteries contributing to atherosclerosis. In hereditary amyloidosis 
(AApoAI), a potentially fatal disease, N-terminal fragments of variant apoA-I 
deposit in vital organs and damage them. There is no cure for apoA-I amyloidosis 
and its structural basis is unknown.  
Previously, AApoAI mutations were mapped on the crystal structure of the 
human C-terminally truncated (185-243)apoA-I. The results suggested that the 
mutation-induced destabilization of the lipid-free protein initiates -aggregation. 
Our biophysical studies showed that amyloidogenic mutations G26R, W50R, 
F71Y and L170P did not necessarily destabilize the native structure, prompting 
us to search for additional triggers of apoA-I misfolding. We mapped residue 
segments predicted to promote -aggregation (termed amyloid hot spots) on the 
atomic structure of (185-243)apoA-I. The results suggested that perturbed 
  ix 
packing of these hot spots, particularly residues 14-22, triggers amyloidosis. This 
enabled us to propose the first molecular mechanism of apoA-I misfolding. 
To explore a potential mechanism, we combined structural, stability, 
dynamics and functional studies of several amyloidogenic mutants and a non-
amyloidogenic control, L159R. All mutants reduced structural protection of the 
segment 14-22, supporting our hypothesis that increased dynamics of this 
segment triggers AApoAI. The non-amyloidogenic mutant showed helical 
unfolding near the mutation site indicating susceptibility to proteolysis. We 
propose that the major factors that make apoA-I amyloidogenic are reduced 
protection of the major amyloidogenic segments combined with the structural 
integrity of the four-helix bundle to facilitate protein aggregation. Together, our 
results suggest that the fate of apoA-I in vivo depends on the balance between 
its misfolding, proteolysis, and protective protein-lipid interactions. 
Our structural and bioinformatics analysis of other members of the 
apolipoprotein family (A-II, A-IV, A-V, B, C-I, C-II, C-III, E, SAA) showed that 
apolipoproteins’ propensity to form amyloid is rooted in the proteins’ 
hydrophobicity, which is key to the lipid binding ability. The overlap of functional 
and pathologic interfaces suggests competition between normal protein function 
and misfolding. Therefore, increasing apolipoprotein retention on the lipid surface 
provides a potential therapeutic strategy against amyloidosis. 
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Chapter 1 Introduction 
 
1.1 Lipoproteins and Apolipoproteins in Lipid Transport and Metabolism 
1.1.1 Major Lipoprotein Classes and their Biochemical Composition and Function 
Lipoproteins are water-soluble heterogeneous nanoparticles that transport 
lipids in plasma, lymph and cerebrospinal fluid. Each lipoprotein is comprised of 
specific proteins, called apolipoproteins (apos), and several hundreds to 
thousands of lipid molecules. Most plasma lipoproteins are secreted by the liver 
or the intestine, while lipoproteins in the central nervous system are secreted 
largely by the glial cells [Ladu et al., 2000; Huang, 2010]. Mature lipoproteins 
contain an apolar lipid core containing mainly cholesterol esters and 
triacylglycerols (TG) and an amphipathic surface containing a monolayer of polar 
lipids, mainly phospholipids and unesterified cholesterol, and apolipoproteins 
(Figure 1.1). Apolipoproteins act as flexible scaffolds on the lipoprotein surface 
and are essential for the lipoprotein structure and function. Apolipoproteins 
confer curvature to the phospholipid monolayer on the particle surface and 
thereby help encapsulate apolar lipids in its core, facilitating the transport of 
water-insoluble lipids in the aqueous environment. In addition, apolipoproteins 
orchestrate lipoprotein metabolism by interacting with lipophilic enzymes, lipid 
transfer proteins, lipid transporters, and lipoprotein receptors [Mahley et al., 
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1984; Goldstein & Brown, 1992; Phillips, 2014; Rached et al., 2014]. Lipid 
metabolism is an extremely complex process whose deficiencies may manifest 
themselves as serious diseases, such as cardiovascular disease that is the 
leading cause of mortality worldwide [Castelli et al., 1992; Toth et al., 2013]. In 
addition to the central role of lipoproteins in the transport and metabolism of 
plasma lipids, lipoproteins and lipoprotein receptors also play major roles in 
normal neuronal functions and are implicated in major neurodegenerative 
diseases such as Alzheimer’s disease [Lane-Donovan et al., 2014]. 
Figure 1.1 shows plasma lipoproteins that are comprised of diverse 
classes differing in the particle size, density, biochemical composition, and 
function. Proteins are denser than lipids and are located on the particle surface. 
Since the surface-to-volume ratio decreases with the increasing size, the particle 
density also decreases accordingly, from high-density lipoproteins (HDL, 
diameter 8-12 nm, density 1.063-1.21 g/mL) to low-density lipoproteins (LDL, 
diameter 20-24 nm, density 1.019-1.063 g/mL), intermediate-density lipoproteins 
(IDL, diameter 25-35 nm, density 1.006-1.019 g/mL), very low-density 
lipoproteins (VLDL, diameter 40-100 nm, density 0.95-1.006 g/mL), and 





Figure 1.1 Cartoon representation of lipoproteins and their main constituents. 
Major classes of plasma lipoproteins, including very-low, low- and high-density 
lipoproteins (VLDL, LDL and HDL), are shown in cross-section. Particle 
diameters are indicated. Intermediate-density lipoproteins (IDL, d=25-35 nm) and 
chylomicrons (d>100 nm) are not shown. Mature lipoproteins contain a core of 
apolar lipids (mainly cholesteryl esters and triacylglycerols, in yellow) surrounded 
by an amphipathic surface comprised of polar lipids (mainly phospholipids and 
cholesterol, in gray) and apolipoproteins. Exchangeable (water-soluble) 
apolipoproteins are in red, non-exchangeable (water-insoluble) apoB is in blue. 
From [Das & Gursky, 2015]. 
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Each lipoprotein class has distinct functions [Mahley et al., 1984]. In humans, 
HDL remove excess cholesterol from peripheral tissues and deliver it to the liver 
for excretion via bile. Generally, plasma levels of HDL cholesterol (called “good 
cholesterol”) and the major HDL protein, apoA-I, correlate inversely with the risk 
of developing atherosclerosis [Gordon et al., 1989; Toth et al., 2013]. LDL are the 
major carriers of cholesterol, in the form of cholesteryl esters, delivering it to 
peripheral tissues. Plasma levels of LDL cholesterol (or “bad cholesterol”) and 
the major LDL protein, apoB, are regarded as the strongest causative risk factors 
in cardiovascular disease [Castelli et al., 1992]. IDL are transient metabolic 
products of VLDL. VLDL are metabolic precursors of LDL and the major plasma 
carriers of TG [Dallinga-Thie et al., 2010; Havel, 2010]. VLDL levels are 
independent risk factors for metabolic syndrome and cardiovascular disease 
[Krauss, 1998]. Chylomicrons are generated in the gut to transport dietary lipids. 
These large particles contain one copy of a truncated form of apoB (N-terminal 
48%, termed B48) and various exchangeable proteins [Pan & Hussain, 2012]. 
Each class of plasma lipoprotein has a distinct protein composition (Figure 
1.2). Each HDL particle contains several copies of exchangeable (water-soluble) 
apolipoproteins, mainly apoA-I (28 kDa) and apoA-II (9 kDa, which forms a 
disulfide linked homodimer in humans) that constitute approximately 70% and 
20% of the total HDL protein mass, respectively. HDL can also contain several 
minor proteins including apoE, apoCs, etc. Each LDL particle contains one copy 
of the non-exchangeable (water-insoluble) apoB (550 kDa) that constitutes ~95% 
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of the total LDL protein mass. Each VLDL particle contains one copy of apoB and 
multiple copies of exchangeable proteins, mainly apoE (33 kDa) and apoCs (6-9 
kDa). Apart from apoB48, chylomicrons also contain exchangeable proteins such 
as apoE, apoCs, etc. Other lipophilic proteins, including apolipoproteins (apoA-
IV, apoA-V, apoD, apoF, apoH, apoJ, etc.), are also found as minor components 
on lipoproteins ([Hoofnagle & Heinecke, 2009, Gordon et al., 2010] and 
references therein). Plasma lipoprotein composition can significantly change 
during inflammation when a fraction of apoA-I is displaced from plasma HDL by 
an acute-phase protein, serum amyloid A (SAA) [van der Westhuyzen et al., 
2007; Eklund et al., 2012]. In contrast to plasma, lipid transport in the central 
nervous system is mediated solely by HDL-like particles that contain apoE as 
their major protein [Huang, 2010; Hauser et al., 2011].  
1.1.2 Exchangeable Apolipoproteins 
Exchangeable apolipoproteins form a multigene family that has evolved 
from a common ancestral gene via the duplication and deletion of 11-mer codon 
repeats [Li et al., 1988]. These proteins have similar gene structure containing 
11-mer tandem repeats encoding for putative amphipathic -helices that form the 
major structural and functional motif in this protein family [Segrest et al., 1990, 
1992, 1994]. Similar 11-mer -helical repeat motifs are also found in other lipid 
surface-binding proteins, including parts of the non-exchangeable apoB, as well 
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as in soluble apolipoprotein-related proteins such as SAA and -synuclein [Colón 
et al., 2015; Uversky, 2015]. 
Although ~90% of all apolipoproteins circulate on lipoproteins, a small 
fraction of the exchangeable proteins can transiently dissociate from the lipid 
surface as illustrated in Figure 1.2. This occurs during normal metabolic 
remodeling of lipoproteins, which alters their surface-to-volume ratio, as well as 
under pathologic conditions such as inflammation. For example, HDL maturation 
from nascent discoidal to mature spherical particles via the lecithin:cholesterol 
acyltransferase (LCAT) reaction [Fielding et al., 1972] or HDL enrichment in TG 
via the action of cholesterol ester transfer protein (CETP) [Melchoir et al., 1994; 
Lamarche et al., 1999] can lead to lipoprotein fusion, which generates excess 
surface material that can dissociate in the form of apolipoproteins that carry little 
lipid. Such proteins are termed “lipid-poor” or “free” to distinguish them from the 
lipoprotein-bound species, even though they may carry several lipid molecules. 
Free apolipoproteins can also be generated de novo. They form a metabolically 
active structurally labile species that can be rapidly recruited to the lipid surface 
for HDL biogenesis [Rye & Barter 2004; Mulya et al., 2008; Jayaraman et al., 
2012] or get degraded or misfolded [Hatters & Howlett, 2002] (Figure 1.2). The 
misfolded apolipoproteins can potentially deposit as amyloid fibers, leading to 





Figure 1.2 Cartoon illustrating apolipoprotein dissociation from a lipoprotein 
particle such as HDL. 
Exchangeable apolipoproteins can reversibly dissociate from the lipoprotein 
surface. The dissociated free apolipoprotein is structurally labile and can: i) 
rapidly bind to lipoprotein surface, i.e. associate with another lipoprotein or get 
recruited to plasma membrane for HDL biogenesis, ii) get cleared, or ii) misfold 
and form amyloid. Arrows indicate directions of reaction but not their rate 




1.2 Apolipoproteins are Prominent in Amyloid Diseases 
Exchangeable apolipoproteins are prominent players in amyloidoses 
[Hatters & Howlett, 2002]. In particular apoE, which is an important 
multifunctional apolipoprotein in the central nervous system and in plasma [Getz 
& Reardon, 2009], is found in most systemic and cerebral amyloid deposits in 
humans and is often co-deposited with other apolipoproteins [Wisniewski & 
Frangione, 1992]. Moreover, human apoE4 isoform is a major risk factor in 
Alzheimer’s and other neurodegenerative diseases [Mahley et al., 2009; Huang, 
2010; Hauser et al., 2011]. Another important plasma apolipoprotein, apoA-I, 
commonly deposits as fibrils in atherosclerotic plaques in a process that probably 
contributes to atherosclerosis [Mucchiano et al., 2001; Röcken et al., 2006; 
Howlett & Moore 2006; Ramella et al., 2011; Teoh et al., 2011]. Moreover, in the 
rare hereditary form of apoA-I amyloidosis, the N-terminal fragments of apoA-I 
deposit as fibrils in vital organs (kidneys, liver, heart, nerves, testes, spleen, etc.) 
and damage them [Obici et al., 2006; Rowczenio et al., 2011; Gursky et al., 
2012]. Approximately 20 mutations in the apoA-I gene have been linked to this 
serious disease, some of which have been studied in this thesis research 
(chapter 3 and 4).  
A similar disease has been linked to stop codon mutations in human 
apoA-II, the second-major protein in plasma HDL. These rare mutations produce 
a C-terminal extension in apoA-II that causes renal amyloidosis and, ultimately, 
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kidney failure in humans [Benson et al., 2001; Benson et al., 2011]. In addition, 
amyloid deposits of a minor apolipoprotein, human apoA-IV, have been found in 
vivo (Bergström et al., 2004). Human apoC-II readily forms amyloid fibrils in vitro 
in a process that was extensively studied by Howlett and colleagues, providing 
the most comprehensive model available to-date for understanding the 
misfolding of larger apolipoproteins [Ryan et al., 2015]. Human apoC-III can also 
form amyloid fibrils in vitro [de Messieres et al., 2014]. More recently, hereditary 
amyloidosis related to mutant forms of apoC-II and apoC-III has also been 
reported [Valleix et al., 2016; Obici et al., 2016; Nasr et al., 2016].  
Apolipoproteins such as apoC-III, apoA-I and apoE were also implicated in 
binding amyloid- (A) peptide in circulation and were proposed as a potential 
biomarkers or risk factors for Alzheimer’s disease [Shih et al., 2014]. The large 
heavily glycosylated non-exchangeable apoB has also been reported to bind A 
peptide [Safar et al., 2006], although the physiological role of this binding 
remains unclear. Moreover, apoB has been proposed to form amyloid-like 
structure in several in vitro studies of LDL [Stewart et al., 2005; Parasassi et al., 
2008; Brunelli et al., 2014], and apoB misfolding in vivo was proposed to 
contribute to atherosclerosis [Ursini et al., 2002; Asatryan et al., 2005; Brunelli et 
al., 2014]. Although aggregation of modified LDL was observed in these and 
other studies, including work from our laboratory [Jayaraman et al., 2007; Lu et 
al., 2012; Lu & Gursky, 2013], none of these studies provided substantial 
evidence for amyloid formation by apoB. Therefore, amyloid formation by apoB 
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or its involvement in amyloid diseases awaits experimental verification.  
Other lipid surface-binding proteins that contain amphipathic -helices are 
also prominent in amyloid diseases. In particular, N-terminal fragments (typically 
residues 1-76) of serum amyloid A (SAA), called amyloid A (AA), an acute-phase 
protein that displaces apoA-I from HDL during inflammation, are deposited in AA 
amyloidosis. AA deposition is the major complication of chronic inflammatory 
diseases including rheumatoid arthritis, Crohn’s disease, tuberculosis and 
atherosclerosis [van der Westhuyzen et al., 2007; Eklund et al., 2012; Ye & Sun, 
2015]. SAA in solution is an intrinsically disordered protein that acquires 
amphipathic -helical structure on the lipid surface [Segrest et al., 1976; 
Jayaraman et al., 2015] and forms cross--sheet in amyloid [Colón et al., 2015]. 
Another apolipoprotein-related protein, -synuclein [Uversky et al., 2015], is also 
intrinsically disordered in solution, acquires an amphipathic -helical structure 
upon binding to a lipid surface, and can form extracellular -sheet rich amyloid 
deposits in neurodegenerative diseases such as Parkinson’s [Silva et al., 2013]. 
In summary, out of nearly 40 peptides and proteins that are known to 
deposit as fibers in human amyloidosis [Sipe et al., 2014], six are apolipoproteins 
(apoA-I, A-II, A-IV, C-II, C-III, E) and two are apolipoprotein-related proteins 
(SAA, -synuclein). The reasons why the apolipoprotein family is prominent in 
amyloid disease are outlined in part 1.3 below and addressed in greater detail in 
our work (chapter 5 and [Das & Gursky, 2015]) 
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1.3 Molecular Underpinnings of Apolipoprotein’s Role in Amyloidoses 
Previous studies from several groups including our laboratory have shown 
that free apolipoproteins in solution adopt a partially folded molten globule-like 
conformation with substantial -helical content, flexible tertiary structure, low 
thermodynamic stability, low unfolding cooperativity, substantial solvent exposure 
of apolar groups, and high aggregating propensity [Gursky & Atkinson 1996 a, b; 
Morrow et al., 2002; Guha et al., 2008]. These properties are likely to facilitate 
protein misfolding and -aggregation. Therefore, it was proposed that low 
structural stability and high conformational flexibility of free apolipoproteins, 
which facilitate their rapid binding to the lipid surface, also make them 
susceptible to misfolding [Hatters & Howlett, 2002]. Importantly, several groups 
postulated that direct precursors of amyloid are the structurally labile free 
apolipoproteins, rather than their stable lipoprotein-bound counterparts [Hatters & 
Howlett, 2002; Benson et al., 2011; Gursky et al., 2012; Hauser & Ryan, 2013].  
Unlike free apolipoproteins, which have relatively low thermodynamic 
stability (G< 3kcal/mol at 25 ˚C), lipoproteins are stabilized by high free energy 
barriers arising from disruption of extensive protein and lipid interactions during 
lipoprotein remodeling [Mehta et al., 2003; Jayaraman et al., 2005a; Jayaraman 
et al., 2006; Guha et al., 2007; Lu et al., 2012]. Such remodeling involves partial 
dissociation of apolipoproteins from the lipid surface and changes in lipoprotein 
morphology such as fusion [Gursky, 2013]. Free energy barriers decelerate 
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dissociation of apolipoproteins from the lipid surface and thereby delay their 
misfolding and proteolysis. 
The amphipathic -helix, which is the major lipid surface-binding motif in 
apolipoproteins and related proteins [Segrest et al., 1990, 1994], was proposed 
to have high intrinsic propensity for self-association and amyloid formation 
[Howlett & Hatters, 2002]. Apolipoprotein -helices, termed class-A helices, are 
distinct from the class-G helices found in globular proteins [Segrest et al., 1990] 
(Figure 1.3). First, class-A helices are comprised of 11-mer tandem repeats 
(rather than 7-mer repeats typical of globular proteins) that are optimized for lipid 
surface binding via the apolar helical faces. These large relatively flat apolar 
faces comprise 30-50% of the total helical surface area (Figure 1.3) as compared 
to ~15% in typical globular proteins. In addition, class-A helices have an 
unusually large fraction of charged residues (~30%) with most basic groups 
flanking the apolar face and most acidic groups located in the middle of the polar 
face (Figure 1.3). Such a charge distribution facilitates formation of salt bridge 
networks and is also thought to contribute to lipid surface binding [Segrest et al., 
1994]. In summary, apolipoprotein -helices are distinct in their distribution of 
hydrophobic and charged residues, which is important for the apolipoprotein 






Figure 1.3 Cartoon representing radial distribution of residues in amphipathic -
helices found in apolipoproteins.  
Basic (in blue), acidic (in red) and hydrophobic (in gray) residues are shown. 
Class A helices are most common in apolipoproteins; they have an apolar face 
flanked by basic residues, while acidic residues occupy the center of the polar 
face. In class G helices typical of globular proteins, charged residues (basic or 




Apolipoproteins can readily self-associate in solution in a process that is different 
from -aggregation. Such self-association is probably mediated, at least in part, 
via the apolar helical faces, and this process can preserve or even enhance the 
helical structure in apolipoproteins [Gursky & Atkinson, 1998]. However, it is not 
clear whether or not the apolipoprotein class-A -helices have high intrinsic 
propensity to convert into cross--sheet in amyloid. Recent advances in 
bioinformatics approaches (described below in section 1.5 and in chapter 3 and 
5) enabled us to test this idea. 
 
1.4 Recent Advances in Structural Studies of Apolipoproteins  
High-resolution structural studies of apolipoproteins are extremely difficult 
owing to unusually high structural flexibility and high aggregation propensity of 
these proteins. After years of careful construct optimization, stable non-
aggregating apolipoproteins amenable to high-resolution structural analyses 
have been produced, and atomic structures of several human apolipoproteins 
have been determined in lipid-free state. These include the solution structure of 
modified full-length apoE determined by NMR [Chen & Wang., 2011] and two 
high-resolution X-ray crystal structures, one of the N-terminal ~75% fragment of 
apoA-I, (185-243)apoA-I [Mei & Atkinson, 2011], described in section 1.6.3.2 
below, and another of the central domain of apoA-IV [Deng et al., 2012]. These 
structures have provided tremendous insights into the functions of these proteins 
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both on and off the lipid surface. In addition, the high-resolution structure of 
serum amyloid A (SAA) has been determined in three crystal forms, providing the 
much-needed structural basis for understanding amyloid formation by this protein 
[Derebe et al., 2014; Lu et al., 2014]. Importantly, all these atomic structures 
represent free proteins that are direct precursors of amyloid [Howlett & Hatters, 
2002; Benson et al., 2011; Das et al., 2014].  
In this dissertation, we combine recent advances in the structural studies 
of apolipoproteins with the newly developed amyloid prediction methods 
(described in the next section) and our own biophysical studies by using a wide 
array of methods (described in Chapter 2) to better understand apolipoprotein 
misfolding. 
 
1.5 Recent Advances in Bioinformatics Approaches to Predict 
Amyloidogenic Segments in Proteins  
Another area of recent advance is the development and improvement of 
the amyloid predicting software. During the last decade, it became increasingly 
clear that a wide variety of unrelated proteins and peptides can form amyloid in a 
process initiated by a limited number of 4- to 10-residue segments, or amyloid 
hot spots, that have high intrinsic propensity for -aggregation [Ventura et al., 
2004; Thompson et al., 2006; Tzotzos & Doig, 2010]. Approximately 20 
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sequence-based algorithms are currently available to predict such segments, 
including Tango, Waltz, Aggrescan, Zyggregator, 3D Rosetta-based method, 
FoldAmyloid and PASTA, to name a few. These algorithms use a variety of 
approaches, from the analysis of side chain distribution to molecular dynamics 
simulations, and apply a wide range of criteria, such as the side chain 
hydrophobicity, charge distribution, average packing density, dual -helix and -
sheet propensity, hidden -helix to -sheet switches, -sheet contiguity, 
correspondence to known amyloidogenic residue patterns, etc. [Galzitskaya et 
al., 2006; López de la Paz and Serrano 2004; Fernandez-Escamilla et al., 2004; 
Conchillo-Solé et al., 2007; Hamodrakas et al., 2007; Trovato et al., 2007; Zhang 
et al., 2007;  Zibaee et al., 2007; Kim et al., 2009; Tian et al., 2009; Maurer-Stroh 
et al., 2010; Garbuzynskiy et al., 2010; O'Donnell et al., 2011]. This multitude of 
criteria and approaches reflects the complexity in the process of -aggregation 
and fibril formation, which can be induced in unrelated proteins by a wide range 
of factors. As a result of this immense complexity, most individual algorithms 
have limited predictive power. To optimize the selectivity and specificity of the 
prediction, i.e. to minimize the probability of false positives and negatives, a 
consensus method has been developed by Hamodrakas and colleagues. We 
used the expanded version of this method, termed AmylPred2.0, which combines 
11 individual algorithms [Tsolis et al., 2013]. 
In addition, we used amyloid prediction software PASTA [Trovato et al., 
2007; Walsh et al., 2014] and its expanded version, PASTA2.0 [Walsh et al., 
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2014], that not only identifies the amyloidogenic segments but also estimates 
free energy of their pairing and thereby predicts which amino acid register and -
sheet orientation, parallel or antiparallel, is energetically favored. 
The main focus of this dissertation is on the apoA-I misfolding. Chapters 3 
and 4 describe our experimental studies of biophysical, structural and amyloid-
forming properties of apoA-I. Other members of the apolipoprotein family and 
their roles in amyloid diseases are briefly described in chapter 5. 
 
1.6 Overview of the Apolipoprotein A-I Structure and Function 
1.6.1 Apolipoprotein A-I in Normal Metabolism 
Human apolipoprotein A-I (243 a. a.) is the major HDL protein that binds 
and activates lipid transporters, lipophilic enzymes, and HDL receptors, and 
thereby orchestrates the crucial steps in HDL biogenesis and function [Navab et 
al., 2011; Philips 2013]. Although plasma levels of apoA-I and HDL cholesterol 
have long been known to correlate inversely with the risk of cardiovascular 
disease [Gordon et al., 1989], recent studies revealed that this relationship is 
much more complex than previously thought and involves additional factors. Of 
particular importance are distinct functional properties of individual HDL 
subclasses [Rothblat & Philips 2010; Navab et al., 2011; Banach, 2014]. The role 
of these factors is intensely investigated in an effort to develop new HDL-based 
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therapies to complement statins and other lipid-lowering drugs [Kingwell et al., 
2014]. The prevailing concept is that the protective function of HDL and apoA-I 
stems mainly from their central role in reverse cholesterol transport (RCT), which 
is the sole pathway of cholesterol removal from the body [Sorci-Thomas & 
Thomas, 2013; Phillips 2014]. Additional protection stems from anti-inflammatory, 
anti-oxidant and antithrombotic effects of apoA-I [Navab et al., 2011]. 
Figure 1.4 depicts the major steps in the complex process of RCT. RCT 
begins with cholesterol efflux from cells to lipid-poor/free apoA-I, which is 
mediated by ABCA1 (ATP-binding cassette transporter A1), to generate nascent 
discoidal HDL [Oram & Heinecke, 2005]. ABCG1 (ATP-binding cassette 
transporter G1) mediates cholesterol transport to nascent HDL [Gelissen et al., 
2006]. Cholesterol is esterified by LCAT and cholesteryl esters move to the 
particle core, converting nascent discoidal into mature spherical particles 
[Rothblat & Phillips, 2010]. Further remodeling of HDL by plasma factors (LCAT, 
CETP, etc.) increases lipid load in HDL. HDL lipids are ultimately delivered to the 
liver via selective lipid uptake mediated by the scavenger receptor BI (SR-BI) 
([Mineo & Shaul, 2012] and references therein). As a result of extensive HDL 
remodeling during RCT, apoA-I must adapt its conformation to fit various particle 
sizes, and also to dissociate from HDL in a lipid-poor/free state at various stages 




Figure 1.4 Cartoon representing selected steps in reverse cholesterol transport  
(1) Nascent “discoidal” HDL is formed via interaction of apoA-I and ABCA1 (2) 
These nascent HDL also takes up cholesterol from the membrane via ABCG1. 
(3) These cholesterol molecules are then esterified by LCAT and moves from the 
HDL surface to its core leading to HDL maturation and formation of spherical 
particles. (4) These small HDL are further remodeled by LCAT and other plasma 
factors, such as CETP to increase the lipid load. (5) This remodeling can cause 
imbalance between the core and surface of HDL leading to protein release and 
lipoprotein fusion to form larger HDL particles. (6) Large lipid-loaded HDL interact 
with the scavenger receptor, SR-BI that selectively uptakes apolar lipids from the 
HDL core. The lipid-poor/free apoA-I released from HDL is either recycled or gets 




In plasma, apoA-I is in a dynamic equilibrium between lipid-bound and 
lipid-poor/free species, and the latter form a metabolically active species that is 
also a protein precursor of amyloid. ApoA-I misfolding is the major focus area of 
this dissertation and is described in section 1.7 below. 
1.6.2 Apolipoprotein A-I Structure 
 Mature apoA-I contains 243 residues encoded by exons 3 and 4. 
Residues 1-43 are encoded by exon 3 and are predicted to form an amphipathic 
class G* -helix similar to the -helices found in globular proteins [Segrest et al., 
1992]. The remaining residues 44-243 are encoded by exon 4 and are predicted 
to form ten continuous helical tandem repeats of 11/22-mer residues each, with a 
proline located in position 1 of most repeats: H1 (44-65), H2 (66-87), H3 (88-98), 
H4 (99-120), H5 (121-142), H6 (143-164), H7 (165-187), H8 (188-208), H9 (209-
219), and H10 (220-243) [Segrest et al.,1992; Marcel & Kiss, 2003]. Extensive 
studies using various biophysical techniques such as protein cross-linking, mass 
spectrometry (MS), electron paramagnetic resonance (EPR), fluorescence 
resonance energy transfer (FRET), site-directed mutagenesis, antibody binding, 
electron microscopy (EM), NMR, calorimetry and molecular dynamics have been 
employed to understand the helical location and arrangement in the secondary 
and tertiary structure of apoA-I ([Calabresi et al., 1993; Li et al., 2000; Okon et 
al., 2002; Tian & Jonas, 2002; Oda et al., 2003; Saito et al., 2004; Bhat et al., 
2005; Kono et al., 2008; Silva et al., 2008; Chetty et al., 2009; Koyama et al., 
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2009; Lagerstedt et al., 2012; Segrest et al., 2014] and references therein). 
Circular dichroism (CD) analysis of lipid-free plasma apoA-I revealed that the 
protein is ~50-60% helical in solution, and the helicity can increase up to 70-80% 
on binding to lipid [Gursky & Atkinson, 1996a; Davidson et al., 1996, Silva et al., 
2005]. EPR studies of the full-length spin-labelled apoA-I reported a ~53% -
helical content spanning the length of the molecule, along with four -strands in 
residues 20-25, 120-129, 150-158, and 214-220 [Lagerstedt et al., 2012]. The 
latter results contrast with the HDX MS experiments of full-length apoA-I in 
solution pioneered by Phillips and Englander [Chetty et al., 2009]. HDX MS 
studies showed that residues 7-44, 54-65, 70-78, 81-115, 147-178 formed -
helices, whereas residues 116-146 and 179-243 lacked a defined structure. 
 Studies of the N-terminal and C-terminal deletion mutants of apoA-I, (1-
43) and (187-243), suggested that the C-terminal truncation does not 
significantly affect the tertiary structure of apoA-I [Rogers et al., 1998]. 
Furthermore, Rogers and colleagues reported that the N-terminally truncated 
mutant exhibited a different secondary and tertiary structure compared to full-
length apoA-I, establishing the importance of the N-terminus in stabilizing the 
apoA-I conformation in solution. The role of the central repeat H5 (residues 121-
143) acting as a hinge connecting the N- and C-terminal parts of apoA-I was 
suggested by segment deletion as well charge inversion studies [Gorshkova et 
al., 2000, 2002, 2006]. Truncation of the C-terminal part, (187-243) and (193-
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243), decreased the phospholipid binding ability of apoA-I, and several studies 
showed that the C-terminal region containing residues 193-243 is responsible for 
the initiation of phospholipid binding as well as for protein self-association ([Ji & 
Jonas, 1995; Fang et al., 2007; Phillips, 2013; Nagao et al., 2014; Mei et al., 
2016] and references therein). The latter was further confirmed by cross-linking 
experiments showing that the C-terminal deletion mutants (185-243) and (209-
243) were unable to form higher-order aggregates in solution [Laccotripe et al., 
1997]. Mutagenesis of hydrophobic residues in the C-terminal region significantly 
decreased lipid clearance and 8-anilino-1-naphthalenesulfonate (ANS) binding, 
further supporting the role of the C-terminal region in lipid binding and 
aggregation ([Lyssenko et al., 2012; Nagao et al., 2014; Mei & Atkinson, 2015] 
and references therein). Overall the role of C-terminal part of apoA-I as a primary 
lipid binding and aggregation site is well-established. 
Amongst the binding partners of apoA-I, interaction with LCAT is relatively 
well characterized. Extensive mutagenesis studies suggested that apoA-I 
residues 143-164 from repeat H6 are involved in LCAT activation [Sorci-Thomas 
et al., 1997, 1998; Roosbeek et al., 2001]. Additional insights into the role of 
repeat H5 in LCAT activation were obtained from the crystallographic studies 
[Mei & Atkinson, 2011]. Although the crystal structure of LCAT has been recently 
determined [Piper et al., 2015], the exact structure of LCAT in complex with 
apoA-I on HDL is unknown, and hence, the structural basis of LCAT activation by 
apoA-I is incompletely understood. The interactions between lipid-free/poor 
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apoA-I and ABCA1 are even less well understood. A naturally occurring mutant 
of apoA-I, E235, showed a decreased ability to promote cellular cholesterol 
efflux via ABCA1, suggesting that the C-terminal region of apoA-I is involved in 
the interaction with ABCA1 [Huang et al., 2000]. The structural basis for apoA-I 
interactions with other functional partners such as SR-BI is also unclear. 
1.6.3 Crystal Structures of Apolipoprotein A-I 
Although the atomic structure of full-length apoA-I in solution or on HDL is 
not available, two x-ray crystal structures of lipid-free truncated forms of human 
apoA-I have been determined (Figure 1.5): a low-resolution 4Å structure of the N-
terminally truncated (1-43)apoA-I [Borhani et al., 1997] and a high-resolution 
2.2Å structure of the C-terminally truncated (185-243)apoA-I [Mei & Atkinson, 
2011]. These important structural studies provided tremendous insights into the 
structure-function relationship of apoA-I on HDL and in solution ([Brouillette et al., 





Figure 1.5 Comparison of the crystal structures of the N-terminally and C-
terminally truncated forms of apolipoprotein A-I. 
(A) The structure of (1-43)apoA-I determined to 4 Å resolution [Borhani et al., 
1997]. In the crystal structure apoA-I forms a tetramer (left) comprised of two 
dimers (right). Each dimer is comprised of two antiparallel helical molecules with 
sequence repeat H5/H5 and H10/H10 aligned in register. The structure is 
proposed to represent the “double belt” conformation of apoA-I on HDL. (B) The 
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structure of (184-243)apoA-I determined at 2.2Å resolution [Mei & Atkinson, 
2011]. ApoA-I forms a semicircular crystallographic dimer with two molecules 
running antiparallel to each other and H5/H5 repeat registry. Residue 43 is 
indicated in magenta. This structure was proposed to represent an intermediate 
conformation between the lipid-free and lipid-bound state of apoA-I. Chimera 





1.6.3.1 Low-resolution Structure of the N-terminally truncated (1-43)apoA-I 
Prior to crystallization of the (1-43)apoA-I construct, extensive 
biophysical studies were performed on the truncated protein [Rogers et al., 
1997]. CD data suggested that the helical content of the (1-43)apoA-I was 
higher than that of the full-length apoA-I. Also, unlike full-length apoA-I, the 
helical content of the truncated protein did not increase upon lipid binding. The 
lipid-binding properties of the full-length and the N-terminally truncated proteins 
were similar as observed by their association with HDL component in plasma and 
formation of reconstituted lipoprotein particles in vitro. Near-UV CD comparison 
of these proteins showed stark spectral differences, and increased ANS binding 
to (1-43)apoA-I suggested increased exposure of hydrophobic residues upon N-
terminal deletion. Based on these observations, the authors proposed that full-
length apoA-I and (1-43)apoA-I had different tertiary structures in lipid-free state 
but adopted similar conformation in the lipid-bound state, and that the 
conformation of lipid-free (1-43)apoA-I resembled the HDL-bound conformation. 
In the crystal structure of (1-43)apoA-I, two elongated apoA-l molecules 
comprised of kinked -helices aligned antiparallel to each other in a horseshoe-
shaped dimer (Figure 1.5A) [Borhani et al., 1997]. The structure had an-helical 
content of nearly 90%, comparable to that of HDL. The two dimer-forming 
molecules formed a double-belt with a maximal diameter circa 12.5 nm, which is 
comparable to the maximal HDL diameter. The helical repeats H5/H5 and 
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H10/H10 in the two antiparallel dimer-forming molecules were aligned in register. 
Subsequent FRET, cross-linking and mass spectrometry studies of reconstituted 
HDL particles containing apoA-I confirmed the proximity of residues in repeat 5 of 
two apoA-I molecules in the lipid-bound state [Li et al., 2000, 2001; Silva et al., 
2005]. Therefore, the crystal structure of (1-43)apoA-I is thought to represent 
important aspects of the apoA-I conformation on HDL. 
In the crystal structure of (1-43)apoA-I, two dimers form a tetramer with 
their hydrophobic faces packed against each other, and thereby protected from 
the aqueous solution. It was proposed that the tetramers dissociate into dimers to 
bind to lipids via this hydrophobic interface and form HDL [Borhani et al., 1997]. 
1.6.3.2 High-resolution Structure of the C-terminally truncated (185-243)apoA-I 
More recently, Mei and Atkinson solved the 2.2Å structure of the C-
terminally truncated lipid-free (185-243)apoA-I (PDB ID: 3R2P) [Mei & Atkinson, 
2011]. In the crystal structure, apoA-I forms a dimer, with the two dimer-forming 
molecules running antiparallel to each other (Figure 1.5B). The dimer is stabilized 
by two four-helix bundles at its ends. The helices are kinked at Pro positions to 
form an arc that is 11 nm in diameter, which is comparable with the diameter of 
HDL. The antiparallel helical arrangement and central repeat H5/H5 registry 
observed in the crystal structure of the (185-243)apoA-I dimer was similar to 




Figure 1.6 Stabilizing interactions in N-terminal helix bundle suggested by the X-
ray crystal structure of (185-243)apoA-I.  
The N-terminal helix bundle in apoA-I contains two aromatic clusters, one at the 
bottom and another at the top (marked N and C, respectively, in the panels on 
the left). Two cation- π interactions between R61-W8 (bottom panel) and K23-




These observations suggest that the crystal structure of (185-243)apoA-I 
represents an intermediate between the globular helix bundle structure of lipid-
free apoA-I and the extended double-belt conformation of apoA-I on HDL 
[Borhani et al., 1997; Davidson & Silva, 2005; Mei & Atkinson, 2011].  
The four-helix bundle observed in the crystal structure is comprised of two 
pairs of helical segments, a shorter pair containing helices I and II (residues 7-41 
and 42-65), and a longer pair containing helices III and IV (residues 66-121 and 
143-184). A narrow hydrophobic cleft was observed between these pairs of 
helices and was proposed to serve as an entry point for lipids during the helix-
bundle opening and its conversion from lipid-free apoA-I into the extended 
double-belt conformation on HDL. A flexible hinge region in residues G65, P66 at 
the bottom of the helix bundle was proposed to facilitate this conformational 
opening [Mei & Atkinson, 2011]. Such a helix-bundle opening exposes the apolar 
faces of the amphipathic helical segments for interaction with lipids. 
In the lipid-free state of apoA-I, the four-helix bundle was proposed to be 
stabilized by two hydrophobic aromatic clusters observed in the crystal structure, 
one at the top and the other at the bottom of the bundle (Figure 1.6). The top 
cluster contains residues F33, F104, and W108, while the bottom cluster 
contains closely packed aromatics F71, W72, and W8. Two cation–π interaction 
between residues K23 and W50 located in the middle of the bundle and residues 
R61 and W8 located at the bottom of the bundle were also proposed to 
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contribute to the structural stability of the helix-bundle. Additional stability is 
probably provided by inter- and intramolecular salt-bridges. 
Furthermore, the crystal structure of (185-243)apoA-I suggests how the 
central repeat H5 (residues 121–143) can facilitate apoA-I dimer to monomer 
conversion via domain swapping. In this conversion, the polypeptide chain is 
proposed to fold back around the dimer two-fold axis that passes through the 
middle of the central repeat 5 (Figure 1.7, circular arrow). This results in 
formation of a globular four-helix bundle in which all four helical segments I-IV 
come from the same molecule of apoA-I (Figure 1.7, right).  
The hydrophobic C-terminal residues 185–243, which are implicated to be 
largely disordered in lipid-free apoA-I in solution ([Chetty et al., 2009; Mei & 
Atkinson, 2011] and references therein), were truncated from the crystallized 
construct to facilitate crystallization. Multiple lines of experimental evidence 
suggest that the C-terminal segment interacts relatively weakly with the N-
terminal four-helix bundle [Bhat et al., 2005; Koyama et al., 2009, Pollard et al., 
2013; Mei et al., 2016]. In fact, deletion of this segment causes minimal changes 
in the near-UV CD spectrum of apoA-I [Mei & Atkinson, 2011], indicating that the 
aromatic packing and, hence, the tertiary structure of the four-helix bundle is not 
affected significantly by its interaction with C-terminal residues 185-243. 





Figure 1.7 Proposed conformation of lipid-free apoA-I monomer. 
Left: molecule 1 of the C-terminally truncated (185-243)apoA-I in the 
crystallographic dimer. Helical sequence repeats 2–7 are indicated; helical 
repeats 6 and 7 are colored in teal. Conversion of the apoA-I dimer to the 
monomer requires these repeats to undergo a domain swapping around the 
dimer 2-fold axis that passes through the central repeat 5 (circular arrow) [Mei & 
Atkinson, 2011]. Right: the proposed conformation of the apoA-I monomer with 
intact four-helix bundle similar to that of the crystallographic dimer but with all 
helices from the same molecule. The C-terminal tail (residues 185-243) that has 




enhanced the protein stability [Mei & Atkinson, 2011]. Together, these 
observations suggest that the helix-bundle conformation observed in the crystal 
structure of (185-243)apoA-I is similar to that of the full-length free apoA-I in 
solution. Additional support for this idea comes from the helical arrangement 
inferred from HDX MS studies of lipid-free full-length apoA-I [Chetty et al., 2009], 
which is in excellent overall agreement with the crystal structure of (185-
243)apoA-I. 
In this dissertation, we have combined our experimental and 
bioinformatics analysis with the crystal structure of the C-terminally truncated 
(185-243)apoA-I to gain insights into apoA-I misfolding (described below). 
 
1.7 Apolipoprotein A-I Misfolding 
1.7.1 An Overview of Apolipoprotein A-I Misfolding 
Human apoA-I amyloidosis manifests itself in two distinct forms, acquired 
and hereditary. Acquired amyloidosis is the most common form where full-length 
non-variant apoA-I deposits as fibers in arteries and tissues [Röcken et al., 2006; 
Howlett & Moore 2006; Ramella et al., 2011]. Such fibrils were found in aortic 
plaques of >50% of patients who underwent atherectomy [Mucchiano et al., 
2001; Röcken et al., 2006]. The apoA-I fibrillar deposits correlated directly with 
the patients’ age and their triacylglycerol levels in plasma [Röcken et al., 2006]. 
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Although the causes and consequences of apoA-I fibril deposition in vivo are 
unclear, increasing evidence suggests that this process is pro-atherogenic 
[Ramella et al., 2011; Teoh et al., 2011]. In fact, apoA-I fibrils reportedly increase 
vulnerability of atherosclerotic plaques (i.e. reduce plaque stability, which may 
potentially lead to a heart attack or a stroke), activate arterial macrophages, and 
are toxic to cells [Suzuki et al., 2005; Lepedda et al., 2009; Patel et al., 2010; 
Adachi et al., 2013]. Moreover, full-length wild-type human apoA-I can form 
amyloid in vitro upon methionine oxidation, suggesting a potential mechanism for 
apoA-I fibrillogenesis in the oxidative environment of atherosclerotic plaques 
[Wong et al., 2010; Chan et al., 2015]. 
Hereditary apoA-I amyloidosis, termed AApoAI, has an entirely different 
clinical presentation. In this autosomal dominant disorder, N-terminal 9-11 kDa 
fragments of mutant apoA-I deposit as fibers in vital organs causing organ 
damage [Obici et al., 2006; Rowczenio et al., 2011, Gursky et al., 2012; Ramella 
et al., 2012]. Currently ~20 naturally occurring human AApoAI mutants have 
been identified that primarily include point substitutions as well as some frame 
shifts and deletions ([Rowczenio et al., 2006; Obici et al., 2006; Gursky et al., 
2012] and references therein). Most of these mutations are located within the N-
terminal residue segment 1-100, which is found in amyloid deposits (so-called 
“inside” mutations), yet several “outside” point mutations have also been found in 
residues 170-178, outside of the fragment deposited as amyloid fibers. 
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The first amyloidogenic mutant of apoA-I, G26R (called apoA-IIowa), was 
identified and described by Benson’s group [van Allen et al, 1969; Nichols et al., 
1988]. This finding was followed by the discovery of several other mutants. The 
site of amyloid deposition varies and can include kidney (most common), liver, 
heart, nerves, skin, spleen, testes, etc. The fiber deposits found in the heart 
mainly contain residue fragments 1-93, while those in other organs can contain 
either shorter or longer fragments ranging from residues 1-80 to 1-100 [Obici et 
al., 2006]. Currently, the only treatment for this potentially lethal disease is end-
stage organ transplant [Gillmore et al., 2006]. 
It is unclear whether the proteolytic cleavage that generates the N-terminal 
9-11 kDa fragments found in amyloid deposits precedes or follows apoA-I 
misfolding [Wong et al., 2010]. Several attempts to detect these fragments in the 
plasma have been unsuccessful [Obici et al., 2006]. However, ex-vivo studies 
using materials from amyloid deposits have shown the ability of 1-93 fragment of 
apoA-I to form cross-beta sheets [Andreola et al., 2003]. Mass spectrometry 
analysis of amyloid fibers obtained from carriers of AApoAI mutations either in 
residues inside (such as E34K, F71Y, etc.) or outside (such as R173P, A175P, 
etc.) of the N-terminal 1-100 fragment, revealed that the fibrillary deposits 
contained only the mutant protein [Nichols et al., 1988; Hamidi Asl et al., 1999; 
Rowczenio et al., 2011]. Some studies of the “outside” mutants such as L178H 
reported the presence of full-length apoA-I and its N-terminal fragments in 
amyloid fibers [de Sousa et al., 2000]. Obviously, the N-terminal apoA-I 
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fragments found in fibrillar deposits of the “outside” mutants lacked the mutation 
site. This raises a question: how can the “outside” mutations in the C-terminal 
half of the apoA-I molecule trigger amyloid deposition by its N-terminal part? This 
question was answered, for the first time, in the studies from our laboratory 
[Gursky et al., 2012). Furthermore, the reasons why different AApoAI mutations 
generate N-terminal fragments cleaved at different sites (which are distant from 
the mutation site) are not known. The identity of the proteases involved in the 
cleavage is also unknown. 
The mechanism of the tissue damage and the pathogenic species (apoA-I 
oligomers or fibrils) are also unknown. Rader and colleagues isolated apoA-I 
from plasma of patients with G26R mutation and compared its in vivo metabolism 
with that of the WT, both in normal subjects and in AApoAI patients [Rader et al., 
1992]. The results revealed an increased catabolism of the mutant protein as well 
as its altered association with HDL. Importantly, 1-93 fragments that contained 
AApoAI mutation failed to demonstrate any significant effect of these mutations 
on the aggregation pathway during apoA-I misfolding [Raimondi et al., 2011]. 
Recent studies on G26R variant of apoA-I have suggested that the fibers of this 
variant target the lysosome to induce the cytosolic release of cathepsin B, 
thereby initiating mitochondrial dysfunction [Kameyama et al., 2016] 
Interestingly, the clinical presentation of the hereditary apoA-I amyloidosis 
varies from mild to severe even in individuals with the same mutation [Obici et 
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al., 2006; Rowczenio et al., 2011]. The disease onset can be in early 20s with 
rapid progression to death by cardiac failure in the 40s, or the disease can 
present itself in the late 50s with a gradually progressing renal failure. These 
variations in the clinical presentation of the AApoAI disease suggest that, in 
addition to apoA-I mutations, other unknown factors are involved. The lipid 
environment and the HDL lipid composition have been proposed to play a critical 
role in influencing apoA-I misfolding [Gorbenko & Kinunnen, 2006; Monti et al., 
2010; Jayaraman et al., 2016]. We posit that the factors that prevent or promote 
apoA-I release from HDL (which includes HDL lipid composition) may influence 
the population of the free protein that is the precursor of amyloid fibers 
(described in chapter 6). 
Typically, AApoAI patients have lower than normal plasma levels of apoA-I 
(30-50%) and HDL, which may result from reduced secretion or enhanced 
degradation of the protein [Marchesi et al., 2011; Arciello et al., 2011]. This is in 
contrast to other amyloid diseases (such as Alzheimer’s disease or AA) which 
often result from protein overproduction. Paradoxically, despite apoA-I and HDL 
deficiency, AApoAI patients are not at a high risk for atherosclerosis [Sorci-
Thomas & Thomas, 2002; Obici et al., 2006; Rowczenio et al., 2011]. This 
illustrates the complex relationship between plasma levels of HDL and 
cardiovascular disease and suggest a possible gain-of-function for AApoAI 
mutants (addressed in chapter 6).  
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1.7.2 Structural Analysis of Apolipoprotein A-I Misfolding 
In order to understand the misfolding mechanism of apoA-I in amyloidosis, 
it is necessary to have a detailed insight into the native structure of the protein. 
The 2.2 Å resolution crystal structure of Δ(185–243)apoA-I [Mei & Atkinson, 
2011] provides the only atomic-level insight available to-date into the structure 
and function of apoA-I in solution and on HDL. Importantly, (185-243)apoA-I 
contains all sites of known AApoAI mutations as well as all three methionine 
residues in apoA-I (M86, M112, M148), whose oxidation is implicated in acquired 
amyloidosis. Therefore, the structure of Δ(185–243)apoA-I provides an excellent 
starting model for understanding the structural basis of protein misfolding in the 
acquired and in the hereditary forms of apoA-I amyloidosis. 
Previously, our laboratory mapped the sites of all amyloidogenic mutations 
on the crystal structure of Δ(185–243)apoA-I [Gursky et al., 2012]. The results 
showed that most “inside” and all “outside” mutation sites were located in the 
well-ordered bottom half of the helix bundle (Figure 1.8). This location helped 
explain the role of the outside mutations suggesting that these mutations 
destabilize the helix bundle and thereby promote its misfolding (Figure 1.9). The 
crystal structure also revealed that the residue segment 44–55 adopted an 
unpaired -strand-like conformation that is unique to apoA-I, suggesting that this 
segment helps initiate -helix to -sheet conversion [Gursky et al., 2012]. These 





Figure 1.8 AApoAI mutations mapped on the crystal structure of (185-243) 
apoA-I 
AApoAI mutations are indicated in space-filled representation and are color-
coded. Yellow denotes point substitutions, green indicates deletions, and pink 
denotes frame shift mutations. Most of the AApoAI point mutations are located at 
the bottom of the helix bundle, while some are present in the middle, and one 
(E34K) at the top of the bundle. In this dissertation, we have studied two point 
mutations at the bottom (F71Y, L170P) and two in the middle of the helix bundle 
(G26R and W50R), along with a non-amyloidogenic L159R mutation near the 




Figure 1.9 Proposed pathway of apoA-I misfolding (top row) and degradation 
(bottom row)  
The scheme suggests that the destabilization of apoA-I upon mutation causes a 
proteolytic cleavage between residues 81 and 100 (in purple), leading to a 
release of the amyloid-forming N-terminal fragments. Research described in this 
thesis helped us to re-evaluate this idea and improve our understanding of the 




1.7.3 The Scientific Premise for this Thesis Research 
The overall goal of this Ph.D. research was to advance our understanding 
of the molecular mechanism of apoA-I misfolding and the factors that can 
influence this pathogenic process. Our focus was on the hereditary form of 
human amyloidosis, AApoAI. The specific aims were: i) to determine the 
molecular mechanism of apoA-I misfolding in AApoAI, by using a multipronged 
biophysical approach; ii) to determine the structural basis underlying the 
prevalence of exchangeable apolipoproteins in human amyloid diseases, by 
combining new bioinformatics studies with existing structural information on 
these proteins. 
When this research began, the first HDX MS and biophysical study of a 
full-length monomeric AApoAI mutant, apoA-I Iowa (G26R) apoA-I, was 
published by Phillips, Englander and colleagues [Chetty et al., 2012]. The 
authors showed that G26R mutation reduced the protein stability in solution and 
decreased the structural protection in the N-terminal ~90 residues [Chetty et al., 
2012]. This study seemed to support the prevailing concept in the field that 
AApoAI mutations destabilize the native protein structure and promote its 
proteolysis to generate the N-terminal fragments that misfold and deposit as 
amyloid fibrils. However, there was no direct evidence that G26R mutation 
actually promoted the protein cleavage between residues 83 and 100. HDX MS 
data showed that these residues partially retained their helical structure (and 
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hence, their protection from proteolysis) as compared to other less structured 
regions. Further, the effects of other AApoAI mutations on the protein 
conformation, stability and proteolysis were unknown. Moreover, it was unclear 
why some destabilizing mutations in apoA-I are amyloidogenic while others are 
not, or why Met oxidation promotes amyloid fibril formation by the full-length wild 
type apoA-I.  
To address some of these and other questions, in this dissertation we 
analyzed the overall protein conformation, structural stability, local dynamics, 
proteolytic susceptibility and lipid interactions by using a series of recombinant 
disease-causing variants of full-length human apoA-I. As an important negative 
control, we used a non-amyloidogenic apoA-I variant, L159R (apoA-I Fin 
mutation), as well as the wild type (WT) protein. The results provided new 
unexpected insights into the effects of these pathogenic mutations on the 
structure, stability and dynamics of lipid-free and lipid-bound apoA-I, and enabled 
us to propose, for the first time, a possible pathway of amyloid formation by 
variant human apoA-I (chapters 3 and 4).  
The lessons learned from the experimental and bioinformatics studies of 
apoA-I were extended toward other members of the apolipoprotein family that 
were analyzed to understand why this protein family plays such a prominent role 




Chapter 2 Materials and Methods 
 
2.1 Protein Expression and Purification 
In 2011 Mei and Atkinson published the 2.2 Å resolution crystal structure 
of lipid-free C-terminally truncated, (1-185) apoA-I, [Mei & Atkinson, 2011]. 
Their protocol for expression and purification of apoA-I was adopted in our 
studies. Active involvement of Dr. Xiaohu Mei in protein purification is gratefully 
acknowledged. 
Figure 2.1 illustrates the basic expression and purification scheme. Briefly, 
the constructs for recombinant apoA-I (wild type or mutant forms) were 
expressed as a soluble fusion protein using His6-Maltose Binding Protein-
Tobacco Etch Virus (His6-MBP-TEV) expression system.  After the cleavage of 
the His6-MBP tag from His6-MBP-apoA-I with the TEV protease, a single 
additional Gly was left at the N-terminus. This is important because any 
extraneous residues at the N-terminal end can potentially disrupt the native 
conformation [Mei & Atkinson, 2011]. 
In our work, recombinant full-length wild-type and mutant apoA-I forms 
were overexpressed in E.coli BL21 (DE3) Codon Plus-RIL cells.  A colony of 
cells, transformed with expression vector, was inoculated in Luria broth 
supplemented with ampicillin (100 g/mL) and chloramphenicol (30 g/mL). The 




Figure 2.1 Schematic pathway of apoA-I purification. 
Recombinant wild-type or mutant apoA-I was expressed using the His6-MBP-TEV 
expression system in E. coli. After proteolytic cleavage of the tag by TEV 




isopropyl-β-D-thiogalactopyranoside (IPTG). After 4 hours, the cells were 
harvested by centrifugation (5000 x for 30 min) and stored at -80 °C. The 
harvested cell pellets were lysed with the lysis buffer (50 mM phosphate buffer, 
pH= 8.0, 100 mM NaCl, 10% glycerol, 25 mM imidazole) using ultrasonication 
(Branson Sonifier 350). Proteins were purified by FPLC. The supernatant, which 
was obtained upon centrifugation of the lysate (15000 x for 30 min), was run 
through the HisTrap affinity column and was eluted by using a linear gradient of 
imidazole (25-200 mM in lysis buffer).  As a result, His6-MBP-apoA-I fusion 
protein was eluted. The fractions were pooled and concentrated by ultrafiltration. 
This was followed by incubation of the concentrated fusion protein with TEV 
protease to release the His6-MBP tag. Protease-treated protein solution was then 
subjected to a second run through the desalting HisTrap column. The flow-
through fraction contained apoA-I while the tag was bound to the affinity column. 
The flow-through was collected, concentrated and subjected to gel filtration in 
order to determine molecular weight and further refine the purification procedure. 
Protein purity was assessed by 10-20% gradient SDS-PAGE (Invitrogen) 
followed by staining with Denville Blue protein stain (Denville Scientific Inc., 




2.2 Protein Storage, Refolding and Concentration Determination 
After purification, the proteins were aliquoted into 1 ml Eppendorf tubes 
and flash-frozen with liquid nitrogen prior to storage at -80 °C. For biophysical 
studies, the protein solutions were thawed and dissolved in 6 M guanidium 
hydrochloride (Gdn HCl) to refold the protein. The solution was then kept on ice 
for at least one hour. This was followed by extensive dialysis against the 
standard buffer (10 mM phosphate buffer, pH 7.5) at 4 °C. Refolded protein stock 
solutions were stored in the dark at 4 °C and were used within four weeks. 
UV-visible absorption spectroscopy was used to measure the 
concentration of the refolded proteins. Aromatic amino acids (Phe, Tyr and Trp) 
absorb at 280 nm, providing the major contribution to the extinction coefficient of 
the protein, . If this coefficient is known, the concentration can be determined 
using Beer-Lambert’s law [Gill & von Hippel, 1989]. The extinction coefficient of a 
protein can be calculated from the extinction coefficients of its aromatic amino 
acids using the equation below.  This method relies solely on the protein amino 
acid composition and does not take into account the effects of amino acid 
sequestration in the folded structure [Gill & von Hippel, 1989]. 
(Protein) = No. of Tyr * (Tyr) + No. of Trp * (Trp) + No. of Cys * (Cys) 
        (Eq 2.1) 
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For solvent-exposed aromatics in water at 280 nm, (Tyr) = 1490; (Trp) = 5500; 
(Cys) = 125  
In our work, Expasy’s ProtParam tool [Gasteiger et al., 2005] was used to 
compute the extinction coefficient and other physiochemical parameters for the 
recombinant proteins. The results are listed in Table 2.1. Absorption 
measurements were taken using Varian Cary-300 UV/Vis spectrophotometer 
(Agilent Technologies Inc.). Standard buffer (10 mM phosphate buffer, pH= 7.5) 
was used to calibrate the baseline. Stock protein solutions were then diluted to a 
concentration of 0.1-0.5 mg/mL and the absorbance at 280 nm was measured. 
The measurements were repeated three times and the average was taken to 
calculate the concentration of the protein solution using the equation below. 
Concentration (mg/mL) = [(Observed OD at 280nm)/ (OD of 0.1% solution from 
ProtParam)] X Dilution factor                                    (Eq 2.2) 
 
2.3 Gel Electrophoresis 
To determine the size of the reconstituted particles and the aggregation 
state of lipid-free proteins, non-denaturing gel electrophoresis was performed 
using 4-20% polyacrylamide gradient gels from Invitrogen (Invitrogen, NY). The 




Table 2.1 Physicochemical parameters of apolipoprotein constructs used in this 
study. 
The values were determined by using ProtParam server. The extinction 




Stoke’s radii. SDS-PAGE was performed using pre-made 10-20% polyacrylamide 
gradient from Invitrogen to assess purity, degradation status and proteolytic 
cleavage products. Samples containing approximately 5-10 μg protein were 
loaded on the gels. Native and SDS gels were run on a Hoefer SE260 (Bio-Rad) 
mini-vertical apparatus or Invitrogen XCell Surelock system at 150-200 V for 1–3 
hours, and were visualized using Denville Blue stain (Denville Scientific Inc., NJ). 
For SDS-PAGE, Bio-Rad’s precision plus dual xtra Standard (Life Science 
Technologies, CA) was used. 
 
2.4 Circular Dichroism Spectroscopy 
2.4.1 Brief Overview of CD Principles and Applications 
Circular dichroism (CD) is a form of absorption spectroscopy widely used to 
determine the structural and folding properties of macromolecules. Circular 
dichroism refers to the difference in absorption of the left and right circularly 
polarized light, which reports on the 3D structural asymmetry (chirality) inherent 
to the molecule under study or induced by the environment. Linearly polarized 
light can be represented as a sum of left and right circularly polarized waves of 
equal amplitude and phase. Chiral molecules including proteins, DNA and many 
other biological macromolecules absorb these components of the polarized light 
to a different extent, resulting in an elliptically polarized light. The ellipticity, is 
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related linearly to circular dichroism and is measured as a function of wavelength 
to record CD spectra,   
The backbone peptide group is the major contributor to the CD spectra of 
peptides and proteins in the far-UV region (185-250 nm). It exhibits a strong band 
around 190 nm (* transition) and a broad band around 210 nm (n* transition), 
specifically determined by the geometry of the peptide bond (angles). 
Therefore, different secondary structures have distinct far-UV CD spectra. Figure 
2.2 shows characteristic far-UV CD spectra for a typicalhelix, -sheet, -turn 
and random coil. CD signal from an -helical protein is dominated by a strong 
negative peak at 222 nm and an overlapping negative peak at 208 nm, along 
with a large positive band centered at 193 nm. -sheet shows a positive peak 
circa 197 nm and a negative peak circa 218 nm, while random coil exhibits a 
prominent negative peak at 203 nm [Woody, 1986]. We have used far-UV CD to 
compare secondary structural changes in variant forms of apoA-I in the lipid-free 
and lipid-bound state. ApoA-I is largely -helical, which makes the structural 
estimation relatively straightforward. However, in lipid-bound forms, the 
secondary structure determination on an absolute scale can be complicated by 
contributions from lipid and UV light scattering by the particles. To mitigate such 
issues, we have largely relied on comparing results of variant forms to the wild 





Figure 2.2 Characteristic far-UV CD spectra of secondary structural elements. 
Each spectrum corresponds to a model peptide that has only one type of 
secondary structure. The spectra at 222 nm are dominated by a signal from an -
helix. This signal, [222], depends linearly on the protein helical content and is 




In an asymmetric environment, the aromatic side chains can show an 
induced CD signal in the near-UV region (250-350 nm) providing information on 
the tertiary structure of the protein. Trp has a peak at 295 nm with a shoulder at 
285 nm, Tyr contributes to the peak at 285 nm, and multiple weak bands 
between 250 nm and 265 nm are attributed to Phe. The disulfide bonds can also 
contribute to near-UV CD around 260 nm ([Woody & Dunker, 1996] and 
references therein). ApoA-I has four Trp (W8, W50, W72 and W108) and seven 
Tyr (Y18, Y29, Y100, Y115, Y166, Y192 and Y236). Since all four Trp and five out 
seven Tyr are located in residues 1-184 that form the N-terminal helix bundle in 
lipid-free apoA-I, near-UV CD of apoA-I reports specifically on the helix bundle 
conformation [Mei & Atkinson, 2011]. We have used near-UV CD to compare the 
aromatic packing in native and mutant forms of apoA-I in lipid-free and lipid-
bound states.  
Changes in CD spectra can also be used to determine thermodynamic 
stability of a biological macromolecule by monitoring CD at a fixed wavelength, 
as a function of temperature, (T), or denaturant concentration, (D). The 
interpretation of such data is straightforward for proteins with a single dominant 
secondary structural motif such as an -helix, whose unfolding can be monitored 
at 222 nm. Thermal unfolding data is used to determine the melting temperature, 
Tm, of a macromolecule, which provides a measure of its thermal stability. For 
thermodynamically reversible transitions, the melting data can also be used to 
determine the van’t Hoff enthalpy of the transition, ΔHv, which provides a 
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measure of the cooperative units within a macromolecule [Pace et al., 1989]. In 
thermodynamically reversible transitions, such as folding/unfolding of lipid-free 
apolipoproteins, the melting data and the transition midpoint, Tm, are independent 
of the rate of heating. Further, the heating and cooling data largely overlap with 
each other [Gursky and Atkinson, 1996a; Gursky et al., 2002]. For 
thermodynamically irreversible transitions, such as lipoprotein denaturation, the 
melting temperature is not an accurate measure of the absolute thermodynamic 
stability, as it depends on the scanning rate and hence, is referred to as apparent 
melting temperature, Tm,app [Gursky et al., 2002]. Tm,app can still be an useful 
parameter to establish the relative rank order of stability within similar systems, 
such as similar-size lipoproteins differing in protein or lipid composition 
[Jayaraman et al., 2008; Gao et al., 2009]. It is, however, essential to maintain 
identical experimental conditions, including sample concentration and the heating 
rate.  
CD can be also used in kinetic experiments to monitor structural changes 
induced by temperature or denaturants as a function of time, (t), at a constant 
wavelength, . This method allows us to monitor the time course of unfolding in 
slow kinetically-controlled transition such as lipoprotein denaturation [Gursky et 
al., 2002]. Such experiments are used to quantitatively determine the unfolding 
rate as a function of temperature, k(T), the Arrhenius activation energy 
(enthalpy), Ea, and the free energy barrier, G*, for the structural transitions, and 
are described in detail in previous lipoprotein studies from our laboratory 
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[Benjwal et al., 2007; Jayaraman et al., 2005; Guha et al., 2008; Gao et al., 
2012]. 
2.4.2 Far-UV and Near-UV CD Measurements 
CD spectra of protein and lipoprotein solutions at 25 °C were measured 
using an AVIV-430 spectropolarimeter (AVIV Biomedical, Lakewood, NJ).  
For far-UV CD (185-250 nm), samples containing 0.05 mg/mL protein in 
standard buffer were placed in a 2 mm cuvette and the data were recorded with 1 
nm step size and 10 seconds accumulation time per data point. At this 
concentration and buffer conditions, apoA-I is predominantly monomeric 
[Barbeau et al., 1979]. Each peptide group in a protein contributes to far-UV CD. 
Therefore, to compare secondary structure of globular proteins varying in 
molecular weight, far-UV CD data is normalized to molar residue concentration. 
Molar residue ellipticity is calculated using the following equation [Woody, 1986]: 
[Θ]222 = Θ222 Mo / (10LC)                                  (Eq 2.3) 
Here Θ222 is measured ellipticity in mdeg, Mo is the mean residue weight of a 
protein (typically 111-117 g/M for a globular protein), L is the cell path length in 
cm and C is the concentration of the protein in mg/mL.  
The signal at 222 nm depends linearly on the -helical content of a 
protein, [Woody, 1986]. Hence the -helical content in our work was estimated 
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from the molar residue ellipticity at 222 nm, [222], using the expression below, 
which assumes that [222] = - 36,000 for 100% -helix and [222] = + 3,000 for 
100% random coil [Mao & Wallace, 1984]: 
% of -helix = {-[222] + 3000} / 39000                        (Eq 2.4) 
For a highly helical protein like apoA-I, the results obtained by this method have 
~5% accuracy, which is mainly limited by the accuracy of the concentration 
determination. Figure 2.3A shows far-UV CD spectra obtained from lipid-free and 
lipid-bound forms of native apoA-I.  
Unlike far-UV CD, the near-UV CD is primarily limited to contribution from 
aromatic residues; therefore, the signal is much weaker than far-UV CD. The CD 
signal is proportional to the path length of light and the protein concentration. 
Hence to improve the signal-to-noise in near-UV CD, more concentrated protein 
solutions and a cuvette with larger path length must be used. For near-UV CD, 
protein stock solutions ranging from 0.5 to 1.0 mg/mL were placed in a 5 mm 
cuvette, the spectra were recorded using 0.5 nm step size and 10 seconds 
accumulation time, and were averaged over three runs. The buffer baselines 
were subtracted, and the spectra were normalized to the molar protein 
concentration. The results were expressed in units of molar ellipticity. Figure 2.3B 




2.4.3 Thermal Unfolding Experiments 
In thermal denaturation experiments,  protein or lipoprotein samples at a 
concentration of 0.05 mg/mL protein were heated and cooled at a constant rate  
of 80 °C h-1  (for free proteins) or 11 °C h-1 (for  lipoprotein complexes). The 
helical unfolding was monitored at 222 nm, 222(T). The melting temperature (Tm) 
for lipid-free proteins and the apparent melting temperature (Tm,app) for lipoprotein 
particles were determined using the peak position of the first derivative function, 
d[222]/dT [John and Weeks, 2000]. For sigmoidal transitions characteristic of 
free proteins, Tm determined by this method corresponded to the transition mid-
point and coincided with the value of Tm determined by the van’t Hoff analysis. 
Figure 2.4A shows thermal denaturation curves for lipid-free and lipid-bound wild 
type apoA-I. 
Thermal unfolding of free apolipoproteins is thermodynamically reversible 
[Gursky & Atkinson, 1996] and hence, only the heating curves of free proteins 
are shown to avoid overlap. Heat denaturation of lipoproteins, on the other hand, 
is thermodynamically irreversible [Gursky et al., 2002; Mehta et al., 2003] and a 
large hysteresis is seen in the melting data. The heating data, which were 
recorded at an identical scanning rate from lipoproteins with similar biochemical 
composition but containing different apoA-I variants, were used to establish the 
rank order of the lipoprotein stability on the basis of their apparent melting 
temperatures. The melting data was analyzed and displayed using ORIGIN  
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Figure 2.3 Far-UV CD spectra of lipid-free WT apoA-I and of apoA-I:DMPC (1,2 
dimyristoyl-sn-glycerol-3-phosphocholine) complexes and near-UV CD spectra of 
WT apoA-I and its point mutant, L159R.  
(A) Far-UV CD spectra for WT lipid-free (solid line) and lipid-bound apoA-I:DMPC 
complex (dotted line) recorded at 25 °C using 0.05 mg/mL protein solution. The 
spectra are typical of highly -helical proteins, with a positive peak at 193 nm and 
negative peaks at 208 and 222 nm. Increase in signal intensity upon lipid binding 
indicates increase in helical content. 
(B) Near-UV CD spectra of full-length apoA-I are dominated by aromatics in the 
helix bundle (residues 1-184 that contain all 4 Trp and 5 out of 7 Tyr). Near-UV 
CD spectra of lipid-free WT apoA-I and its naturally occurring L159R variant 
show significant differences in their aromatic packing, suggesting that the 




software (OriginLab, Northampton, MA). 
Van’t Hoff analysis was done following the classical two-state transition 
model for protein unfolding. The baselines for folded and unfolded states were 
obtained by linear extrapolation of the observed CD signal, [222], from the pre- 
and post-transitional region of the heating data. The equilibrium constant, Keq, 
was measured from the observed CD signal in the transition region using the 
following equation,  
Keq = [U] / [F] = ([222] – [ F]) / ([ u] – [ 222])              (Eq 2.5) 
Here [ 222] is CD signal at a selected temperature T, [ F] and [ U] are linearly 
extrapolated signals from the pre- and post-transitional region, and [U] and [F] 
are concentrations of the unfolded and folded states, respectively. 
Van’t Hoff plots, ln Keq versus 1/T, were created and were approximated 
by a linear function to determine the enthalpy, ΔHv, according to the Van’t Hoff 
equation: 
ln Keq = - (Hv/R) (1/T) + (S/R)                          (Eq 2.6) 
Here R is the universal gas constant with a numerical value of 8.3144598(48) J 
mol−1 K−1, T is temperature in Kelvin, S=SU-SF is change in entropy upon 
unfolding. The slope of the linear plot provides the value of Hv, and the X-axis 
intercept corresponds to 1/Tm. 
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2.4.4 Kinetic Temperature-Jump Experiments 
In kinetic temperature-jump (T-jump) experiments, the rate of protein 
unfolding in lipoproteins was measured as a function of time by using the CD 
signal at 222 nm, 222 (t). The denaturation was triggered by a rapid increase in 
temperature at t=0. Lipoprotein samples containing 0.05 mg/mL protein were 
placed in 2 mm cells, and the temperature was rapidly increased from 25 °C to a 
higher constant value (between 75 °C and 95 °C). The reaction time course was 
monitored with 10 sec increment for up to 21 h. Previous studies from our 
laboratory showed that the temperature-jump data of lipoproteins such as apoA-I: 
DMPC complexes do not depend on the starting temperature or the lipid phase 
(gel or liquid crystalline), only on the final temperature. Thus, the standard 
starting temperature used in our work was 25 °C. T-jumps were recorded from 
fresh samples from the same lipoprotein batch at five to six different final 
temperatures. Figure 2.4B illustrates the kinetics of protein unfolding in DMPC 





Figure 2.4 Thermal denaturation of apoA-I:DMPC discs is a slow 
thermodynamically irreversible transition: melting and kinetic far-UV CD data. 
(A) Melting data recorded at 222 nm for free apoA-I (solid line) or for lipoprotein 
complexes (dotted line). Lipid binding increases the thermodynamic stability of 
apoA-I, as evident from the large increase in the melting temperature 
(Tm,app>>Tm). In contrast to lipid-free protein, thermal denaturation of lipid-bound 
apoA-I is thermodynamically irreversible and involves a hysteresis, i.e. non-
coincidence between the heating and cooling curves. (B) Kinetic far-UV CD data, 
222(t), were recorded at 222 nm from apoA-I:DMPC complexes in T-jumps from 
25 °C to higher constant temperatures ranging from 75 ˚C to 95 ˚C (indicated on 
the lines). The data of DMPC complexes with WT (black) and F71Y (green) 
apoA-I are shown. The results show that the unfolding is faster at higher 
temperatures, indicating high activation energy of thermal denaturation [Gursky 
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et al., 2002]. At each temperature, DMPC disks containing the mutant protein 
show slightly faster unfolding suggesting slightly lower structural stability as 




2.5 Fluorescence Spectroscopy 
Fluorescence spectroscopy is a versatile and powerful tool for structural 
and physicochemical studies of biological molecules. In our work, steady-state 
fluorescence measurements using intrinsic (Tyr, Trp) and extrinsic fluorophores 
(optically active dyes) were performed to compare tertiary structural features of 
apoA-I variants and obtain better insights into structural changes induced by 
mutations. The fluorophores used in our work are shown in Figure 2.5. All 
measurements were performed on a Fluoromax-5 fluorescence 
spectrophotometer (Instruments S.A. Inc.).  
2.5.1 Intrinsic Protein Fluorescence 
The aromatic amino acids (Phe, Trp, and Tyr) contribute to the intrinsic 
protein fluorescence. In proteins that contain both Tyr and Trp, the dominant 
fluorescent signal comes from Trp due to energy transfer from Tyr to Trp [Teale 
& Weber, 1957; Lacowicz, 2006]. The high extinction coefficient and 
fluorescence quantum yield paired with extreme sensitivity to local environment 
make Trp a useful probe for monitoring label-free protein structure [Pierce & 
Boxer, 1995; Lacowicz, 2006]. Owing to their largely apolar nature, Trp residues 
are often buried fully or partially in the hydrophobic core or are located at the 
domain interface or at the protein-lipid interface. However, disruption in structure 
upon mutation or chemical or physical perturbation can increase solvent 
exposure of Trp residues [Royer, 2006]. Such conformational changes can be 
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observed as a red shift in Trp emission spectra resulting from a high dipole 
moment of its excited state, which is sensitive to the local environment. As a 
result, the positions of the emission maxima of Trp can range from about 309 nm 
(in the hydrophobic protein interior) to a more typical value circa 335 nm (partially 
buried). A fully exposed Trp in water has an emission maximum at 355 nm 
[Reshetnyak et al., 2001]. While unfolding invariably results in red shift of 
emission spectra, the effect on emission intensity is harder to predict because of 
interactions with the peptide main and side chain and the possibility of energy 
transfer. However, in the absence of any major quenching in the native state, 
unfolding leads to solvent quenching of Trp residues resulting in an overall 
reduction in emission intensity [Roumestand et al., 2001].  
In apoA-I, the four-helix bundle (in residues 1-184) contains all four Trp 
(W8, W50, W72 and W108) and five out of seven Tyr (Y18, Y29, Y100, Y115, 
Y166). The remaining two Tyr (Y192 and Y236) are located in the flexible C-
terminal tail. Therefore, the emission spectra of apoA-I report on the aromatic 
packing in the helix bundle. In our study, small changes in these spectra were 
used to assess mutation-induced conformational changes in the bundle.  
For intrinsic aromatic fluorescence of apoA-I, proteins at a concentration 
of 0.05 mg/mL were excited either at 295 nm (to selectively excite Trp but not 
Tyr) or at 280 nm (where all aromatics absorb) and the emission spectra were 
recorded at 300 - 500 nm. The buffer baselines were subtracted and the data 
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were normalized to protein concentration and displayed using ORIGIN software. 
The results were correlated with near-UV CD spectra that provide 
complementary information on the protein tertiary structure. 
2.5.2 ANS Binding 
ANS (1-anilinophthalene-8-sulfonate) is an apolar fluorescent probe that 
binds to large solvent-accessible hydrophobic cavities that are found in molten-
globular folding intermediates but are typically absent from the fully folded or fully 
unfolded globular proteins [Lacowicz, 2006]. ANS binding to a protein increases 
fluorescence emission due to decreased quenching by the solvent. In our 
studies, ANS binding was used to assess overall conformational changes in 
solvent-accessible surfaces in apoA-I, which were caused by mutations. 
To compare solvent-accessible hydrophobic surfaces in apoA-I variants, 
emission spectra were recorded by adding ANS in standard buffer to protein. The 
final concentrations were 0.25 mM ANS and 0.05 mg/mL apoA-I. The probe was 
excited at 395 nm and the emission spectra were recorded at 400-600 nm. The 
excitation and emission slit widths were 5 nm and 2.5 nm, respectively. ANS 









2.5.3 Thioflavin T (ThT) Binding 
Thioflavin T is an external fluorescent probe that binds to -sheet rich 
structures such as amyloid aggregates and exhibits enhanced fluorescence due 
to reduced solvent quenching [LeVine, 1999]. ThT is widely used to monitor 
amyloid formation in real time [Khurana et al., 2005; Krebs et al., 2005]. 
However, ThT binding and increased fluorescence is not limited to amyloid and 
was detected in other systems such as lipid micelles and lipoproteins [Nielsen et 
al, 2001; Jayaraman et al., 2011]. As a result, this dye should be used with 
extreme caution in lipoprotein studies. Still, in the absence of lipids or other 
hydrophobic molecules, ThT binding/fluorescence provides a useful tool to 
monitor amyloid fibril formation, especially if combined with other methods, such 
as fibril visualization by electron microscopy used in our study.  
ThT was used to monitor fibril formation in a peptide fragment 
corresponding to apoA-I residues 9-28 (DRVKDLATVYVDVLKDSGRD), which 
encompasses the major predicted amyloid “hot spot” (apoA-I residues 14-22). 
The lyophilized peptide was freshly diluted to the final concentration of 100 mM. 
To this solution, 10 mM of ThT in standard buffer (10 mM phosphate buffer, 
pH=7.5) was added to a final volume of 100 l. After 10 minutes of incubation at 
25 °C, the probe was excited at 444 nm and the spectra were recorded from 450 




2.6 Limited Proteolysis 
Limited proteolysis is often used to probe structural features of a protein 
[Fontana et al., 2004]. Some common applications include probing flexible 
regions within a protein, analyzing partly folded states and identifying protein 
regions forming the amyloid core. In our studies, limited proteolysis was used to 
understand conformational changes in apoA-I by identifying the changes in the 
cleavage pattern upon mutations. 
Limited proteolysis was performed by incubating lipid-free WT or mutant 
apoA-I with trypsin (substrate:enzyme weight ratio 500:1) in standard buffer at 25 
°C in a shaking water bath. Aliquots were collected at various time points during 
the first hour of incubation. To stop the reaction, SDS gel loading buffer was 
added to each aliquot, followed by immediate heating and incubation at 100 °C 
for 2 min. The proteolytic products were separated on SDS PAGE using 10-20% 
Tris/Tricine system. The gels were stained with Denville blue protein stain. 
 
2.7 DMPC Clearance Kinetics 
The ability of apoA-I variants to bind to multilamellar vesicles of DMPC 
and remodel them into smaller particles was monitored at 24 °C by turbidity at 
350 nm using a Varian Cary-300 UV/Vis spectrophotometer (Agilent 
Technologies Inc., Santa Clara, CA, USA). The liposomes were prepared by 
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using the thin-film evaporation method [Jonas, 1986]. Lipid films were made by 
dissolving 3-7 mgs of DMPC powder in 2:1 chloroform: methanol (v/v) solution, 
followed by drying under a steady stream of nitrogen. DMPC films were stored 
for 12 hours or more in vacuum at 4 ˚C to eliminate traces of the solvent. For 
measuring clearance kinetics, the lipid film was brought up to room temperature 
and re-suspended in standard buffer by vortexing until completely suspended. 
Next, 0.05 mg/mL protein in standard buffer was added to 0.2 mg/mL DMPC and 
the decrease in turbidity at 350 nm, which resulted from remodeling of liposomes 
(>1000 nm) into smaller lipoprotein particles (~12 nm), was monitored for at least 
1 hour. Since lipid-free apoA-I is fully monomeric under these conditions, protein 
self-association did not interfere with protein-lipid binding and clearance. The 
plots of turbidity as a function of time were compared for apoA-I variants to 
establish the rank order of the clearance rate. 
 
2.8 Lipoprotein Reconstitution 
Model lipoproteins were obtained by spontaneous reconstitution. DMPC 
was purchased from Avanti Polar Lipids. DMPC complexes with apoA-I variants 
were obtained upon overnight incubation at 24 °C using 4:1 lipid to protein weight 
ratio. The incubation temperature was close to the temperature of the gel to liquid 
crystal phase transition of DMPC where lipid dissolution is fast [Cullis et al., 
1991]. Uncomplexed lipid was removed by centrifugation at 12000 x for 20 min. 
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Lipoprotein formation was confirmed using non-denaturing gel electrophoresis 
and negative-stain electron microscopy. 
 
2.9 Negative-Stain Electron Microscopy 
Negative-stain transmission electron microscopy (EM) was used to 
visualize protein-lipid complexes and amyloid fibers at 24 °C. 300 mesh copper 
grids were coated with films made from 0.18-0.25 % formvar and carbon. Prior to 
loading the sample, the grids were cleaned and the surface was made 
hydrophilic by glow discharge. Sample solutions (4 L) containing lipoproteins or 
protein fibers were incubated on the grids for 10 seconds and excess liquid was 
removed by blotting. This was followed by immediately staining the samples with 
1% w/v sodium phosphotungstate at pH 7.4 (4 L) for 10 seconds. Excess stain 
was removed by blotting and the grids were air-dried. Images were recorded 
using a CM12 transmission electron microscope (Philips Electron Optics, 
Eindhoven, Netherlands). Figure 2.6 shows typical EM images obtained from 
reconstituted apoA-I:DMPC particles. These experiments were done with help 







Figure 2.6 Electron micrographs of negatively-stained apoA-I:DMPC disc.  
To the left of the EM image is a cartoon representing “discoidal” DMPC particles 
formed by apoA-I. ApoA-I helices (red) wrap around the lipids to screen them 
from solvent in an antiparallel helical double belt [Borhani et al., 1999]. 





2.10 Fibril Formation by Peptide Fragment of apoA-I 
The peptide fragment corresponding to apoA-I residues 9-28 
(DRVKDLATVYVDVLKDSGRD), which encompasses the major predicted 
amyloid “hot spot” residues 14-22, was used in fibril growth experiments. The 
peptide was obtained commercially by solid-state synthesis and purified by HPLC 
to 95%+ purity, followed by buffer exchange to remove organic solvent. The N- 
and C-termini of the peptide were not blocked. The amino acid sequence was 
confirmed by mass spectrometry.  
Freshly prepared stock solution (5.0 mg/ml peptide in 100 mM Na 
phosphate buffer, pH 7.4) was diluted to prepare samples varying in peptide 
concentration (0.1-0.5 mg/ml), pH (6.8-7.4) and salt (0-150 NaCl). The samples 
were incubated with and without stirring for up to 17 days and were monitored for 
amyloid formation by EM and by ThT binding / fluorescence. 
 
2.11 Cellular Cholesterol Efflux Assay 
  To understand the influence of apoA-I variants on the early rate-limiting 
steps of reverse cholesterol transport (RCT), which are particularly important for 
cardioprotection, we performed a cholesterol efflux assay [Wang et al., 2000; 
Sankaranarayanan et al., 2011]. RCT starts with cholesterol efflux from cells to 
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monomeric lipid-poor / free apoA-I, mediated by lipid transporter ABCA1 (ATP 
binding cassette transporter) [Phillips, 2014].  
For the cholesterol efflux assay, mouse macrophages (J744 cell line) 
expressing ABCA1 endogenously were plated in 24-well plates using RPMI 
(Rosewell Park Memorial Institute) growth media at 37 °C. After the cells reached 
a confluent stage (usually in 24 hours), they were labelled using BODIPY (boron 
dipyrromethene) -cholesterol, in RPMI media with 0.02% albumin. The BODIPY-
cholesterol was complexed with methyl--cyclodextrin at a 1:30 ratio to increase 
the efficiency of the uptake by cells. After one hour of labeling, the media were 
removed and the cells were washed with media to remove traces of BODIPY-
cholesterol that was not taken up by the cells. The ABCA1 in labeled cells was 
then upregulated using CPT (8-(4-chlorophenylthio) adenosine 3′,5′-cyclic 
monophosphate sodium salt) overnight. CPT is a membrane-permeable analog 
of cAMP (cyclic adenosine 3′,5′-cyclic monophosphate) that upregulates the 
expression of ABCA1 on the membrane surface [Lawn et al., 1999; Bortnick et 
al., 2000]. Following upregulation, the cells were treated with apolipoprotein 
acceptors in media A [MEM (minimum essential medium) with HEPES (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid) modification with 0.1% albumin] 
at a concentration of 10-30 g/mL to initiate lipid efflux. Change of media from 
RPMI to MEM was used to reduce any inherent contribution to the fluorescent 
signal. As acceptors, we used WT and mutant forms of lipid-free apoA-I. The 
efflux was carried out for 24 hours. The efflux media was removed, filtered and 
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the fluorescence intensity was recorded using an Infinite M1000 plate reader 
(excitation 490 nm, emission 520 nm). The cell monolayer was solubilized with 
1% sodium cholate on a plate shaker for up to 4 hours and the fluorescence 
intensity was recorded. Efflux was reported as percentage of total labelled 
cholesterol uptake. The non-upregulated cells as well as those that did not 
receive any acceptor served as negative controls. To measure efflux over time, 
aliquots of the efflux media were collected at set time points followed by 
fluorescence measurements. These experiments were done under the direction 
and with help of Dr. Haya Herscovitz. 
 
2.12 Western Blotting 
To visualize the particles formed during the cholesterol efflux assay, from 
cells to apoA-I acceptors, Western blotting was performed using mouse apoA-I 
antibodies and cholera toxin B (CTB) as probes. Briefly, the filtered efflux media 
was loaded and run on a 4-20% gradient native gel using Hoefer SE260 Bio-Rad 
vertical system for 1.5-3 hours at 150 V. Proteins on the gel were transferred to a 
polyvinylidene fluoride (PVDF) membrane. The conditions for transfer were 1 h at 
100 V. The PVDF membrane was then incubated in blocking buffer (non-fat milk 
in buffer containing 10 mM Tris HCl, pH 7.5, 0.1% v/v 150 mM NaCl, 0.05% w/v 
Tween-20) and was probed with primary antibodies to apoA-I. Washed PVDF 
membranes were then probed with horseradish peroxidase (HRP)-conjugated 
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secondary antibodies and were visualized using an enhanced chemiluminescent 
system (Perkin Elmer.  
 
2.13 Bioinformatics Tools 
Until 1990s, protein misfolding from a native functional conformation to 
aberrant cross-sheet rich fibrils was thought to be limited to a small number of 
disease-related proteins such as prions or Alzheimer’s amyloid-. However, more 
recent observations of amyloid formation in vitro and in vivo by a wide variety of 
unrelated proteins and peptides have promulgated the idea that the ability to form 
amyloid is a ubiquitous property of the polypeptide chain encrypted within the 
amino acid sequence [Sipe et al., 2014]. Studies pioneered by David Eisenberg 
and colleagues have suggested that amyloid formation is initiated by a limited 
number of 4- to 10-residue segments, or “hot spots”, that have high intrinsic 
propensity for -aggregation [Ventura et al. 2004; Thompson et al. 2006; Tzotzos 
& Doig 2010]. Currently there are over 20 sequence-based algorithms available 
to predict such segments. Some of the widely used ones include Tango, Waltz, 
Aggrescan, Zyggregator, 3D Rosetta-based method, FoldAmyloid and PASTA 
(Table 2.2). These algorithms rely on the application of a wide range of criteria, 
such as the side chain hydrophobicity, charge distribution, average packing 
density, dual -helix and -sheet propensity, hidden -helix to -sheet switches, 
-sheet contiguity, correspondence to known amyloidogenic residue patterns, 
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etc. ([Das & Gursky, 2015; Dovidchenko & Galitskaya, 2015] and references 
therein). The inherent complexity in the process of -aggregation and fibril 
formation makes the prediction difficult and necessitates the use of multiple 
criteria and approaches to improve the prediction accuracy. To optimize the 
selectivity and specificity of the prediction, i.e. to minimize the probability of false 
positives and negatives, a consensus method termed AmylPred has been 
developed by Hamodrakas and colleagues. The consensus analysis has the 
advantage of balancing the specificity and sensitivity in the hot spot prediction. 
High specificity means low probability of predicting too many amyloid-prone 
segments (few false positives) while high sensitivity means low probability that 
such segments are mistakenly omitted (few false negatives). These criteria are 
discussed in chapters 3 and 5. 
In our apolipoprotein studies, we used AmylPred and its expanded 
version, AmylPred2 [Tsolis et al. 2013], which combines 11 individual algorithms 
and is one of the most reliable prediction meta-servers currently available 
[Dovidchenko & Galitskaya, 2015]. The algorithms included in Amylpred2 are 





Table 2.2 Individual algorithms used in the consensus sequence-based amyloid 




The prediction process involves submitting the protein sequence to the 
meta-server (http://aias.biol.uoa.gr/AMYLPRED2). The data output includes the 
amyloidogenic profile, i.e. the number of algorithms predicting amyloid-forming 
propensity versus residue number. If residue segments are predicted to form 
amyloid by five or more out of eleven methods, they are termed major hot-spots 
In addition, we used amyloid prediction software PASTA [Trovato et al. 
2007; Walsh et al. 2014] and its expanded version, PASTA 2.0 [Walsh et al. 
2014], which is one of two most reliable tools that are not meta-servers 
[Dovidchenko & Galitskaya, 2015]. PASTA is unique in identifying not only the 
amyloidogenic segments but also estimating the free energy of their pairing, and 
thereby predicting the energetically favored amino acid register and the -strand 
orientation, parallel or antiparallel. This important feature helped us to propose a 
molecular mechanism of apoA-I misfolding, which is described in Chapter 3 and 
in [Das et al., 2014].  Our analysis was based upon the assumption that a reliable 
prediction of the -sheet pairing corresponds to favorable (negative) PASTA 
energy of -4 units or lower (1 PASTA energy unit = 1.192 Kcal/mol). This 
threshold value corresponds to 73.8% sensitivity and ~15% selectivity, reflecting 
the respective rates of false negatives and positives [Walsh et al., 2014]. In our 
work, we focus on segment pairings with PASTA2.0 energy circa -4 or lower as 
possible amyloid hot spots. The results of predictions by PASTA2.0 and by 
AmylPred2 were compared, for the total of 12 prediction methods. Figure 2.7 





Figure 2.7 Amyloid hot spots predicted in a small human apolipoprotein, apoC-II. 
(A) Amylpred2 predicts two hot spots with 5 or more hits. These include residues 
16-17 (up to 5 hits) and 62-76 (up to 9 hits). (B) Residues 62-75 are also 
predicted to have strong -aggregation propensity by using PASTA2 server. 
Moreover, PASTA2 also predicts that the most energetically favorable 
arrangement of these residues in amyloid is parallel in-register -sheets. From 




“hot spots” in residues 16-17 and 62-76. Similar results for apoA-I are discussed 
in Chapter 5. Importantly, all predictions of amyloid hot spots in human apoA-I 
have been verified experimentally in the peptide fragment studies by us and 
others [Adachi et al., 2014; Das et al., 2014; Mendoza-Espinsosa, 2014; Louros 
et al., 2015].  
 
2.14 Hydrogen Deuterium Exchange Mass Spectrometry 
 Hydrogen deuterium exchange (HDX) detected by mass spectrometry 
(MS) is a valuable tool to analyze protein structure, folding and dynamics. The 
underlying principle relies on the difference in the rate of exchange of amide 
hydrogen for deuterium between well-ordered and disordered regions of a 
polypeptide chain. Because the side chains exchange deuterium for hydrogen 
very fast, most studies focus on the backbone exchange, i.e. backbone amide 
hydrogens. The overall work flow for HDX MS is shown in Figure 2.8 and is 
discussed below.  
All amino acids in a protein, except for proline and the N-terminal residue, 
contain an N-H bond. Backbone amide hydrogen atoms can be replaced by 
deuterons within 10 secs of a peptide being incubated in D2O at pD 7.0 ([Wales 
& Engen, 2006] and references therein). This exchange is modulated uniquely by 
the local protein conformation and dynamics. While the exchange is fast in 
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unfolded regions, regions with extensive hydrogen bonding and restricted solvent 
access exhibit slow exchange with half-lives that can extend to months. In fact, 
exchange rates in slowly exchanging amide hydrogens can be reduced by up to 
10-8 times of their unfolded counterpart in the same protein [Englander & 
Kallenbach, 1983]. The exchange occurs as a result of structural fluctuations 
within a protein facilitated by short-lived open conformations. The rate of 
opening/ closing events, either global or local, determines the amount of 
deuterons incorporated in various segments.  The overall exchange mechanism 
can be described by the following equation ([Konermann et al., 2011] and 
references therein)  




N − H (open)
kex




N − D(closed)    (Eq 2.7) 
        
Here kop, kcl, kex are the rate constants for opening, closing and exchange events. 
Their values can be unique for every N-H bond in a protein. If kex>>kcl, this 
implies that the exchange can occur in the first opening event and the 
phenomenon is called EX1 kinetics. On the other hand, if kex<<kcl, multiple 
opening and closing events occur before amide hydrogen exchanges. This is 
called EX2 kinetics. Under physiological conditions, EX2 kinetics is observed 
more frequently than EX1 [Konermann et al., 2011]. These types of exchange 
can be readily distinguished by mass spectrometry. [Miranker et al., 1993]. 
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 Most HDX studies, including ours, utilize a continuous labelling method 
whereby the deuterium incorporation is monitored as a function of time that can 
range from few seconds to hours. The increase in mass of a protein is 
determined. Spatially resolved experiments can give information on the 
conformation and dynamics within different regions of the protein.  
The amount of deuterium incorporated is detected by a classic 
combination of proteolysis and mass spectrometry, also called bottom-up 
approach [Zhang & Smith, 1993]. Typically, continuous labeling is followed by 
acid quenching and the protein is subjected to limited proteolysis in the presence 
of an acid-tolerant protease such as pepsin.  The non-selective nature of acid 
proteases makes it necessary to perform tandem MS prior to actual HDX 
measurement ([Konermann et al., 2011] and references therein). The proteolytic 
fragments are then analyzed by electrospray ionization (ESI) mass spectrometry 
revealing relative deuterium uptake in different regions. Quenching and 
subsequent steps are performed at about 0 ˚C to prevent back exchange of the 
incorporated deuterium. For the same reason, the proteolysis and 
chromatographic separation are conducted in minimal time. High rates of the 
back exchange from the side chains prohibit extraction of any meaningful 
information. 
In our studies, we have used HDX MS to compare local dynamics in 
variant forms of apoA-I. All HDX MS experiments were performed and analyzed 
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by Christopher Wilson in the Engen laboratory at Northeastern University. The 
methodology used in the experiments is outlined below. 
Stock solutions of apoA-I were diluted to 1 mg/ml in equilibration buffer (10 
mM potassium phosphate, 150 mM NaCl, pH 7.0, H2O). Continuous labeling was 
initialized independently for each protein with an 18-fold dilution into D2O buffer 
(10 mM potassium phosphate, 150 mM NaCl, pD 7.0) at 4 °C.  Exchange was 
allowed to proceed for predetermined times, from 5 seconds to 4 hours, 
whereupon labeling was quenched with a 1:1 (volume) dilution with 0 °C quench 
buffer (150 mM potassium phosphate, pH 2.4, H2O). Quenched protein was 
immediately frozen on dry ice and held at -80 °C until analysis (within 5 days).  
Steps following the sample quenching were performed at 0 °C to limit deuterium 
back-exchange.  Frozen samples were gently thawed to 0 °C and immediately 
digested for 5 min on ice with a pepsin solution (10 mg/mL pepsin, H2O) at a 1:5 
protein:pepsin molar ratio.  Each digested protein (~75 pmol) was injected into a 
Waters NanoAcquity UPLC with HDX technology, and peptides were separated 
on a Waters BEH C18 analytical column during a 6 minute, 5-35% 
water:acetonitrile gradient.  A Waters Synapt G2 mass spectrometer equipped 
with a standard ESI source was used for mass analysis. Peptic fragments were 
identified with a combination of exact mass measurement and MSE by the 
ProteinLynx Global Server (PLGS) 3.0 software (Waters).  All deuterium level 












Figure 2.8 Schematic representation of the work flow in HDX MS. 
Exchange of HD begins when the protein is placed in D20 (red). The exchange 
is terminated by quenching after a predetermined time period (seconds to hours). 
The labeled protein is proteolyzed and peptide fragments are subjected to mass 





Chapter 3 Probing the Molecular Mechanism of ApoA-I Destabilization and 




Previous structure-based studies from our laboratory have suggested that 
amyloidogenic mutations may have multiple potential effects leading to apoA-I 
misfolding [Gursky et al., 2012]. The mutations may: i) decrease the protein’s 
affinity for lipid and promote dissociation of free apoA-I from HDL; ii) destabilize 
the helix bundle structure in free apoA-I and increase its susceptibility to 
proteolysis between residues 80 and 100 to release N-terminal fragments found 
in amyloid deposits in humans; iii) increase solvent accessibility of the extended 
residue segment 44-55 that was proposed to initiate α-helix to β-sheet 
conversion [Gursky et al., 2012]. To determine experimentally whether the 
amyloidogenic mutations actually exert these effects, we have analyzed the 
structural stability, proteolytic susceptibility and lipid interactions of full-length 
recombinant human AApoAI mutants. Two common mutants described in this 
chapter contain point mutations in the middle of (W50R) or adjacent (G26R) to 




Figure 3.1 Locations of the amyloidogenic mutations in the proposed structure of 
lipid-free apoA-I  
Proposed structure of lipid-free apoA-I monomer obtained from the dimer structure 
via the domain swapping (indicated by circular arrows) of residues 121-184 (in teal) 
from molecule 2 to molecule 1 around the 2-fold axis. Thin irregular line represents 
C-terminal residues 185-243 that are largely unfolded in solution and have been 
deleted from (185-243)apoA-I to facilitate crystallization [Mei & Atkinson, 2011]. 
Extended segment in residues 44-55 is in red. The cleavage sites between residues 
83 and 100, which are characteristic of the protein fragments found in patient-
derived amyloid deposits, are indicated; X indicate major cleavage sites upon 
processing of free apoA-I by the broad-specificity proteases. Locations of the two 
mutations studied in this work, G26R and W50R, are shown. Adopted from [Gursky 
et al., 2012]. 
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AApoAI mutant G26R, also known as apoA-IIowa, was the first 
amyloidogenic mutant of apoA-I to be identified in an Iowa kindred of British 
ancestry [Van Allen, 1969] and studied at a molecular level [Nichols et al., 1988]. 
This finding was followed by the discovery of several other amyloidogenic 
mutants, including W50R [Booth et al., 1995]. ApoA-IIowa has been used in 
several studies to gain a mechanistic insight into apoA-I misfolding. While G26R 
results from a single base mutation of guanine to cytosine in exon 3, W50R is 
caused by thymine to cytosine substitution in exon 4. The patients with G26R 
mutation in their genome exhibit neuropathy and nephropathy, whereas in 
patients carrying W50R mutation the liver is usually the main site of amyloid 
deposition. Both G26R and W50R mutations are associated with 
hypoalphalipoproteinemia, i.e. reduced levels of apoA-I and HDL in plasma 
[Nichols et al., 1969; Booth et al., 1995; Rader et al., 1992; Sorci-Thomas & 
Thomas, 2002]. 
We have determined the effects of G26R and W50R mutations on the 
stability of the full-length protein in solution and on reconstituted HDL, and 
mapped the residue segments predicted to promote or prevent amyloid formation 




3.2 Effects of G26R and W50R Mutations on the Structural Stability of Lipid-
Free ApoA-I  
Circular dichroism spectroscopy was used to analyze the structure and stability 
of full-length lipid-free apoA-I. Figure 3.2A shows far-UV CD spectra for the 
mutants and wild type apoA-I. While G26R mutation caused a marginal, ~3% 
reduction in the α-helical content, W50R mutation did not affect the helical 
content of apoA-I compared to WT. Figure 3.2B shows the thermal denaturation 
curves for the mutants and WT apoA-I. Both mutations caused a decrease in the 
melting temperature by approximately 3 °C, suggesting a small reduction in 
stability. This agrees with the previous studies of G26R apoA-I that reported a 
slight reduction in the helical content and stability of this mutant [Lagerstetd et al., 
2007; Ramella et al., 2012; Adachi et al., 2013]. Our melting data also showed 
that G26R mutation reduced the unfolding cooperativity, which can potentially 
augment protein misfolding [Dumoulin et al., 2005]. W50R showed comparable 
or smaller effects than G26R on the secondary structure, stability and unfolding 
cooperativity of lipid-free apoA-I, suggesting that the W50-K23 π-cation 
interaction observed in the crystal structure [Mei & Atkinson, 2011] contributes 
little to the overall conformation and stability of lipid-free protein in solution. 
Interestingly, similar studies of several naturally-occurring, non-amyloidogenic 
mutants, including apoA-I Milano (R173C) and Nichinan (ΔE235), showed 
comparable or larger decrease in the helical content, structural stability and 





Figure 3.2 Secondary structure and stability of lipid-free apoA-I analyzed by far-
UV CD.  
(A) Far-UV CD spectra of recombinant human WT, G26R and W50R apoA-I 
were recorded at 25 °C. The -helix content estimated from these spectra is 52% 
for WT, 51% for W50R, and 49% for G26R. The overall accuracy in the 
determination of the -helical content is ~5%. (B) Heating data of free proteins 
were recorded at a rate of 80 °C/h. The melting temperature (Tm) determined 
from these data is reported as mean±SE, which reflects the accuracy in data 
fitting. Tm is 63±0.5 ˚C for WT, 60±0.9 ˚C for W50R and 61±0.7 ˚C. G26R also 
shows a more gradual heat-induced change in CD signal indicating reduced 
cooperativity. From [Das et al., 2014].  
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et al., 2009; Kono et al., 2010; Weers et al.; 2011]. Therefore, a decrease in 
stability alone does not necessarily lead to amyloidosis. 
 
3.3 Effect of Mutations on Limited Proteolysis of ApoA-I 
To test whether AApoAI mutations promote the release of the N-terminal 
9-11 kDa proteolytic fragments, we performed limited tryptic digestion of free 
protein whose products have been well-characterized for WT apoA-I [Ji & Jonas, 
1995] but not for the AApoAI mutants. Trypsin and other broad-specificity 
proteases have multiple cleavage sites in apoA-I as shown in Figure 3.3 Initially 
these enzymes process WT at two flexible sites, one near G185, G186 and 
another in the central part in helix 5, producing a ~22 kDa and a 14 kDa 
fragment, respectively, followed by the generation of shorter fragments resulting 
mainly from proteolysis of the flexible C-terminal part [Ji and Jonas, 1995; 





Figure 3.3 Schematic representation of the major proteolytic products of apoA-I. 
ApoA-I is 28 kDa protein, which is cleaved at Gly containing flexible sites (shown 
by arrows) by common proteases. Major early proteolytic products contain one 
22 kDa fragment (cleaved near G186) or two 14 kDa fragments (cleaved in the 
middle of the molecule between residues 121 and 142). Specific proteases 
cleaving apoA-I in AApoAI are yet to be identified. Vertical bars represent 11/22-
mer residue repeats in apoA-I sequence with residues 1-43 (encoded by exon 3) 
represented in darker shade of gray. Green segment represents AApoAI 




1999; Eberini et al., 2002; Lagerstedt et al., 2007]. Figure 3.4 shows the time 
course of proteolysis as monitored by SDS-PAGE. The major tryptic fragments 
were formed at comparable rates in WT and mutant apoA-I. There were also 
subtle differences; perhaps the most relevant to AApoAI was the observation that 
W50R mutant showed a well-defined ~9 kDa band (arrow in Figure 3.4C) that 
was not detected in WT (Figure 3.4A) and was less well-defined in G26R apoA-I 
(Figure 3.4B). This was the only band matching in size to the N-terminal 
fragments found in AApoAI deposits in patients [Obici et al., 2006]. In summary, 
G26R and W50R mutations had little effect on the overall rate of proteolysis, and 
G26R did not significantly enhance the release of the 9-11 kDa fragments, 
consistent with the previous proteolytic studies of this mutant using matrix 
metalloproteinase 12, MMP-12 [Ramella et al., 2012]. 
 
3.4 Effect of Mutations on Protein-Lipid Interactions 
To test the ability of lipid-free proteins to bind to a phospholipid bilayer and 
remodel it into rHDL, we monitored the clearance of multilamellar vesicles of the 
model phospholipid, DMPC, at 24 °C by turbidity. As shown in Figure 3.5A, lipid 
clearance was slightly retarded for G26R and slightly increased for W50R when 
compared to the WT apoA-I. Therefore, AApoAI mutations did not necessarily 
decrease the protein’s ability to bind to a phospholipid surface and form 














Figure 3.4 Time course of limited tryptic digestion of lipid-free WT and mutant 
apoA-I.  
The proteins were incubated with trypsin for 0-40 minutes (indicated at the 
bottom of each panel), the products were separated on SDS-PAGE. Molecular 
weight standards (St) are indicated. Full-length apoA-I (28 kDa) and its two major 
proteolytic fragments, 22 kDa and 14 kDa are indicated. Bracket shows the range 
where the acidic N-terminal 9-11 kDa fragments are expected to migrate. Arrow 




3.5B show that W50R and G26R readily formed rHDL with DMPC, which were 
comparable in size to similar WT-containing complexes (~12 nm). 
To test the effects of AApoAI mutations on rHDL stability and apoA-I 
dissociation from the lipid surface, WT and mutant proteins were reconstituted 
into complexes with DMPC, and the structure and stability of these complexes 
were analyzed by CD. (Figure 3.6). Far-UV CD spectra of these complexes 
(Figure 3.6A) showed that G26R caused a ~5% reduction in the protein’s α-
helical content on the rHDL particles, while W50R did not. CD melting data, 
exhibited in figure 3.6B, showed comparable apparent melting temperatures for 
the WT and mutant rHDLs. As noted in Chapter 2, lipoprotein stability is subject 
to kinetic control. Therefore, we carried out kinetic temperature-jump experiments 
that are particularly sensitive to small changes in lipoprotein stability [Mehta et 
al., 2003]. The results in Figure 3.7 showed that the unfolding rate increased with 
increasing temperature indicative of reduced kinetic stability. Further, G26R 
(Figure 3.7C) and W50R (Figure 3.7B) mutations had no detectable effect on the 
stability of apoA-I: DMPC complexes. Since rHDL destabilization involves 
lipoprotein fusion and apoA-I dissociation [Guha et al., 2008, Gursky, 2013], we 






Figure 3.5 Effects of the mutations on apoA-I binding to lipid.  
(A) Time course of DMPC clearance by WT and mutant apoA-I. The proteins 
were added to aqueous suspensions of DMPC liposomes at t=0, and the 
remodeling of these liposomes into smaller lipoproteins was monitored by 
turbidity. (B) Electron micrographs on negatively-stained “discoidal” complexes 
reconstituted from apoA-I and DMPC. The complexes are seen face-up or 
stacked on edge (bottom). The results show that, although G26R slightly retards 
and W50R slightly accelerates DMPC clearance as compared to WT apoA-I, all 





Figure 3.6 Secondary structure and stability of lipid-bound full-length apoA-I 
variants analyzed by circular dichroism.  
(A) Far-UV CD spectra of apoA-I:DMPC complexes at 25 °C. The -helix content 
estimated from these spectra is 74% for WT, 73% for W50R, and 67% for G26R. 
Accuracy of helical content determination is 5%. (B) Heating and cooling data of 
apoA-I:DMPC complexes recorded at a rate of 80 °C/h show a 
thermodynamically irreversible transition. The apparent transition temperature, 
Tm,app, suggest similar structural stability. Tm,app  is 84.1±0.05 °C for WT, 82.1±0.1 





Figure 3.7 Comparison of the thermal unfolding kinetics of DMPC complexes 
with recombinant human wild type (WT) and mutant apoA-I. 
Thermal denaturation of these complexes was triggered by a rapid increase in 
temperature from 25 °C to a higher constant value ranging from 75 to 95 °C 
(indicated on the lines). The time course of protein unfolding, which is coupled to 
protein dissociation from the lipid and lipoprotein fusion, was monitored by CD 
signal at 222 nm, [222](t). The results show no detectable difference in the 
kinetic stability of DMPC complexes with WT apoA-I or its two amyloidogenic 




3.5 Summary of the Experimental Studies of G26R and W50R apoA-I 
Our results show that AApoAI mutations can either slightly reduce (G26R) 
or slightly increase (W50R) the protein’s ability to recruit lipids and form rHDL 
(Figure 3.5). Further, the mutations do not destabilize apoA-I on rHDL and do not 
promote dissociation of free protein from these rHDL particles (Figure 3.6, 3.7). 
Moreover, the effects of G26R and W50R mutations on the conformation and 
stability of free apoA-I are comparable or smaller than the destabilizing effects of 
certain non-amyloidogenic mutations such as Milano or Nichinan [Alexander et 
al., 2009; Kono et al., 2010; Weers et al., 2011], indicating that such 
destabilization alone is insufficient to cause amyloidosis. Finally, the G26R 
mutant shows little increase in the production of the 9-11 kDa fragments (Figure 
3.4) that could potentially contribute to amyloidosis. Together, our results 
suggests that the amyloidogenic properties of the apoA-I mutants result, at least 
in part, from factors other than their reduced affinity for lipid, reduced stability of 
the dissociated proteins in solution, or increased production of their N-terminal 
fragments. These results prompted us to search for additional triggers of protein 




3.6 Analysis of Aggregation Propensity Using AmylPred2 
Protein misfolding is commonly initiated by short self-recognition elements 
that are four- to ten-residue segments with high propensity to self-aggregate into 
β-sheets and act as “hot spots” in amyloid formation [Ventura et al., 2004; 
Thompson et al., 2006; Belli et al., 2010; Maurer-Stroh et al., 2010; Tzotzos & 
Doig, 2010]. To identify such segments in apoA-I, we used the consensus 
algorithms AmylPred and AmylPred2 [Hamodrakas, 2011; Tsolis et al., 2013] that 
utilize five and eleven sequence-based amyloid predicting methods, respectively. 
The consensus analysis optimizes the balance between the specificity and 
sensitivity in the hot spots prediction. Here, high specificity means low probability 
of predicting too many amyloid-prone segments (few false positives) while high 
sensitivity means low probability that such segments are mistakenly omitted (few 
false negatives) [Tsolis et al., 2013]. In AmyPred2, the prediction specificity is 
~85% for consensus agreement by five out of 11 methods, and increases with 
increasing the number of hits [Tsolis et al., 2013]. Hence, the hot spots predicted 
by more than five hits have better than 85% specificity and are referred to as 
“major” henceforth. Consensus agreement by five or fewer hits can also reveal 
potentially important amyloidogenic segments, such as the “minor” hot spots 
described below. In addition, we used the PASTA server [Trovato et al., 2007] to 





Figure 3.8 Amino acid sequence of apoA-I and its segments that are predicted to 
be important for amyloid formation. 
(A) Linear representation of the amino acid sequence. Residues 1-43, encoded 
by exon 3, form N-terminal G-repeats (dark grey). Residues 44-243, encoded by 
exon 4, form ten 11/22-mer tandem repeats with high helical propensity, 1-10, 
punctuated by Pro or Gly. Repeats 1-7 are in dark grey and 8-10 are in white. 
Positions of Pro and Gly are indicated. Green boxes show amyloid hot spots 
formed by residues 14-22 (LATVYVDVL), 53-58 (VTSTFS), 69-72 (QEFW), and 
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227-232 (VSFLSA) predicted by using AmylPred2. Violet box shows the putative 
-breaking motif (EKETEG) in residues 76-81. Green double arrow shows the 
amyloid core in the N-terminal fragments forming AApoAI deposits. Dashed box 
shows cleavage sites between residues 83 and 100 characteristic of AApoAI 
deposits. X show cleavage sites characteristic of free apoA-I in solution. 
Positions of G26R and W50R mutations are indicated. Red diamonds show 
methionine residues. Black double arrow indicates (185-243)apoA-I construct 
whose 2.2Å resolution crystal structure [Mei & Atkinson, 2011]. (B) Output of 
AmylPred2 consensus sequence analysis of human apoA-I plotted as a number 
of algorithms predicting -aggregating propensity (from the total of 11) versus 
residue number. Segments predicted by a consensus of more than five hits 
(above the blue dotted line) are termed major amyloid hot spots; those predicted 
by three to-five hits (between the two dotted lines) are termed minor hot spots. 
Double line indicates 20-residue peptide fragment 9-28 predicted to have the 
highest amyloid-forming propensity. This segment was synthesized and analyzed 






Figure 3.8 and Table 3.1 show the amyloidogenic profile of apoA-I 
obtained by using AmylPred and AmylPred2. The results predicted two major 
and two minor amyloid hot spots containing residues 14-22 (LATVYVDVL), 53-58 
(VTSTFS), 69-72 (QEFW) and 227-232 (VSFLSA), with the following rank order: 
(14-22) > (227-232) > (53-58) > (69-72) . Each of these segments is rich in large 
hydrophobic residues, contains at least one aromatic residue in the middle, may 
contain an acidic group but hardly any basic groups, and has other 
characteristics of amyloidogenic sequences. PASTA predicted three strongest 
hot spots in the same rank order as AmylPred, (14-22) > (227-232) > (53-58), 
shown in Figure 3.9. Similar amyloidogenic segments were predicted in other 
studies [Hamodrakas, 2011; Adachi et al., 2014]. In summary, segment 14-22 
was by far the strongest hit predicted by up to 11 out of 12 methods, suggesting 
better than 90% prediction specificity. The fourth and only hot spot located 
outside the N-terminal half was predicted in residues 227-232 from the C-







Table 3.1 Summary of apoA-I sequence analysis by using AmylPred 2 and 
PASTA. 
Boxed regions show amyloid hot spots predicted by the consensus of 4 or more 
methods. Residues 44-55 (extended strand in the crystal structure of (185-














Figure 3.9 Amyloidogenic profile of apoA-I predicted by PASTA.  
The results show three (I, II, and IV) out of four hot spots predicted by AmylPred 




In addition to amyloidogenic segments, the apoA-I sequence contains 
several short motifs that are expected to disrupt the β-sheet propagation. The 
longest of such motifs, EKETEG (residues 76-81), is predicted to have a β-
breaking potential resulting from the Coulombic repulsion among three proximal 
Glu located on the same side of the β-strand, followed by the β-breaking Gly. 
This repulsion is expected to diminish at acidic pH upon Glu protonation and 
potential carboxyl pair formation [Das et al., 2014]. In summary, the sequence 
analysis suggests that the N-terminal part of apoA-I has high propensity to form 
amyloid that encompasses the first 75 residues but may not readily propagate 
beyond the β-breaking segment 76-81 at near-neutral pH. 
 
3.7 Fiber Formation in Peptide Fragment Encompassing Hot Spot 14-22 
Several lines of experimental evidence support the predicted amyloid-
forming segments in the N-terminal part of apoA-I. First, the AmylPred2 and 
PASTA profiles (Figure 3.8 and 3.9) of apoA-I suggest that the amyloid-forming 
propensity resides largely within the first ~100 residues. This prediction is 
validated by the ability of the recombinant apoA-I fragment 1-83 and 1-93 to 
readily form amyloid fibrils in cell culture and/or in vitro [Raimondi et al., 2011; 
Adachi et al., 2014]. The prediction is also consistent with the finding of residue 
fragments 1-83 to 1-100 in patient-derived AApoAI deposits [Obici et al., 2006; 
Ramella et al., 2012]. Second, synthetic apoA-I fragment 46-59, which contains a 
  
105 
minor predicted hot spot 53-58, forms amyloid fibrils in vitro [Wong et al., 2012], 
validating this prediction. Third, recent studies report that fragment 1-43 that 
contains the major predicted hot spot, 14-22, readily forms amyloid fibrils in vitro 
at pH 7.4 [Adachi et al., 2014]. In comparison, fragment 44-65 that contains a 
minor hot spot 46-59 is less prone to amyloid formation, while fragment 66-83 
that contains the predicted pH-dependent β-breaking motif in residues 76-81 
does not form amyloid at pH 7.4 [Adachi et al., 2014]. These results are in 
excellent agreement with the sequence-based predictions. 
To further validate the major predicted hot spot 14-22, we explored 
amyloid formation in vitro by using a synthetic 20-residue peptide fragment 
containing apoA-I residues 9-28. These residues are centered on segment 14-22 
that is predicted to have the highest amyloid-forming propensity in the N-terminal 
half of apoA-I. The peptide was obtained commercially using solid-state 
synthesis. HPLC was used to purify the peptide to 95% purity that was confirmed 
by mass spectrometry. Peptide solutions of 0.1-0.5 mg/ml concentrations in 100 
mM Na phosphate buffer at pH 7.4 were incubated at 22 °C for up to 17 days. 
Negative-stain EM showed fibril formation after 6 days, followed by visible 
precipitation after 10 days. The fibrils were approximately 10 nm in width and 
hundreds of nm in length, and often formed clusters as seen in Figure 3.10a. 
Binding of a diagnostic dye, thioflavin T (ThT), followed by fluorescence 
measurements showed a large increase in ThT emission upon the peptide 





Figure 3.10 Amyloid fibrils formed by synthetic fragment 9-28 observed by 
negative stain EM and ThT fluorescence. 
Fibrils were formed upon incubation of peptide solution in 100 mM Na phosphate 
buffer at pH 7.4, 22 °C for 6 days. Fluorescence was measured from buffered 
solutions containing 10 M ThT alone (1) or in the presence of 100 M peptide 
that was either freshly dissolved (2) or formed fibrils (3) upon incubation at 22 °C 
for 17 days as described in Chapter 2. Increase in ThT fluorescence suggests 




In summary, electron microscopy and ThT binding indicate rapid amyloid fibril 
formation by apoA-I fragment 9-28 that encompasses the major predicted 
amyloid hot spot, 14-22, further validating this prediction. 
Notably, the two major hot spots, 14-22 and 227-232, were predicted 
strongly by PASTA to form parallel intermolecular β-sheet in amyloid (Table 3.2 
and Figure 3.9). In agreement with this prediction, FTIR spectra of fibrils formed 
by fragment 1-43 lack the diagnostic peak near 1690 cm-1 [Wong et al., 2012] 
and hence, are indicative of a parallel β-sheet. Spectroscopic data show that 
parallel in-register β-sheet is the major structural motif in protein fibrils containing 
β-strands longer than four residues [Tycko, 2006; Margittai & Langen, 2008]. 
Notably, parallel β-sheet was observed by EPR and by solid-state NMR in the 
fibrils of two related proteins, apoC-II [Teoh et al., 2011] and α-synuclein [Der-
Sarkissian et al., 2003; Lv G et al., 2012], that contain lipid surface-binding 11-
mer sequence repeats homologous to those in apoA-I [Segrest et al., 1992]. 
These observations support the prediction of the parallel β-sheet as the preferred 









Table 3.2 Sequence analysis of human apoA-I by PASTA. 
PASTA was used to assess the major amyloidogenic hot spots and their 
preferred orientation in fibrils (parallel or antiparallelstrands). In fibrils, -
pairings generally have PASTA energies of -4.0 or lower. PASTA output for top 
apoA-I pairings between residue segments with energies below -4 is listed. 
These include two major amyloidogenic hot spots in the N-terminal (blue) and C-
terminal (red) regions. Importantly, PASTA predicts that both major hot spots in 




3.8 Mapping Amyloid Hot Spots on the Structure of Δ(185-243)apoA-I 
Figure 3.11 shows the three N-terminal amyloid hot spots predicted by 
AmylPred, together with the β-breaking segment, mapped on the proposed 
structure of apoA-I monomer, which was derived from the crystal structure of 
Δ(185-243)apoA-I via the domain swapping around the dimer two-fold axis [Mei 
& Atkinson, 2011]. In the crystal structure, all these amyloidogenic segments are 
α-helical, except for the second hot spot, 53-58, that partially overlaps with the 
extended strand, 44-55, and the following α-helix, 56-64. The first and strongest 
hot spot, 14-22, forms an α-helix kinked at Y18, and is packed against the 
second hot spot in residues 53-58. The third hot spot, 69-75, and the following β-
breaking region, 76-81, form a short helix at the bottom of the bundle. In the 
crystal structure, this well-ordered region forms extensive interactions in the 
“bottom” hydrophobic cluster [Mei & Atkinson, 2011]. All three predicted N-
terminal hot spots are located in or near this cluster. We propose that such a 
tertiary packing and the native -helical structure help protect lipid-free apoA-I 
from misfolding. Similarly, the amyloid hot spots in other proteins often adopt 





Figure 3.11 Residue segments predicted to promote or prevent amyloid 
formation mapped on the proposed structure of lipid-free apoA-I monomer.  
Three N-terminal amyloid hot spots predicted in residues 14-22, 53-58, and 69-
72 are mapped on the proposed structure of lipid-free (185-243)apoA-I 
monomer. The fourth predicted hot spot, 227-232, is in the flexible C-terminal 
region (irregular line) that forms the primary lipid binding site in apoA-I driving its 
adsorption to phospholipid surface. Residues 76-81 that are expected to form a 
-breaking motif at pH 7 are in purple. Extended segment 44-55 is in red. From 




The C-terminal region containing the fourth apoA-I hot spot, 227-232, was 
truncated from (185 243) apoA-I to facilitate protein crystallization. This region 
forms the primary lipid binding site in apoA-I ([Chetty et al., 2009; Mei & Atkinson, 
2011] and references therein) and is largely -helical on the lipid. In the low-
resolution crystal structure of the N-terminally truncated apoA-I, which is thought 
to represent the lipid-bound conformation, residues 228-232 form the beginning 
of the C-terminal -helix [Borhani et al., 1997]. We posit that this highly -helical 
conformation, together with the rapid protein adsorption to the phospholipid 
surface via the C-terminal end [Jayaraman et al., 2012], help protect the C-
terminal hot spot from initiating the apoA-I misfolding.  
The extended strand 44-55 observed in the crystal structure of (185-
243)apoA-I [Gursky et al., 2012] partially overlaps with the minor hot spot, 53-58, 
suggesting that this strand has modest amyloid-forming propensity, consistent 
with the relatively polar character of residues 44-55, LKLLDNWDSVTS. X-ray 
crystallography and HDX MS studies indicate high solvent accessibility of 
residues 44-55 in the free protein [Chetty et al., 2009; Mei & Atkinson, 2011; 
Adachi et al., 2013]. This contrasts with the amyloid-prone segments in globular 
proteins, which are usually protected by extensive native packing [Tzotzos & 
Doig, 2010]. We propose that, despite its native strand-like geometry, segment 
44-55 has limited amyloidogenic propensity which, together with the W50-K23 -
cation interaction that may restrict conformational mobility of this segment in free 
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apoA-I [Mei & Atkinson, 2011], helps protect it from -aggregation.  
Previous studies reported that AApoAI mutations reduce the -helical 
propensity of apoA-I [Obici et al., 2006] and perturb the radial distribution of 
charged and apolar residues characteristic of apolipoprotein -helices [Gursky et 
al., 2012]. Sequence-based prediction algorithms including AmylPred2 and 
PASTA showed no significant increase in the amyloid-forming propensity upon 
W50R, G26R or other AApoAI mutations. This suggests that the primary effect of 
such mutations is on the native conformation of apoA-I. 
 
3.9 Revised Mechanism of Misfolding in AApoAI Mutants 
These results, together with the previous HDX MS analyses of WT and 
G26R apoA-I [Chetty et al., 2009] and in vitro amyloid formation by apoA-I 
fragments [Wong et al., 2012; Adachi et al., 2014], suggest that protein 
misfolding in AApoAI is triggered by perturbations of the native structure in the N-
terminal amyloid hot spots, increasing their solvent exposure and/or mobility. In 
the crystal structure of free protein, G26 is juxtaposed to W50 in the middle of the 
extended segment 44-55 (Figure 3.1). This segment is loosely packed and forms 
few specific interactions with the rest of the protein molecule. These interactions 
probably contribute little to the overall protein stability, as suggested by minimal 
effects of W50R mutation on the structure and stability of free protein (Figure 
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3.2). Notably, W50R mutation replaces the-cation attraction, W50-K23 (Figure 
3.1), with the Coulombic repulsion, R50-K23, which is expected to perturb the 
local conformation and dynamics of the strand 44-55. This perturbation can 
propagate from the mutation site at residue 50 to the nearby hot spot, 53-58, 
perturbing its interactions with the adjacent major hot spot, 14-22. We proposed 
that this perturbed hot spot packing can trigger amyloid formation by W50R 
apoA-I. An experimental test of this idea is described in chapter 4. 
A similar mechanism probably contributes to amyloid formation by G26R 
apoA-I. In G26R mutant, Coulombic repulsion between K23 and R26, which are 
adjacent in the -helix, would also disrupt the -cation interaction, W50-K23, and 
once again perturb the local conformation and dynamics of the extended 
segment 44-55 and the nearby hot spots. Our results show that G26R slightly 
reduces the overall structural stability and cooperativity (Figure 3.2B) of free 
apoA-I and eliminates Gly26 that may be -blocking. Finally, both G26R and 
W50R reduce the net negative charge on apoA-I, particularly on its acidic N-
terminal part, which generally favors -aggregation [Tzotzos & Doig, 2010; 
Winkelmann et al., 2010]. A combination of these factors probably contributes to 
amyloid formation by G26R and W50R apoA-I. 
We speculated that other AApoAI mutations promote amyloid formation 
via a combination of similar factors. In fact, 11 out of 14 known sites of AApoAI 
point mutations are located in the bottom half of the helix bundle in direct contact 
  
114 
with one or more N-terminal hot spots, shown in Figure 3.11. Close inspection of 
the sites of these mutations suggests that they may perturb native packing in 
these hot spots. Of the remaining three AApoAI point mutations, two (G26R and 
W50R) are located near the middle of the helix bundle (Figure 3.1); structural 
perturbations caused by these mutations are described above. The remaining 
AApoAI point mutation, E34K, is unusual as it is located near the top of the helix 
bundle distant from the predicted hot spots. E34K decreases the net negative 
charge by 2, the largest decrease among AApoAI mutations, which is expected to 
favor -aggregation [Tzotzos & Doig, 2010; Winkelmann et al., 2010]. Other 
AApoAI mutations involve deletions and frame shifts [Obici et al., 2006; 
Rowczenio et al., 2011; Gursky et al., 2012] that potentially alter the helix registry 
in the bundle or truncate it, which can be detrimental to protein stability 
[Gorshkova & Atkinson, 2011].  
Of the nearly 20 known AApoAI mutations, only one most conservative 
substitution, F71Y, is located in the middle of the minor predicted hot spot, 69-72. 
This raises a possibility that the disruptive mutations inside hot spots promote 
apoA-I misfolding and sequestration in inclusion bodies [Chiti & Dobson, 2009; 
García-Fruitós et al., 2011; Hamodrakas, 2011] and thereby interfere with the 
secretion of the mutant protein [Marchesi et al., 2011]. Experimental analysis of 
F71Y mutation is reported in Chapter 4. 
In summary, of the 14 known AApoAI point mutations, at least 13 are 
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expected to perturb local packing in the N-terminal hot spots in free apoA-I. Such 
a perturbation was observed by HDX MS in G26R, the most common AApoAI 
mutant [Chetty et al., 2009]. This observation strongly supports our hypothesis 
that local perturbations of the native structure and dynamics in the N-terminal hot 
spots in free apoA-I trigger its misfolding in AApoAI. These perturbations can be 
synergistic with other factors, such as reduced overall structural stability and 
cooperativity, but do not require them. Hence, our proposed mechanism helps 
uncouple apoA-I destabilization from misfolding and explains why many 
mutations, such as Milano or Nichinan, reduce structural stability of free apoA-I 
but do not cause amyloidosis [Sorci-Thomas & Thomas, 2002; Obici et al., 2006; 
Alexander et al., 2009; Kono et al., 2011; Weers et al., 2011 Ramella et al., 2012] 
 
3.10 Role of Methionine Oxidation in Amyloid Formation by ApoA-I 
 Our mechanism also helps explain why Met oxidation causes misfolding of 
full-length non-variant apoA-I [Wong et al., 2010; Teoh et al., 2011, Chan et al., 
2015]. Apolipoprotein Met residues are highly susceptible to oxidation [Garner et 
al., 1998; Shao et al., 2008]. Met oxidation can alter protein function, stability, 
and propensity to form amyloid [Shao et al., 2008; Wong et al., 2010]. ApoA-I 
contains three Met residues, M86, M112 and M148 that are located in the apolar 
lipid-binding faces of the -helices, and can be converted into Met sulfoxides 
(MetO) in vivo [Sigalov & Stern, 2001; Pankhurst et al., 2003]. Replacement of 
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the apolar Met with polar MetO in these locations is expected and observed to 
diminish protein affinity for lipid and decrease protein stability in solution 
[Anantharamaiah et al., 1988; Sigalov & Stern, 2001; Jayaraman et al., 2008], 
probably because of the perturbed hydrophobic core packing in the helix bundle. 
The effect of Met oxidation on the structural stability and lipid binding of apoA-I is 
expected to resemble certain AApoAI mutations, such as L60R, L64R or L178H, 
that also replace apolar with polar or basic groups in the hydrophobic core of the 
helix bundle [Gursky et al., 2012]. Hence, similar to these mutations, Met 
oxidation is expected to augment amyloid formation by apoA-I. In fact, full-length 
non-variant human plasma apoA-I forms amyloid upon Met oxidation in vitro, 
suggesting that mild oxidation in vivo can promote apoA-I deposition in 
atherosclerotic plaques [Wong et al., 2010]. 
To clarify the role of individual Met residues in misfolding of apoA-I, we 
examined Met packing in the crystal structure of (185-243)apoA-I (Figure 3.12). 
M86 is located in the “bottom” hydrophobic cluster, with the Met side chain 
forming extensive interactions with the residues from the amyloid hot spots. First, 
well-ordered S and C atoms of M86 are only 4–5 Å away from C of Y18 in the 
middle of the major hot spot, 14-22 (Table 3.3). Second, S in M86 is packed in 
the predominantly hydrophobic region close to carbonyl carbons from residues 
173, 174 and 177 located in the helical segment 170-178 that contains “outside” 
point mutations in AApoAI (Figure 3.12). This segment interacts directly with all 





Figure 3.12 Locations of the 3 Met residues in free apoA-I. 
Positions of M86, M112, and M148 (red diamonds) are mapped on the crystal 
structure of (185-243)apoA-I. Polypeptide chain is in rainbow colors from N- to 
C-terminus (blue to yellow). Circles indicate sites of all known “outside” point 
mutations in AApoAI, including L170, R173, L174, A175 and L178 (top to 
bottom). Main chain of Tyr18 located in the middle of the major spot, 14-22 
(blue), and its selected nearest neighbors that include Met86 side chain are 
indicated. Inserts: Electron density map showing M86 (bottom) and M112 and 
M148 (top) (Courtesy Dr. X. Mei). The 2Fo-Fc map was generated by using the x-
ray diffraction data (observed amplitudes, Fo) and the refined 2.2Å crystal 
structure of (185-243)apoA-I. From [Das et al., 2014]. 
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expected to perturb these interactions and thereby promote apoA-I misfolding. 
In contrast, M112 and M148 are located at the top of the helix bundle, 
remote from the amyloidogenic point mutations or hot spots (Figure 3.12). M112 
and M148 sulfurs are less than 6 Å apart. Unlike M86, M112 and M148 side 
chains are not well ordered in the crystal structure, as evident from the electron 
density map (Figure 3.12 left) and the temperature factors of S (B=60 Å2 in M86 
as compared to ~95 Å2 in M112 and M114). These details help explain several 
reports that M112 and M148 are more susceptible to oxidation in vivo and in vitro 
than M86 ([Sigalov & Stern, 2001; Brock et al., 2008] and references therein). 
They also explain why in apoA-I isolated from plasma of hyperglycemic patients, 
M112 and M148 correlate in their oxidation degree [Brock et al., 2008]. We 
propose that spatial proximity of the M112 and M148 sulfurs in the free protein 
explains correlation in their oxidation degrees, while sequestration of the M86 
side chain in the well-ordered hydrophobic cluster explains its reduced 
susceptibility to oxidation. 
In summary, our structural analysis shows that in free apoA-I, M86 is 
located near the bottom of the helix bundle where it forms extensive hydrophobic 
interactions with Y18 and other groups from the major amyloid hot spots, 14-22 
(Table 3.3). M86 oxidation is expected to perturb these interactions. In contrast, 
oxidation of M112 and M148, which are located at the top of the helix bundle, 
probably has little direct effect on the packing of the hot spots near its bottom. 
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Therefore, we propose that oxidation of M86 is the likely trigger of apoA-I 
misfolding in atherosclerotic plaques.  
Interestingly, experimental analyses by Cavigiolio and colleagues [Chan et 
al., 2015] helped establish the role of individual Met oxidation in apoA-I 
fibrillogenesis. They showed that under oxidative conditions that mimic 
atherosclerotic environment, full-length apoA-I can form amyloid fibers. 
Furthermore, it was revealed that oxidation of M86 and M148, but not M112, 
played predominant role in amyloid fiber formation by wild type apoA-I. In spite of 
the close proximity of M112 and M148 in the crystal structure, they had very 
different effects on apoA-I misfolding. The molecular basis for this effect is 





Table 3.3 Nearest neighbors of Met86 sulfur in the helix bundle structure of free 
apoA-I.  
Atoms located within 5 Å from Met86 S in the crystal structure of lipid-free 
(185-243)apoA-I (PDB ID 3R2P) are listed. Apolar atoms are in black, polar in 
green, charged in blue (positive) and red (negative). Packing of Met86 sulfur in 
this predominantly apolar environment suggests strongly that polar Met sulfoxide 
will disrupt this packing. This will perturb the packing of Tyr18 in the middle of the 
major amyloidogenic hot spot (residues 14-22), and thereby promote -
aggregation. The closest contacts between Met86 and Tyr18 include 4.0 Å (M86 
C to Y18 C) and 4.9 Å (M86 S to Y18 C). From [Das et al., 2014]  
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3.11 Common Mechanism of apoA-I Misfolding in Familial and Acquired 
Amyloidosis 
Taken together, the results reported here suggest that apoA-I misfolding in 
familial and in acquired amyloidosis is triggered by perturbed native structure in 
the amyloid hot spots, increasing their mobility and solvent accessibility. On HDL, 
all hot spots are protected from misfolding by the protein-lipid interactions, with 
additional protection conferred by the helical packing in the antiparallel “double-
belt” conformation of apoA-I dimer on HDL [Borhani et al., 1997; Huang et al., 
2011; Mei & Atkinson, 2011; Chetty et al., 2012; Gursky, 2013]. This antiparallel 
helical packing must be disrupted prior to formation of the parallel intermolecular 
-sheet predicted for apoA-I amyloid (Figure 3.13). This underscores the 
importance of free monomeric apoA-I as a direct progenitor of amyloid.  
In lipid-free apoA-I, the N-terminal hot spots are normally protected from 
misfolding by the interactions within the helix bundle [Chetty et al., 2009; Mei & 
Atkinson, 2011] (Figure 3.11A). The C-terminal hot spots located in the primary 
lipid binding site is probably protected by its helical native conformation and by 
the bound lipids [Jayaraman et al., 2012]. We propose that AApoAI mutations or 
Met86 oxidation perturb native packing in one or more of the N-terminal hot spots 
in free apoA-I, particularly in residues 14-22, and thereby lessen their protection 
from misfolding. This local perturbation (described in Chapter 4) can be 
synergistic with other amyloidogenic factors such as the reduced protein affinity 
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for lipid, reduced stability and cooperativity of free protein structure, increased 
susceptibility to oxidation and proteolysis, reduced net charge and solubility, 
removal of the -breaking groups such as Pro or Gly, etc. [Winkelmann et al., 
2010]. 
Our hypothetical mechanism is supported by multiple lines of experimental 
evidence and helps resolve several important issues. First, it uncouples structural 
destabilization of free apoA-I from local perturbations in its amyloid-prone 
segments, and explains why some but not all destabilizing apoA-I mutations are 
amyloidogenic [Sorci-Thomas & Thomas, 2002; Obici et al., 2006]. A similar 
concept may apply to other globular proteins whose amyloidogenic propensity 
correlates with the structural stability but is not tightly coupled to it [Chiti & 
Dobson, 2009; Winkelmann et al., 2010].  
Second, the proposed mechanism explains why patient-derived AApoAI 
deposits contain N-terminal proteolytic fragments cleaved between residues 83 
and 100 [Obici et al., 2006; Lagerstedt et al., 2007; Ramella et al., 2012], even 
though in native apoA-I these residues form ordered -helical structure that is 
protected from proteolysis [Borhani et al., 1997; Chetty et al., 2009; Mei & 
Atkinson, 2011]. We propose that the intermolecular parallel -sheet readily 
propagates through the N-terminal 75 residues that are predicted and observed 
to be amyloidogenic. At near-neutral pH, the gate-keeping motif EKETEG in 
residues 76-81 is expected to impede the propagation of the-zipper. Hence, the 
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N-terminal ~75 residues form the protease-resistant amyloid core; polypeptide 
outside this core can be readily proteolyzed (Figure 3.13C). In summary, we 
propose that apoA-I cleavage can occur after the amyloid core formation in 
AApoAI, still we cannot completely exclude the accepted pathway in which apoA-
I is partially cleaved prior to misfolding. The former mechanism explains why the 
attempts to find the 9-11 kDa N-terminal fragments of apoA-I in circulation have 
been unsuccessful [Obici et al., 2006], and suggests that the proteolytic 
environment at the site of the amyloid deposition determines the cleavage site in 
AApoAI.  
Third, our proposed mechanism suggests why arterial deposits in acquired 
amyloidosis commonly contain full-length apoA-I. At acidic pH reaching pH 5.5 in 
deep atherosclerotic plaques [Nguyen et al., 2012], partial protonation of the 
adjacent Glu in the EKETEG residues 76-81 is expected to reduce their -
breaking propensity and facilitate the-sheet propagation from the N- to the C-






Figure 3.13. Hypothetical pathway of apoA-I misfolding in familial and in 
acquired amyloidosis.  
(A) Lipid-free apoA-I monomer, generated de-novo or dissociated from HDL, 
forms a four-helix bundle containing residues 1-184 (helix ribbon) followed by the 
partially unstructured C-terminal residues 185-243 (thin line) containing the 
primary lipid binding site. Four predicted amyloid hot spots are color-coded. 
AApoAI mutation in familial amyloidosis or M86 oxidation in acquired amyloidosis 
may perturb native structure in these hot spots and initiate -aggregation. This 
leads to formation of the protease-resistant amyloid core in the first 75 residues 
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containing N-terminal amyloid hot spots (in blue, teal and green) (B). In the 
parallel in-register -sheet predicted for apoA-I, each hot spot (color-coded) 
stacks in register against its counterparts from the adjacent molecules. At pH~7, 
the -breaking EKETEG residues 76-81 probably impede the amyloid core 
propagation towards the C-terminus and hamper the in-register stacking of the 
similarly charged groups. As a result, amyloid core stops at residues 76-81, 
leading to protein cleavage shortly thereafter. This explains why amyloid core in 
the patient-derived AApoAI deposits contains residue segments 1-83 to 1-100 
(C). (D) At acidic pH, partial protonation of the adjacent Glu is expected to 
diminish the -breaking potential of the EKETEG motif. This facilitates the -
sheet propagation towards the C-terminus and formation of fibrils containing full-
length apoA-I, such as those found in atherosclerotic plaques. In the resulting 
parallel in-register -sheet structure, different hot spots within the molecule act in 
synergy (D), while similar secondary structural elements from different molecules 




Chapter 4 Structural Stability and Local Dynamics of Disease-Causing 
Mutants of Human Apolipoprotein A-I 
 
4.1 Introduction 
In chapter 3, our biophysical studies of two naturally occurring AApoAI 
variants of human apoA-I, G26R and W50R, showed that large global 
destabilization of lipid-free or lipid-bound apoA-I is neither necessary nor 
sufficient for amyloidosis. Bioinformatics analysis identified four 4- to 9-residue 
hydrophobic segments, particularly residues 14-22 (LATVYVDVL), with high 
propensity to trigger amyloid formation [Adachi et al., 2014; Das et al., 2014; 
Mendoza-Espinosa et al., 2014; Louros et al., 2015]. These amyloid hot spots 
are normally protected from misfolding by their native -helical structure in lipid-
free or lipid-bound apoA-I. Based on these observations, we hypothesized that 
reduced protection of the hot spots upon mutations or other modifications 
promotes apoA-I misfolding.  
To test this hypothesis, we explored the structure, stability and lipid-
binding properties of several naturally occurring disease-causing mutants of full-
length human apoA-I. These include F71Y (the most conservative AApoAI 
mutation) and L170P (one of the “outside” AApoAI point mutations that cluster in 
residues 170-178 located outside the 9-11 kDa N-terminal segments found in 
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amyloid deposits). Both these mutations were identified as amyloidogenic 
relatively recently [Eriksson et al., 2009; Rowczenio et al., 2011]. The main 
organs associated with amyloid deposition were liver and palate for F71Y and 
larynx for L170P. From a structural perspective, F71Y and L170P mutation sites 
are located in the “bottom” half of the helix bundle (Figure 4.1) where most other 
AApoAI mutations are clustered [Gursky et al., 2012].  
As a non-amyloidogenic control, we studied L159R variant (Fin) and the 1-
159 fragment, which can be generated upon proteolysis of Fin variant in plasma 
[McManus et al., 2001]. L159R mutation impedes HDL maturation, leading to 
lack of -migrating HDL, and has been associated with an increased risk of 
atherosclerosis [Sorci-Thomas et al., 2012].  
We used an array of biophysical methods to determine the effects of these 
mutations, along with G26R and W50R mutations described in chapter 3, on the 
local backbone conformation and dynamics in solution. The results shed new 
light on what makes the protein amyloidogenic and provide insights into the 






Figure 4.1 Amyloid hot spots and mutation sites mapped on the proposed 
structure of apoA-I monomer. 
The structure was obtained from the crystallographic dimer observed in 
the 2.2 Å structure of (185-243)apoA-I (PDB ID 3R2P) via the domain swapping 
of helix IV (residues 143-184) around the dimer 2-fold (circular arrow). The 
flexible C-terminal tail (residues 185-243, drawn by line) was absent from the 
crystallized construct. Disease-causing point substitutions explored in the current 
study are indicated, including four amyloidogenic (G26R, W50R, F71Y, and 
L170P) and one non-amyloidogenic (L159R) mutation. Residue segments that 
were proposed to be important for amyloidosis are indicated: 14-22 (blue) is the 
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major predicted amyloid hot spot; 53-58 (teal) and 69-72 (yellow) are weakly 
predicted amyloid hot spots; 44-55 is the sole -strand-like segment seen in the 
crystal structure; 83-93 contain the cleavage sites generating 1-83 to 1-93 
fragments found in AApoAI deposits in vivo; and 227-232 (red) is the predicted 
C-terminal amyloid hot spot. The latter segment overlaps the C-terminal -helix 




4.2 Effects of Mutations on the Protein Structure and Stability in Solution 
First, we tested the effects of amyloidogenic (F71Y and L170P) and non-
amyloidogenic mutations (L159R) on the secondary structure of free protein at 25 
˚C. Figure 4.2A shows that the far-UV CD spectra of WT and mutant apoA-I 
superimposed at 200-250 nm indicating ~50% -helical content. Decreased CD 
signal at 185-200 nm indicate structural disordering caused by mutations. 
Mutants G26R and W50R showed similar but smaller effects. CD melting data 
were recorded to test protein stability. Figure 4.2B shows that in F71Y, the 
melting temperature decreased by 5 ˚C compared to WT, indicating a small 
destabilization upon mutation. Comparable destabilization was seen in W50R 
and G26R (Tm=-3 ˚C, Figure 3.2B in chapter 3). L159R and L170P showed 
much larger destabilization with Tm= -11 ˚C (Figure 4.2B). These mutants also 
exhibited a 2-fold decrease in the transition steepness at Tm. The van’t Hoff’s 
enthalpy of unfolding decreased accordingly, from about 40 kcal/mol for WT and 
F71Y to about 20 kcal/mol for L159R and L170P, indicating a 2-fold decrease in 






Figure 4.2 Secondary structure and stability of lipid-free full-length apoA-I 
variants analyzed by circular dichroism.  
(A) Effects of selected mutations on the secondary structure assessed by far-UV 
CD at 25 °C. Insert shows SDS-PAGE of the selected mutants. The -helical 
content estimated from the spectra is 52% for WT, 50% for F71Y, 50% for L159R 
and 48% for L159R, with an accuracy of 5%. (B) Effects of mutations on the 
structural stability assessed by far-UV CD. Melting data were recorded at 222 nm 




Next, we used near-UV CD to probe the effect of mutations on the 
aromatic packing of free proteins, exhibited in Figure 4.3B. Residues 1-184, 
which form the “putative” N-terminal four-helix bundle, contain all four Trp (W8, 
W50, W72 and W108) and five out of seven Tyr in apoA-I (Y18, Y29, Y100, Y115 
and Y166). Hence, near-UV CD of free full-length apoA-I primarily reports on the 
tertiary structure in the helix bundle. In WT the spectra showed a downward-
pointing peak at 295 nm with a shoulder at 285 nm, which is dominated by Trp 
with a contribution from Tyr, and bands at 255-280 nm coming from Tyr and Phe 
(Figure 4.3A, black). Human plasma apoA-I (Figure 4.3B, black) and in its 1-184 
fragment have a similar spectrum, which is a signature of native aromatic 
packing in the helix bundle [Mei & Atkinson, 2011]. The helix bundle consists of 
two aromatic clusters: the bottom cluster containing residues W8, F71 and W72, 
and the top cluster with residues F33, F104 and W108. Additionally, a -cation 
interaction was noted in the middle of the bundle between residues W50 and K23 
[Mei & Atkinson, 2011]. G26R, W50R and F71Y caused distinct changes in near-
UV CD, which is not surprising since these mutations directly interfere with the 
aromatic packing in the middle (W50R, G26R) or the bottom (F71Y) of the 
bundle. L159R and L170P showed the largest spectral changes, with more 
negative CD signal at 255-280 nm and an upward pointing peak at 293 nm 
(Figure 4.3A). Intriguingly, similar spectra are characteristic of normal human 
plasma HDL (Figure 4.2B, red) and of model discoidal lipoproteins containing 
apoA-I [Leroy et al., 1993; Gao et al., 2012]. Therefore, L159R and L170P 
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mutations mimic aspects of the lipid-induced changes in the aromatic packing of 
non-variant apoA-I. 
ApoA-I binding to lipid involves opening of the helix bundle, probably along 
the hydrophobic cleft between the two pairs of helices (Figure 4.1, arrow) to form 
an antiparallel helical “double belt” on HDL surface [Brouillette et al., 2001]. The 
remarkable similarity between the near-UV CD spectra of HDL-bound non-variant 
apoA-I (Figure 4.3B, red) and lipid-free L170P and L159R mutants (Figure 4.3A, 
violet and pink) suggests that these mutations in the apolar core of the helix 
bundle might increase the cleft between the helix pairs. A two-fold decrease in 
the unfolding cooperativity of L159R and L170P mutants supports this idea 
suggesting that the cooperative units in these mutants contain two helices, as 
compared to four in WT and F71Y (Figure 4.2B). 
The local environment of the tryptophan residues in the helix bundle was 
assessed by intrinsic Trp fluorescence, as shown in Figure 4.4B. The wavelength 
of the maximal fluorescence in all proteins was ~338 nm, typical of Trp largely 
buried in an apolar environment. G26R, W50R, and F71Y mutations caused 
relatively little spectral changes. L159R and L170P showed a small increase in 
the emission intensity, which was particularly pronounced at the excitation 
wavelength ex=280 nm where both Tyr and Trp absorb. Such an increase in 
emission probably reflects reduced Trp quenching by the solvent and perhaps 




Figure 4.3 Tertiary structure of lipid-free full-length apoA-I variants analyzed by 
circular dichroism. 
(A) Aromatic packing assessed by near-UV CD at 25 °C. The spectra are 
dominated by aromatics in the helix bundle that contains all four Trp and five out 
of seven Tyr in apoA-I. (B) Near-UV CD spectra of non-variant human plasma 
apoA-I free in solution (black) and on HDL (red) are shown for comparison. From 




To compare the solvent-accessible hydrophobic surfaces in lipid-free 
proteins, 1-anilino-8-naphthalenesulfonate (ANS) fluorescence spectra were 
recorded. ANS is an apolar fluorescent probe that binds to large solvent-
accessible hydrophobic cavities, which are found in molten-globular folding 
intermediates but generally not in fully-folded or fully-unfolded globular proteins in 
solution. ANS binding increases its fluorescence emission due to decreased 
quenching by the solvent. Lipid-free WT apoA-I has molten-globular properties 
[Gursky & Atkinson, 1996a] and binds ANS [Rogers et al., 1998; Gorshkova et 
al., 2014], which causes increased emission. Our results in Figure 4.4A showed 
that the less destabilizing mutants F71Y, W50R and G26R exhibited minimal 
increase in ANS emission compared to WT. In contrast, L159R and L170P, 
which are more destabilizing than the other mutants, showed decreased ANS 
emission  
In summary, spectroscopic studies showed that the mutations produce 
little disorder in the secondary structure of free apoA-I at 25 ˚C. G26R, W50R, 
and F71Y show slightly reduced thermal stability (Tm=-3 ˚C to -5 ˚C) and slightly 
altered aromatic packing. L159R and L170P mutants are not only much less 
stable (Tm=-11 C) but also showed a 2-fold decrease in the unfolding 
cooperativity and HDL-like aromatic packing, suggesting an increased cleft 
separating two pairs of helices in the 4-helix bundle. Other distinct properties of 
the two “outside” mutants include increased Trp emission and decreased ANS 




Figure 4.4 Conformation of lipid-free full-length apoA-I variants analyzed by 
fluorescence spectroscopy. 
(A) ANS binding to apoA-I variants assessed by fluorescence at 25 °C. The 
spectrum for ANS in protein-free buffer is shown for comparison. (B) Intrinsic Trp 
fluorescence of apoA-I variants. The emission spectra were recorded using an 




categories: mildly destabilizing “inside” mutations (W50R, G26R and F71Y) and 
strongly destabilizing “outside” mutations (L170P and L159R). The latter include 
the non-amyloidogenic variant, L159R. These results support our idea that global 
structural destabilization in solution is neither necessary nor sufficient to make 
the protein amyloidogenic [Das et al., 2014]. Therefore, additional factors are 
likely important in AApoAI, including local dynamics, proteolysis and protective 
protein-lipid interactions. 
 
4.3 Effect of Mutations on Protein-Lipid Interactions 
To determine the effects of mutations on lipid interactions of apoA-I, 
mutant proteins were studied in the context of apoA-I:DMPC complexes, which 
are used as simple models of nascent HDL. Figure 4.5A shows the time-course 
of clearance of DMPC liposomes (diameter d>100 nm) by apoA-I variants to form 
reconstituted HDL-particles (d~11nm) at 24 C, which was monitored by turbidity. 
G26R, L159R and L170P had no significant effect on the time course of 
clearance, while F71Y and W50R slightly accelerated it (Chapter 3 and [Das et 
al., 2014]). The latter probably reflects local effects of aromatic substitutions 
rather than global protein destabilization, which was relatively small in F71Y or 
absent in W50R. Non-denaturing gel electrophoresis and negative-stain electron 
microscopy showed that all mutant proteins formed similar-size lipoproteins 
(~11nm) that mimic nascent “discoidal” HDL (Figure 4.5B, C). Figure 4.6A shows 
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the far-UV CD spectra that indicated 60-65% -helix content in these 
lipoproteins. The melting data showed that the mutations decreased lipoprotein 
stability (Figure 4.6B). The apparent melting temperature, Tm,app, decreased from 
83 ˚C for DMPC complexes with WT to 78.5 ˚C (F71Y), 74 ˚C (L170P), and 67 ˚C 
(L159R). DMPC complexes with W50R or G26R showed little destabilization 
[Das et al., 2014; described in chapter 3]. 
In summary, the mutations did not impair the ability of apoA-I to bind 
model phospholipid and remodel it into HDL-like complexes, nor did they alter the 
size or secondary structure of these complexes. However, the mutations 
decreased the lipoprotein stability in the order of WT ≥ W50R ≥ G26R > F71Y > 
L170P > L159R. The largest destabilization was observed in the two “outside” 
mutants, L170P (amyloidogenic) and, particularly, L159R (non-amyloidogenic). 
This is in contrast to the common AApoAI mutation, W50R, which did not 
significantly destabilize the reconstituted lipoprotein particle. If a mutation in 
apoA-I destabilizes plasma HDL, it is expected to shift the population distribution 
from the lipid-bound (protected) to lipid-free (labile) apoA-I, and thereby 
potentially augment amyloidosis [Gursky et al., 2012]. However, our results 
suggest that such destabilization is neither necessary (W50R) nor sufficient 





Figure 4.5 Biophysical characterization of model “discoidal” HDL reconstituted 
from DMPC and mutant apoA-I.  
Protein to lipid ratio in all preparations was 1:4 mg/mg. (A) Time course of DMPC 
liposome clearance by apoA-I monitored by turbidity.  (B) Negative-stain electron 
micrographs of the apoA-I:DMPC complexes. Most “discoidal” particles are seen 
stacked on edge. (C) Non-denaturing gel electrophoresis of variant apoA-I:DMPC 
complexes; free proteins are shown for comparison. The results suggest that 
despite small differences in DMPC clearance rate, all apoA-I variants form 





Figure 4.6 Secondary structure and stability of model “discoidal” HDL 
reconstituted from DMPC and full-length apoA-I variants analyzed by circular 
dichroism. 
(A) Effects of selected mutations on the secondary structure assessed by far-UV 
CD at 25 °C. The estimated -helical content is 61% for F71Y, 62% for L170P 
and 60% for L159R, with an accuracy of ~5%. (B) CD melting data recorded at 
222 nm of apoA-I:DMPC complexes upon heating and cooling from 5 to 95 °C at 
a rate of 11 °C/hour. Apparent melting temperatures decreased from Tm, app= 
83±0.05 °C for WT to 78.6±0.07 °C (F71Y), 74±0.17 °C (L170P), and 67±0.17 °C 




4.4 Effects of Mutations on Local Conformation and Dynamics in the Helix 
Bundle 
To monitor the effects of the mutations on the local backbone 
conformation and dynamics, each protein was probed with HDX MS. These 
experiments were performed by Christopher Wilson with the help of Dr. Thomas 
Wales from the laboratory of Dr. John Engen at Northeastern University. Figure 
4.7 shows the time course of deuterium uptake for representative polypeptide 
regions. Increased deuteration indicates less extensive main chain H-bonding 
and/or higher solvent accessibility, a direct result of changes to protein 
fluctuations [Englander & Kallenbach, 1983]. 
The N-terminal half of apoA-I consists of residues 1-121 encompassing 
helices I-III from the 4-helix bundle [Mei & Atkinson, 2011]. In this region, large 
mutation-induced changes were observed in residues 14-22 (Figure 4.7B, C), 
which are predicted to form the major amyloid hot spot [Adachi et al., 2014; 
Mendoza-Espinosa et al., 2014; Das & Gursky, 2015; Louros et al., 2015]. These 
residues form a well-ordered kinked helical segment in the middle of the helix 
bundle in the crystal structure [Mei & Atkinson, 2011]. This well-ordered structure 
is consistent with the slow deuteration of this segment observed in WT (Figure 
4.7 B, C, black) [Chetty et al., 2009]. The mutant proteins exhibited increased 
deuteration in the 14-22 segment and the order of protection from exchange was 
WT > F71Y > W50R > G26R > L159R ≥ L170P (Figure 4.7B, C). This order 
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supports our hypothesis that perturbed native packing in residues 14-22 can 
trigger apoA-I misfolding. Surprisingly, the non-amyloidogenic L159R mutant also 
showed reduced protection in residues 14-22. This suggests that reduced 
structural protection of the major amyloid hot spot is not sufficient to cause 
amyloidosis. 
The HDX MS data showed a similar rank order of protection for other 
largely -helical N-terminal segments (Figure 4.7D, G, H, I). This included 
residues 76-104 which encompass the cleavage sites 83-93 associated with 
AApoAI [Obici et al., 2006; Rowczenio et al., 2011; Gursky et al., 2012; Ramella 
et al., 2012]. Chetty and colleagues reported that G26R mutation reduced 
protection at these sites and proposed that this helps in generating the proteolytic 
fragment 1-83 found in AApoAI deposits [Chetty et al., 2012]. Our results indicate 
that, while some AApoAI mutations such as G26R and L170P greatly reduced 
protection from exchange in the 83-93 region, the non-amyloidogenic mutation 
L159R exhibited a similar or even larger destabilizing effect in this region (Figure 
4.7H, I). Overall, these observations suggest that reduced protection of the 
segment 83-93 does not always cause AApoAI. Furthermore, AApoAI mutations 
W50R and F71Y caused minimal increase in deuteration of residues 83-93, 
suggesting that these variants retained their well-ordered -helical conformation 
similar to WT (Figure 4.7H, I, orange and green). Therefore, contrary to the 
prevailing notion, amyloid formation by at least some AApoAI mutants, such as 





Figure 4.7. Time course of deuterium uptake for selected regions of lipid-free 
monomeric apoA-I variants measured by HDX MS.  Mutants are color-coded as 




cleavage in positions 83 to 93. 
Interestingly, no significant effects of mutations were detected in residues 
44-57, which showed high levels of deuteration in all proteins (Figure 4.7E, F). 
These residues contain an extended-strand-like segment 44-55 observed in the 
crystal structure [Mei & Atkinson, 2011], which overlaps with a minor predicted 
amyloid hot-spot 53-58 (Figure 4.1) [Wong et al., 2012; Das et al., 2014]. The 
extended segment 44-55 is largely polar and was predicted not to have high 
amyloidogenic potential [Das et al., 2014; Chapter 3]. However, it was proposed 
to facilitate -helix to -sheet conversion [Wong et al., 2010; Gursky et al., 2012]. 
In fact, peptide fragments encompassing this segment have been shown to form 
amyloid fibrils in vitro [Mendoza-Espinosa et al., 2014; Louros et al., 2015]. Lack 
of mutational effects in the HDX of segment 44-55 (Figure 4.7E, F) suggests that 
changes to the native state of this largely unprotected segment do not occur on 
the time scale of labeling used here, or do not occur at all. Hence, although 
segment 44-55 may potentially contribute to apoA-I misfolding, it is unlikely to 
trigger AApoAI. 
To summarize, HDX MS revealed that most -helical segments in the N-
terminal half of apoA-I have a rank order of protection of WT > F71Y > W50R > 
G26R >> L170P ~ L159R. Although the rank order of global protein stability 
determined by CD was somewhat different, WT ≥ W50R > G26R > F71Y >> 
L170R ≥ L159R (Figure 4.2B), all data consistently show that L170P and L159R 
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mutations cause the largest local and global perturbations in the helix bundle.  
 
4.5 Effect of Mutations on the Central Linker Region 
Surprisingly, our HDX MS results revealed that the rank order of protection 
in apoA-I variants is different for the N-terminal half, the central linker, and the C-
terminal tail (Figure 4.7). The central region of apoA-I contains a flexible linker in 
residues 121-142. This is a part of the helical repeat H5 out of 11 11/22-mer 
amino acid sequence repeats in apoA-I [Segrest et al., 1992]. In the crystal 
structure of (185-243) apoA-I, this central linker is highly flexible with backbone 
B-factor of ~80 Å2. This flexible segment was proposed to facilitate domain 
swapping of helix IV (residues 143-184) in the 4-helix bundle during dimer-to-
monomer conversion [Mei & Atkinson, 2011]. Furthermore, on HDL, parts of 
repeats 5 and 6 were proposed to form a flexible loop encompassing residues 
134-146 that can dissociate from the lipid [Maiorano et al., 2004; Martin et al., 
2006]. Consistent with this inherent flexibility, all apoA-I variants showed 
relatively high levels of deuteration in this region. (Figure 4.7 K-O) [Chetty et al., 
2009].  
Notably, L159R showed marked reduction in protection in residues 143-
164 near the mutation site as compared to all other proteins explored (Figure 4.7 
M-O). In fact, this was the only region showing a significant difference between 
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this non-amyloidogenic mutant and its amyloidogenic counterpart, L170P. We 
propose that in L159R, loss of protection in this region makes it susceptible to 
proteolysis. Basic pairs are preferred substrates for certain proteases that are 
thought to cleave apoA-I in vivo [McManus et al., 2001]. Hence adjacent basic 
residue pair R159, R160 formed upon mutation may also augment proteolysis. 
Transgenic mouse studies showed that human L159R apoA-I in plasma gets 
cleaved by an unknown protease to generate ~18 kDa proteolytic fragment 
consisting of approximately first 159 residues of apoA-I [McManus et al., 2001]. 
This fragment was proposed to be structurally unstable and undergo rapid 
degradation in vivo [McManus et al., 2001; Sorci-Thomas et al., 2012]  
 
4.6 Structure and Stability of 1-159 Fragment 
To test the idea that cleavage near L159R produces a structurally labile 
fragment, we analyzed the structure and stability of the recombinant 1-159 
fragment. The far-UV CD data of free protein showed that, although this fragment 
lacks the disordered C-terminal tail, it is only 40% -helical at 25 °C, suggesting 
a loss of a large part of the helix bundle structure (Figure 4.8A). HDX MS data 
showed that, compared to full-length proteins, the 1-159 fragment had lost its 
protection in residue segments 1-70 and 125-159, suggesting substantial helical 
unfolding in these segments (Figure 4.8D-G and K; light-blue and brown line in 
Figure 4.8C). However, the 1-159 fragment retains protection in residues 72-113 
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(Figure 4.8H-J), indicating a substantially intact helix III (gray ribbon in Figure 
4.8C). These results suggest that the cleavage of full-length L159R apoA-I near 
the mutation site removes the C-terminal tail and a part of helix IV from the 
bundle. This destabilizes the remaining helices, including part of helix IV along 
with helices I and II (brown and light-blue, Figure 4.8 C). Loss of ordered 
structure in this region is expected to accelerate proteolytic degradation. The 
thermal denaturation data of the 1-159 fragment is shown in figure 4.8B. The 
results showed that the melting temperature, Tm, was 43 C and indicated only 
~30% -helical content at 37 °C. Taken together, these results suggest that local 
helical unfolding near the mutation site renders the mutant protein, L159R, 
susceptible to proteolysis in this region thereby generating a structurally labile 
substantially unfolded 1-159 fragment. Such a local unfolding followed by 
degradation would explain why L159R apoA-I does not form amyloid in vivo 






Figure 4.8. Conformation and stability of lipid-free 1-159 fragment of human 
apoA-I.  
Far-UV CD spectra (A) and the melting data (B) were recorded as in Figure 4.2. 
(C) Structural model depicting the conformation of the 1-159 fragment. The 
actual a-helical content is lower than that shown in the model, with the part in 
blue largely unfolded, as suggested by our HDX-MS data. (D-K) Representative 
deuteration curves of 1-159 fragment compared to full-length WT and variant 
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apoA-I. Although the 1-159 fragment lacks the largely disordered C-terminal tail, 
CD data show that its helical content in solution does not exceed 30% at 37 °C 
(A). HDX-MS data in panels D-G and K suggest that this helical loss occurs 
mainly in residues 1-70 and 125-159 (light blue and brown in panel C). From 
[Das et al., 2016]. 
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4.7 Propagation of Conformational Changes to Distant Sites 
Our data also provided interesting insights into the propagation of the 
conformational changes from the mutation sites in the helix bundle to the C-
terminal tail (residues 185-243). In WT, the flexible C-terminal tail has low 
protection [Chetty et al., 2009] and is thought to interact weakly with the helix 
bundle ([Mei & Atkinson, 2011; Jayaraman et al., 2012; Segrest et al., 2014] and 
references therein). HDX MS data showed that while F71Y and W50R mutations 
had little effect on the deuteration of the C-terminal tail, G26R slightly increased it 
(Figure 4.7T-V) pointing towards reduced protection. Surprisingly L159R and 
L170P significantly decreased deuteration in the C-terminal tail (Figure 4.7T-V), 
except for its very end (Figure 4.7W). This is in contrast to the behavior exhibited 
by these two outside mutants in other parts of the protein where the structural 
protection is decreased. We propose that the decrease in deuteration of the C-
terminal tail observed in the two outside mutants indicates a more extensive 
packing of the tail against the helix bundle. 
Our spectroscopic studies helped explain this observation. The “HDL-like” 
aromatic packing in free L170P and L159R detected by near-UV CD (Figure 
4.3A, B), together with a large destabilization of these mutants and a 2-fold 
decrease in their unfolding cooperativity observed by far-UV CD (Figure 4.2B), 
suggest an increased cleft separating the two pairs of helices in the helix bundle 
(Figure 4.1). We posit that the widening of this narrow hydrophobic cleft can 
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potentially accommodate the hydrophobic C-terminal tail in L170P and L159R 
mutants. Sequestration of the C-terminal tail in the cleft is expected to compete 
with ANS binding at these sites. This explains reduced ANS binding observed in 
L170P and L159R (Figure 4.4A). Such an interaction of the C-terminal with the 
helix bundle is expected to improve shielding from solvent quenching of the four 
Trp in the helix bundle, thereby explaining the observed increase in Trp emission 
for L170P and L159R (Figure 4.4B). A contribution to this increased Trp emission 
may also result from the energy transfer from the two Tyr residues in the C-
terminal tail (Y192, Y136) to the Trp residues in the helix bundle (W8, W50, W72, 
W108).  
In summary, the results of our HDX MS, far-and near-UV CD, ANS binding 
and Trp fluorescence, mapped on the crystal structure of (185-243)apoA-I, 
revealed how mutation-induced local perturbations in the core of the well-ordered 
helix bundle in the N-terminal part of the protein can shift the conformational 
equilibrium in the flexible C-terminal tail. Such a template-induced shift in the 
conformational equilibrium of the disordered region differs from the classical 
structure-based view of propagation of conformational changes to distant site 
and is akin to the newly developed concepts of the ensemble nature of allostery 




4.8 Summary of the Mutational Effects on the Conformation of Free ApoA-I 
Our results reveal the effects of several disease-causing point mutations 
on the local and global structural dynamics of full-length lipid-free human apoA-I. 
HDX MS data show that, although the overall protein fold is retained, each 
mutation elicits distinct structural responses in the helix bundle and the C-
terminal tail. First, L170P and L159R show overall higher deuteration yet lower 
deuteration in the C-terminal tail. We attribute these effects to the enhanced 
hydrophobic interactions between the flexible tail and the helix bundle cleft that is 
widened in these two “outside” mutants. Second, L159R mutant is the only 
protein that shows increased deuteration in the linker region adjacent to the 
mutation site, which reflects the local helical unfolding near this site upon 
substitution of the hydrophobic Leu159 with charged Arg in the core of the helix 
bundle.  
Some mutations (L159R, L170P and G26R) cause increased disorder in 
the well-ordered -helical segment 83-93 that is cleaved in AApoAI deposits, 
while others (F71Y, W50R) do not. This suggests that cleavage at these sites 
may be secondary to protein misfolding, at least in some AApoAI mutants (F71Y, 
W50R), supporting the idea that the apoA-I misfolding can precede proteolysis at 
these sites rather than follow it [Wong et al., 2010; Das et al., 2014].  
Finally, segment 44-55 that adopts a -strand-like conformation in the 
crystal structure of (185-243)apoA-I remains invariant upon mutations (Figure 
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4.7E). Consequently, although this segment may possibly be involved in -helix 
to -sheet conversion in apoA-I, it probably does not trigger AApoAI.  
 
4.9 Hypothesis: What Makes the Protein Amyloidogenic? 
Based on our results, we can propose what makes apoA-I amyloidogenic. 
We posit that WT apoA-I is protected from misfolding by sequestering the major 
amyloid hot-spot 14-22 in the middle of the helix bundle. Previously we proposed 
that reduced protection of this sensitive segment upon mutations or other 
modifications can trigger its conversion into an intermolecular -sheet [Das et al., 
2014]. In fact, our HDX MS data reveal that one of the major effects of all 
disease-causing mutations explored here is reduced protection in residues 14-22 
(Figure 4.7B, C). However, this effect alone does not always cause amyloidosis, 
as L159R does not form amyloid in vivo despite greatly reduced protection in 
residues 14-22. We propose that the in vivo behavior of L159R mutant is 
probably due to its rapid proteolytic degradation after cleavage near the mutation 
site. Such cleavage generates a ~18kDa N-terminal fragment observed in 
plasma [McManus et al., 2006], and our HDX MS results suggest that this 
cleavage is facilitated by local helical unfolding near 159R (Figure 4.7M, N). 
Structural analysis further indicates that cleavage at residue 159 deletes a large 
part of one helix from the 4-helix bundle and generates a labile 1-159 fragment 
that is largely unfolded at near-physiologic conditions, with only ~30% -helix 
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content at 37 C and Tm=43C (Figure 4.8). As a result of substantial unfolding of 
helices I, II and IV, which is indicated by the HDX MS analysis of the 1-159 
fragment (Figure 4.8), this proteolytic fragment of L159R is expected to be rapidly 
degraded in plasma. In contrast, all AApoAI mutants studied here, including 
L170P whose overall conformation and stability closely resemble that of L159R, 
have intact structure in their inter-helical linker. Therefore, they retain their native 
helix bundle conformation long enough to initiate -aggregation. 
In summary, our results suggest that two factors are necessary to make 
apoA-I amyloidogenic: i) reduced protection of the major amyloid hot spot 
(residues 14-22), and ii) its presentation in the context of the native helix-bundle 
structure whose life time is sufficient to augment protein aggregation rather than 
rapid clearance.  
The competition between protein generation, clearance and misfolding 
underlies the observation that the extent of the overall structural destabilization in 
apoA-I and other amyloidogenic proteins (e. g. transthyretin and immunoglobulin 
light chain) does not always correlate with amyloid formation in vivo [Shnyrov et 
al., 2000; del Pozo Yauner et al., 2008; Kilmtchuk et al., 2010; Das et al., 2014]. 
The delicate balance between the protein generation, proteolysis and 
aggregation (called proteostasis), which depends, in part, on the local backbone 
conformation and dynamics in the amyloid hot spots versus protease-sensitive 
regions, is probably a fundamental determinant for globular protein misfolding 
  
155 
and amyloid deposition in vivo. Therefore, the results of our apoA-I research are 





Chapter 5 Amyloid-Forming Properties of Human Apolipoproteins: 
Sequence Analyses and Structural Insights 
 
5.1 Recent Advances in Structural and Bioinformatics Studies  
Last decade saw important progress in clinical and basic research of 
apolipoproteins as well as in molecular-level studies of amyloids. In previous 
chapters, we have described recent advances in structural studies of apoA-I and 
combined them with our experimental findings to better understand apoA-I 
misfolding. Here, we combine similar sequence-based predictions and, whenever 
possible, their experimental validations with the available structural information 
on other apolipoproteins to glean new insights into the complex processes of 
their misfolding. Comparison of these proteins lead to surprising new results and 
help to understand why some of them readily form amyloid in vivo while others 
do not. 
 
5.2 Apolipoprotein A-II 
Apolipoprotein A-II (77 a. a.) is the second-major HDL protein and the 
most hydrophobic exchangeable apolipoprotein. Human apoA-II forms a 
homodimer, which is linked via a disulfide bond at Cys 6, and circulates largely 
on mature mid-size plasma HDL that also contain apoA-I [Gillard et al., 2009; 
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Gao et al., 2012]. Although the exact function of apoA-II is far from being clear, 
the emerging consensus is that apoA-II restricts the apoA-I conformation of HDL 
and, hence, indirectly influences the interactions of apoA-I with its functional 
ligands, which are critical to HDL metabolism ([Silva et al., 2007; Gao et al., 
2012; Maiga et al., 2014] and references therein). 
Our current knowledge of the apoA-II structure is limited to low resolution. 
Human apoA-II is proposed to form a highly -helical antiparallel dimer on HDL 
[Silva et al., 2007], yet in solution the protein is only partially folded and 
marginally stable [Gursky & Atkinson, 1996b]. Figure 5.1 shows the amino acid 
sequence of apoA-II, which is predicted to form class-A amphipathic -helices 
with particularly large apolar faces spanning ~180º as compared to ~120 typical 
for other exchangeable apolipoproteins [Segrest et al., 1994]. As a result, apoA-II 
-helices insert more deeply into the phospholipid monolayer and bind more 
strongly to mature HDL than any other apolipoproteins ([Gao et al., 2012] and 
references therein). We propose that this strong association with mature HDL, 
which makes wild type human apoA-II practically non-exchangeable, helps to 
protect it from misfolding.  
In humans, apoA-II misfolding can cause hereditary amyloidosis 
(AApoAII), a rare autosomal dominant disorder resulting from stop codon 
mutations that produce a 21-residue C-terminal extension consisting of additional 












Figure 5.1 Amphipathic class-A -helix is the major structural and functional 
motif in apolipoproteins. 
Helix wheel representation of residues 9-30 of human apoA-II is shown as an 
example. Class-A -helix has a large apolar face (gray filled circles) flanked by 
basic residues (+, blue letters), with acidic residues (-, red letters) located in the 
middle of the polar face. Polar face of the helix interacts with the aqueous 
solution (light-blue), while the apolar face can bind lipid surface (beige) or interact 




deposits primarily in kidneys, causing renal damage and failure. The only existing 
treatment for apoA-II amyloidosis is dialysis followed by kidney transplant [Magy 
et al., 2003].  
Amino acid sequence analysis showed that the mutant but not wild-type 
human apoA-II forms amyloid in vivo [Gursky 2014]. In wild-type human apoA-II, 
two amyloid hot spots are predicted strongly in residues 10-18 [LVSQYFQTV] 
and 60-70 [LVNFLSYFVEL]. These hydrophobic segments are predicted by 8 out 
of 11 combined methods in AmylPred2 and have PASTA2 energies ranging from 
-4.4 to -7.1 (Figure 5.2A, B). Importantly, these two predicted amyloidogenic 
segments in apoA-II have been verified experimentally in peptide fragment 
studies of murine apoA-II that is homologous to the human protein [Sawashita et 
al., 2009]. Notably, the amyloidogenic segments in apoA-II are located inside the 
predicted lipid-binding class-A -helices (Figure 5.1), which is expected to protect 
them from misfolding. 
One likely reason for the C-terminal extension to cause AApoAII 
amyloidosis could be the inability of this extension to form an amphipathic -helix 
to bind lipid surface, unlike the rest of apoA-II [Benson et al., 2011; Gursky, 
2014]. Although this C-terminal extension (residues 78-98, 
GSVQTIVFQPQLASRTPTGQS) has substantial hydrophobic amino acid content, 
the helix-wheel analysis showed a random pattern of distribution of these amino 
acids with no apparent polar and apolar face [Gursky, 2014]. As a result, the lipid 
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binding affinity of the mutant protein is expected to decline, shifting the 
population distribution from HDL-bound to free apoA-II that is labile to misfolding.  
Another likely reason could be the potential synergy between the 
additional amyloidogenic segment predicted in the C-terminal extension and the 
existing major amyloidogenic segment in residues 60-70. In fact, both these 
segments are predicted strongly to form parallel in-register -sheet in amyloid, 
which facilitates their synergistic action in the intermolecular parallel cross--
sheet formation shown in Figure 5.2C [Gursky, 2014].  
Compared to other exchangeable apolipoproteins, normal human apoA-II 
is the most hydrophobic, binds most strongly to mature HDL, and has the highest 
sequence propensity to form amyloid. The strong association of native human 
apoA-II with mature HDL, enhanced by the protein dimerization via the disulfide 
link formed by Cys6, most likely protects it from forming amyloid. This disulfide 
may also potentially interfere with the structural transition from an antiparallel 
helical dimer [Silva et al., 2007] into a parallel intermolecular -sheet. 
Therefore, the C-terminal extension that causes apoA-II amyloidosis in humans 
is expected to have a dual effect: reduced lipid-binding affinity of the protein and 





Figure 5.2 Predicted amyloidogenic segments in human apoA-II and its C-
terminal extension. 
Amyloidogenic profiles obtained by AmylPred2 [Gursky, 2014] (A) and PASTA2 
(B) for human apoA-II with C-terminal extension 78-98 (dark red) that causes 
human amyloidosis. The major amyloidogenic segments predicted by five or 
more methods in AmylPred2 are shown by residue numbers. Double arrows 
show the orientation of the intermolecular -sheet predicted by PASTA2.0. The 
predicted native secondary structure is shown at the bottom; rectangles and 
residue numbers indicate -helices. Cys6 that forms an intermolecular disulfide 
link in human apoA-II dimer is in orange. Amino acid sequence of human apoA-II 
with C-terminal extension is shown; amyloidogenic segments are color-coded. 
(C) Cartoon showing parallel in-register -sheet predicted for apoA-II with 
amyloidogenic extension. Different protein molecules are in different shades of 
gray. Modified from [Gursky 2014]. 
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5.3 Apolipoprotein A-IV 
Human apoA-IV (376 a. a.) is the largest known exchangeable 
apolipoprotein. It is synthesized in the gut, secreted on chylomicrons, and 
circulates in plasma in HDL-bound and in lipid-free states [Green et al., 1980]. 
This minor apolipoprotein is proposed to regulate chylomicron assembly, 
modulate reverse cholesterol transport, serve as an anti-oxidant and as a satiety 
signal, as well as perform other functions in lipoprotein metabolism ([Deng et al., 
2012] and references therein). ApoA-IV was also implicated in the clearance of 
A peptide in the brain [Cui et al., 2011]. A case of human cardiac amyloidosis 
has been reported in which the N-terminal 70-residue fragment of wild-type 
apoA-IV deposited as fibrils [Bergström et al., 2004].  
Similar to other exchangeable apolipoproteins, apoA-IV structure is mainly 
comprised of amphipathic-helices. ApoA-IV contains a globular core domain 
(approximately residues 97-311) flanked by the N- and C-terminal segments 
whose interactions regulate lipid binding [Walker et al., 2014].  The x-ray crystal 
structure of the core domain residues 64-335, which was determined to 2.4 Å 
resolution by Davidson’s team [Deng et al., 2012], closely resembled the C-
terminally truncated apoA-I [Mei & Atkinson, 2011]. Similar to the N-terminal 75% 
of apoA-I, the core domain of apoA-IV forms a four-helix bundle that dimerizes 
via the domain swapping of a helical segment (Figure 5.3C) [Deng et al., 2012]. 
In contrast to the highly curved apoA-I dimer that matches the HDL surface 
  
163 
curvature, the apoA-IV dimer is nearly linear, consistent with its ability to bind 
much larger lipoproteins with lower surface curvature. 
Compared to other exchangeable apolipoproteins, apoA-IV binds lipid 
surface relatively poorly, as evident from its near-equal plasma distribution 
between lipid-bound and lipid-free states [Green et al., 1980]. Modest lipid 
binding affinity of apoA-IV is attributed to the strong interactions between its N- 
and C-terminal domains that hold the protein molecule in a closed conformation 
via the “clasp mechanism” that modulates helix bundle opening on the lipid 
[Walker et al., 2014]. Aromatic residues W12, Y14, F334 and F335 are implicated 
to be essential in “clasping” and in lipid binding as shown in Figure 5.3D [Walker 
et al., 2014]. For example, the lipid binding of apoA-IV is increased upon 
substitution of Phe for Ala at 334 position [Tubb et al., 2007].   
We propose that the “clasping” of the N- and C-terminal parts protects 
apoA-IV from misfolding. This idea is based on our sequence analysis of human 
apoA-IV (Figure 5.3A, B). Both AmylPred2 and PASTA2 predict two major 
aromatic-rich amyloidogenic segments in residues 7-16 (VATVMWDYFS) and 
331-336 (VNSFFS) from the N- and C-terminal parts, respectively. PASTA2 
predicts that these segments are likely to form parallel in-register -sheet in 
amyloid. In addition, Figure 5.3A shows that AmylPred2 predicts two weaker 
amyloidogenic segments around residues 40-41 of the N-domain and 221-222 of 
the core domain. Three other major predicted amyloid hot spots are located in 
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the putative helical regions that are outside (residues 7-16 and 40-41) or at the 
edge (residues 331-336) of the crystallized construct, and the fourth hot spot 
(residues 221-222) is located inside the -helical region in the crystal structure 
(Figure 5.3C) [Walker et al., 2014]. These amyloidogenic segments are probably 
protected from misfolding by their native helical structure, as well as by the 
tertiary interactions in lipid-free full-length apoA-IV. In fact, aromatic residues 
W12, Y14 and F334, F335 that are proposed to be essential for lipid binding and 
for “clasping”, as well as F223 that modulates lipid binding, are located inside or 
adjacent to the amyloidogenic segments (Figure 5.3A, D). Hence, these sensitive 
regions are probably sequestered via the “clasp” mechanism in free protein or via 
the lipid binding on HDL. 
In summary, we propose that the major predicted amyloidogenic 
segments in native lipid-free apoA-IV are protected from misfolding via the same 
“clasp” mechanism that regulates protein-lipid interactions (Figure 5.3D). Further, 
the presence of two amyloid hot spots in residues 7-16 and 40-41 helps explain 
the deposition of the N-terminal fragment containing these residues in systemic 





Figure 5.3 Amyloidogenic profile and the structure of human apoA-IV. 
AmylPred2 (A) and PASTA2.0 profiles (B) of full-length apoA-IV are shown. N- 
and C-terminal regions flanking the core domain are indicated. Residue numbers 
indicate amyloidogenic segments predicted by five or more methods (at or above 
the dotted line). Aromatic residues implicated in lipid binding are in purple. Green 
bar shows N-terminal fragments found in human apoA-IV amyloidosis [Benson et 
al. 2001]. Predicted residue pairing and PASTA energy in the major 
amyloidogenic segment is shown. (C) Helix bundle structure of the monomeric 
core domain of apoA-IV (residues 64-335) obtained via the domain swapping 
from the X-ray crystal structure of the dimer [Deng et al. 2012]. Residues in the 
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amyloidogenic segments predicted by AmylPred2 are indicated. (D) Cartoon 
showing the molecular architecture of free full-length apoA-IV according to 
[Walker et al. 2014]. Circles H1-H4 designate -helices forming four-helix bundle 
in the core domain. N-terminal segment is in blue and C-terminal is in red. Filled 
ovals show amyloid hot spots predicted in our work. Aromatic residues involved 
in “clasp” formation and lipid binding are in purple [Walker et al. 2014]. From [Das 




5.4 Apolipoprotein A-V 
ApoA-V (343 a. a.) is a hydrophobic protein that is a potent reducer of 
plasma triacylglycerides (TG) [Nilsson et al., 2011]. Similar to its physiological 
antagonist apoC-III (described in section 5.5 below), apoA-V is secreted by 
hepatocytes and circulates in plasma as a minor component of VLDL and HDL. 
To our knowledge, no amyloid diseases resulting from the deposition of apoA-V 
have been reported to-date. This is not surprising given minute concentration of 
this protein in plasma (~150 ng/ml). Nevertheless, apoA-V has emerged as an 
important modulator of TG metabolism, which can influence secretion, 
processing and clearance of TG-rich lipoproteins via several mechanisms 
[Sharma et al., 2013].  
Structural analysis of apoA-V, pioneered by Ryan and colleagues 
[Weinberg et al., 2003; Beckstead et al., 2007; Wong et al., 2008; Mauldin et al., 
2010; Sharma et al., 2013], has been complicated by the low protein solubility. 
Most experiments have been performed in solution at pH 3 and have been 
limited to low-resolution techniques. The protein structure was inferred to contain 
tandem amphipathic -helices, which in apoA-V form distinct domains [Weinberg 
et al., 2003; Beckstead et al., 2007; Wong et al., 2008]. The N-terminal residues 
1-146 are proposed to form a helix bundle [Wong et al., 2008]. The central 
domain (residues 147-292) contains a basic stretch (residues 186-227) 
implicated in binding to acidic ligands. Finally, the C-terminal 51 residues are 
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implicated in modulating lipid binding by apoA-V [Beckstead et al., 2007, Mauldin 
et al., 2010]. 
Our amino acid sequence analysis using AmylPred2 predicts one strong 
amyloidogenic segment in residues 269-277 (TYLQIAAFT) and three weaker 
ones in residues 118-120, 150-151 and 204-210, shown in Figure 5.4. One 
predicted amyloidogenic segment, 119-121, is in the N-domain, the other three 
are in the central domain, and all four are located inside the amphipathic -
helices predicted in the native structure [Weinberg et al., 2003]. Notably, a strong 
amyloidogenic segment predicted in residues 204-210 forms a hydrophobic 
stretch inside a larger predominantly basic segment 190-225 that is implicated in 
binding to the receptor and to heparan sulfate proteoglycans (Figure 5.4). This 
larger segment contains eight basic residues, no acidic residues, and three 
structure-breaking Pro. Since stretches of similarly charged residues are 
disfavored in the parallel in-register amyloid -sheet due to inter- and 
intramolecular electrostatic repulsion, it is unlikely that this residue segment 
initiates -aggregation. In fact, our analysis using PASTA2 does not predict a 
strong pairing energy for this segment. Further, PASTA2 predicts parallel in-
register -sheet for apoA-V, with the most favorable pairing energy of -3.9, just 
below the threshold of -4. Hence, this prediction by PASTA should be taken with 





Figure 5.4 Amyloidogenic profile of human apoA-V obtained by AmylPred2. 
Residue numbers indicate amyloidogenic segments predicted by five or more 
methods (above the dotted line). Blue bar and +++ indicate residue segment that 
contains eight uncompensated basic residues and three Pro and is implicated in 
binding to the lipoprotein receptor and to heparan sulfate proteoglycans. From 




In summary, apoA-V is a minor hydrophobic protein that is an important 
modulator of TG metabolism. The atomic structure of apoA-V is unknown. The 
predicted amyloidogenic potential is localized mainly to the central domain 
(Figure 5.4). Similar to other apolipoproteins, the amyloidogenic segments in 
apoA-V are hydrophobic, are located in the amphipathic -helices in the native 
structure, and are predicted to form parallel in-register -sheet in amyloid. These 
segments are expected to be protected from misfolding by their native protein-
lipid and/or protein-protein interactions. Amyloidogenic segment 204-210 is 
probably also protected from misfolding by its location inside a basic stretch that 
forms a binding site for VLDL receptor. 
 
5.5 Apolipoproteins C-I, C-II and C-III  
ApoC-I (6 kDa), C-II (10 kDa) and C-III (10 kDa) are the smallest human 
apolipoproteins that circulate mainly on VLDL and are also found as minor 
proteins on HDL and other lipoproteins. ApoCs are particularly important for 
metabolism of triglyceride-rich lipoproteins, as they modulate the activity of 
lipophilic enzymes, lipid transfer proteins, and other plasma factors that remodel 
these lipoproteins in vivo. ApoC-I inhibits cholesterol ester transfer protein, apoC-
II is a physiological activator of lipoprotein lipase, while apoC-III is its inhibitor 
and is also implicated in VLDL production [Jong et al., 1999; Shachter, 2001; Yao 
& Wang, 2012]. NMR structures of apoC-I, apoC-II and apoC-III have been 
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determined in lipid-mimetic environment on the micelles of sodium dodecyl 
sulphate (SDS) or dodecylphosphocholine (DPC) [Rozek et al., 1999; MacRaild 
et al., 2001, 2004; Gangabadage et al., 2008]. These structures showed that 
amphipathic class-A -helices form the lipid surface-binding motif in apoCs 
(Figure 5.5, bottom panels). Compared to larger apolipoproteins, apoCs make 
fewer contacts on the lipoprotein surface and can dissociate from it relatively 
easily [Jayaraman et al., 2005a]. Such dissociation is also expected to occur in 
vivo, e. g. during VLDL conversion to LDL. Amyloid deposition in kidneys by a 
rare D25V mutant of human apoC-III [Valleix et al., 2016] and amyloidosis 
caused by a rare mutation of apoC-II has been reported recently [Obici et al., 
2016]. Previously, apoC-III was also shown to form amyloid fibrils in vitro [de 
Messieres et al., 2014]. The latter clinical observation is consistent with the 
extensive studies of apoC-II fibril formation in vitro by Howlett’s team, which have 
provided the most detailed model currently available for understanding 
apolipoprotein misfolding ([Ryan et al., 2015] and references therein). 
Here, we report amyloidogenic profiles of human apoCs. AmylPred2 
predicts that apoC-II has a substantial amyloid-forming potential, especially in the 
C-terminal part, while the sequences of apoC-I and apoC-III are less 
amyloidogenic (Figure 5.5). Similarly, PASTA2 data in Figure 5.6 suggests 
substantial amyloid-forming potential in the C-terminal part of apoC-II and 




Figure 5.5 Predicted amyloidogenic profiles and the structures of human apoCs.  
Top: AmylPred2 profiles of human apoC-I (A), apoC-II (B), and apoC-III (C). 
Residues predicted to form amyloidogenic segments by five or more methods 
(above the dotted line) are indicated.  Middle: Secondary structures of apoCs that 
were predicted [Segrest et al. 1992] or observed by NMR on SDS or DPC 
micelles [Rozek et al. 1999; MacRaild et al. 2001, 2004; Gangabadage et al. 
2008]. Rectangles and residue numbers indicate helical segments. Bottom: NMR 
structures of human apoCs on SDS micelles. Predicted amyloidogenic segments 
are mapped on the structures and color-coded. Amino acid sequences of the 












Figure 5.6 PASTA2.0 profile of human apoC-II and its experimental validation.  
C-terminal segment 66-75 is predicted to form parallel in-register -sheet, which 
is experimentally validated by EPR [Teoh et al., 2011].  Residue segments that 
are resistant to proteinase digestion and hydrogen-deuterium exchange and are 
implicated in amyloid core formation are shown in patterned bars. Fragments 
implicated in amyloid formation in vitro are in solid bars [Wilson et al., 2007]. 




Most favorable pairing energies predicted for apoC-I (-1.9) and apoC-III (-2.7) are 
well below the threshold of -4 and hence, are not very reliable. Nevertheless, 
human apoC-III can form amyloid fibers both in vitro and in vivo [de Messieres et 
al., 2014; Valleix et al., 2016].  
The strongest predicted amyloidogenic segment in human apoCs is 
located in the C-terminal part of apoC-II (residues 62-76, TYTGIFTDQVLSVLK) 
from the native class-G helix. This prediction has been verified experimentally in 
careful studies by Howlett’s group [Wilson et al., 2007] (Figure 5.6). These 
studies showed that in fibers of full-length human apoC-II, the C-terminal 
segment is resistant to proteolysis and to HD exchange, which is characteristic of 
an amyloid core. The authors also showed that peptide fragments corresponding 
to the C-terminal segments of apoC-II readily form amyloid in vitro. Finally, 
structural analysis of apoC-II fibrils revealed parallel in-register sheets [Wilson 
et al., 2007], which verifies our prediction by PASTA (Figure 5.6). In summary, 
extensive experimental evidence validates the prediction of the major amyloid hot 
spot in residue segment 62-76 of apoC-II and suggests that this segment initiates 
protein misfolding, from the predominantly helical native structure to parallel 
in-register intermolecular -sheet in amyloid. 
We speculate that the native -helical structure in this segment, which 
forms the major lipid-binding site in apoC-II, anchors the protein to the lipid 
surface and thereby protects it against -aggregation in vivo. Notably, this 
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segment forms a class-G helix that, in contrast to class-A helices, has random 
radial distribution of charged residues. Therefore, amyloidogenic properties of 
apolipoproteins are not limited to class-A -helices in the native structure. 
 
5.6 Apolipoprotein E  
ApoE (299 a. a.) is arguably the most extensively studied apolipoprotein 
(~22,000 hits on PubMed) that is an important mediator of lipid transport in 
plasma and in the central nervous system. ApoE is found in most systemic and 
cerebral amyloid deposits and is particularly pertinent to the development of 
Alzheimer’s disease ([Hauser & Ryan, 2013] and references therein). Plasma 
apoE circulates mostly on VLDL where it serves as a ligand for LDL-like receptor 
that mediates VLDL uptake and maturation to LDL [Hauser et al., 2011; 
Holtzman et al., 2012]. During this process, TG in the lipoprotein core are 
hydrolyzed by lipoprotein lipase, generating excess surface material that can 
dissociate in the form of free apolipoproteins or small apoE-containing particles 
that join the plasma pool of HDL [Musliner et al.,1991]. Hence, in addition to 
VLDL, apoE also circulates as a minor protein on plasma HDL. In contrast to 
plasma, lipid transport in cerebrospinal fluid is mediated solely by HDL-like 
particles whose major protein is apoE. This explains the prominence of apoE in 
neurodegenerative diseases. Notably, the apoE4 isoform is the strongest genetic 
predictor of Alzheimer’s disease and is directly associated with the amyloid load 
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in this disease ([Hauser & Ryan, 2013] and references therein). Although the 
exact role of apoE in the development of Alzheimer’s disease is not fully 
understood, the consensus is that apoE interacts directly in an isoform-specific 
manner with A peptide and thereby influences aggregation, accumulation and/or 
clearance of A from the brain [Strittmatter et al., 1993; Ladu et al., 2000; Hauser 
& Ryan 2013].  
Three major isoforms of human apoE differ in Cys/Arg substitutions at two 
sites: apoE2 (C112, C158), apoE3 (C112, R158) and apoE4 (R112, R158), 
resulting in differences in charge, structural stability and functional properties. 
Compared to apoE3, which is the most common isoform, apoE4 is a strong 
causative risk factor for Alzheimer’s disease, while apoE2 is neuroprotective 
[Strittmatter et al., 1993; Verghese et al., 2011; Suri et al., 2013]. ApoE4 is linked 
strongly to earlier age of the late-onset Alzheimer’s disease and more severe A 
deposition in the brain, while apoE2 has an opposite effect [Verghese et al., 
2011; Suri et al., 2013]. Thus, the predisposition to Alzheimer’s disease 
increases in the order E2<E3<E4. Although the molecular mechanism via which 
apoE isoforms differentially influence A accumulation in the brain is subject of 
debate, the prevailing idea is that this difference resides in the isoform-specific 
domain interactions in apoE, which influence its interactions with A [Hauser & 
Ryan 2013]. 
Structurally, apoE is often described as a two-domain protein comprised of 
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a globular 22 kDa N-terminal domain that forms a helix bundle in solution and 
contains a receptor and a heparan binding site in residues 136-150, and a C-
terminal 10 kDa domain that is less structured in solution and forms the primary 
binding site for lipids and AChen & Wang, 2011. The four-helix bundle 
structure of the N-terminal domain of lipid-free apoE3, which was determined by 
x-ray crystallography to 2.2 Å resolution, was the first known atomic structure of a 
mammalian apolipoprotein [Wilson et al., 1991]. This structure is consistent with 
the solution conformation of the full-length lipid-free modified apoE3 determined 
20 years later by NMR [Chen & Wang, 2011]. In the NMR structure, the globular 
N-terminal domain (residues 1-167) forms a template for folding of the hinge 
region (168-205) and the C-terminal domain (206-299) (Figure 5.7, 5.8). The two 
residues, 112 and 158, differing among the apoE isoforms are located in the N-
terminal -helices (orange, Figure 5.7, 8). Cys to Arg substitution at either site 
weakens the inter-helical interactions and reduces structural stability of the N-
terminal domain and of the full-length lipid-free apoE [Acharya et al., 2002; 
Weers et al., 2003; Nguyen et al., 2014]. The experimentally determined rank 
order of free protein stability is E4<E3<E2, opposite to that of the pre-disposition 
to Alzheimer’s disease [Mahley et al., 2009]. A similar trend was observed in 
other proteins whose reduced structural stability often correlates with enhanced 
amyloid formation and is thought to contribute to it [Hatters et al., 2005].  
Tertiary structural stability of apoE isoforms and other free apolipoproteins 
in solution correlates inversely with the probability of their helix bundle opening 
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on the lipid, which is a necessary step in lipoprotein formation. Therefore, apoE 
isoform stability in solution was proposed to correlate inversely with the lipid 
binding affinity [Morrow et al., 2000; Acharya et al., 2002; Weers et al., 2003]. To 
our knowledge, relative dissociation rates of apoE isoforms from HDL, which 
determine relative kinetic stabilities of HDL containing these isoforms, have not 
been reported. Furthermore, no isoform-specific effects have been observed in 
apoE association with HDL in cerebrospinal fluid ([Verghese et al., 2011] and 
references therein). Therefore, it is unclear whether or not differential affinity of 
apoE isoforms for lipid contributes to the isoform-specific effects in amyloid 
deposition.  
Another potential origin of the isoform-specific effects is in the intrinsic 
sequence propensity of apoE to form amyloid. In fact, apoE misfolding was 
proposed to be a primary event that helps nucleate amyloid formation by A [Ma 
et al., 1994; Wisniewski et al., 1995; Hatters et al., 2005]. To test this idea, we 
analyzed the amino acid sequence of apoE by using AmylPred2 and PASTA2 
(Figure 5.7).  
Surprisingly, both methods predicted relatively weak amyloidogenic 
potential for apoE as compared to other exchangeable apolipoproteins. The 
major amyloidogenic segment is predicted by both methods in residues 33-42, 
with the PASTA2 energy of -3.9, just below the threshold of -4, shown in Figure 




Figure 5.7 Amyloidogenic profile of human apoE3 predicted by AmylPred2 (A) 
and PASTA2.0 (B). 
Amyloidogenic segments predicted by at least 5 methods in AmylPred2 are 
marked. Orange dots show locations of Cys / Arg substitutions that differ among 
the three major isoforms: apoE2 (C112, C158), apoE3 (C112, R158), and apoE4 
(R112, R158). Helical segments observed in the NMR structure of the modified 
full-length human apoE3 [Chen & Wang., 2011] are shown by rectangles. Color 
code: N-terminal helix bundle domain (violet), the connecting hinge (gray), and 
the C-terminal domain (purple). + + + + show a basic stretch (residues 136-152) 
implicated in binding to receptor and to heparan sulfate proteoglycans. Protein 
amino acid sequence with predicted amyloidogenic segments color-coded. From 











Figure 5.8 NMR structure of the full-length modified human apoE3, determined 
by Chen and Wang, 2011.  
N-terminal helix bundle (violet), hinge (gray), and C-terminal domain (purple).  
Helices H1 and H1’ with their connecting loop in the N-domain, and helix HC1 in 
the C-domain are indicated. Helical nomenclature follows [Chen & Wang, 2011]. 
Cys / Arg substitutions at positions 112 and 158 that distinguish the apoE 
isoforms are in orange.  The major predicted amyloidogenic segments are color-
coded as in Figure 12: residues 34-42 (blue), 113-116 (teal) and 159-163 
(green). Residue segment 136-150 from helix H4, which encompasses the 
receptor and heparan sulfate binding site, is indicated (+ + + +). From [Das & 
Gursky, 2015].  
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antiparallel-sheet. Another surprise was that the predicted amyloidogenic 
propensity of apoE resides mainly within the N-terminal domain, even though the 
C-terminal domain is more hydrophobic, binds A, and fragments corresponding 
to this domain can form fibers in vitro [Cho et al., 2001]. This illustrates the ability 
of most polypeptides to form amyloid under certain conditions. We suggest that 
the absence of strong amyloidogenic segments in the C-terminal domain of 
apoE, which adopts a dynamic solvent-exposed conformation in solution, helps 
protect free protein from misfolding in vivo. 
In the N-terminal domain of apoE3, three amyloidogenic segments are 
predicted in residues 33-42, 113-116 and 159-163 by five to seven methods in 
AmylPred2 (Figure 5.7). Mapping these segments on the NMR structure of the 
modified full-length protein shows that they are located in the amphipathic -
helical regions (Figure 5.8). The only exception is residues 41 and 42 that are 
located in a solvent-exposed inter-helical loop (blue arrow, Figure 5.8) and 
hence, are potentially labile to misfolding. Notably, sites 112 and 158 that 
distinguish apoE isoforms are located at the edges of the two respective 
amyloidogenic hot spots, 113-116 and 159-163. Cys to Arg substitutions at these 
sites slightly reduce the amyloid-forming potential of the adjacent hot spots. This 
is not surprising, since the amyloid-forming potential of Arg is lower than that of 
free Cys in most contexts. Further, amyloidogenic segment 159-163 is close to 
the basic stretch in residues 136-150 that form the receptor and heparan sulfate 
binding site in apoE [Wilson et al., 1991]. We speculate that, in the absence of 
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polyanionic ligands such as heparan sulfate proteoglycans, this basic stretch 
may help block the -zipper propagation along the polypeptide chain.  
 Since apoE has been previously found to directly nucleate A aggregation 
in amyloid [Ma et al., 1994, Wisniewski et al., 1995, Hatters et al., 2005], we 
tested whether a particular segment in apoE is likely to pair with A to nucleate 
an intermolecular -sheet co-polymer. To do so, we used AmylPred2 and 
PASTA2 to analyze a chimeric amino acid sequence comprised of apoE and 
A42 sequences. Figure 5.9 shows that the two strongest hot spots in AmylPred2 
came from A42. Likewise, PASTA2 did not predict any favorable pairings 
between A and apoE. This analysis suggests that apoE is unlikely to nucleate 
amyloid formation by A via the segment pairing between the two proteins. 
 Our analysis can be summarized as follows. First, despite its prominence 
in amyloid diseases, apoE has weaker sequence propensity to form amyloid than 
many other apolipoproteins. Second, this propensity decreases slightly upon Cys 
to Arg substitutions at sites 112 and 158 that differentiate apoE isoforms. Hence, 
the amyloid-forming sequence potential increases in order E4<E3<E2, which is 
reverse of the isoform-specific predisposition to neurodegenerative diseases. 
Consequently, this pre-disposition must result from factors other than sequence 
propensity of apoE isoforms for -aggregation. Together, these findings suggest 
that apoE misfolding is probably not a major factor in amyloid deposition in 
Alzheimer’s disease.  
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Third, the NMR structure of free full-length apoE shows that a part of the 
strongest predicted amyloidogenic segment 33-42 is located in the solvent-
accessible loop, which makes it potentially labile to -aggregation. This loop 
(residues V40, Q41, T42, L43) links N-terminal helices H1 and H1’, and is 
packed against helix HC1 from the C-domain (Figure 5.8). Since inter-domain 
interactions in apoE are isoform-specific, the protection of the major amyloid hot 
spot by these interactions is also expected to be isoform-specific. We 
hypothesize that: (i) in lipid-free full-length apoE, the major amyloid hot spot in 
residues 33-42 is protected from misfolding by secondary and tertiary structure, 
including inter-domain interactions, (ii) destabilization of the N-domain and 
changes in its interactions with the C-domain reduce this protection in an 
isoform-specific manner, from E2 (most stable and most protected) to E4 (least 
stable and least protected). These differences in protection of amyloid hot spots 
in the N-domain may potentially contribute to the isoform-specific effects in 










Figure 5.9 Amyloidogenic profile of Alzheimer’s A(1-42) peptide obtained by 
AmylPred2 and Pasta2.0.  
Pairing energies exceeding -4 PASTA units are shown; residue numbers indicate 




5.7 Serum amyloid A  
Human SAA (104 a. a.) is an intrinsically disordered protein from a family 
of highly conserved acute-phase proteins whose normal function in immune 
response is the subject of debate [van der Westhuyzen et al., 2007, Eklund et al., 
2012, Kisilevsky & Manley, 2012; Colón et al., 2015]. SAA is synthesized 
predominantly by the liver, circulates mainly on plasma HDL, and is best known 
for its role in secondary amyloidosis linked to inflammation. In this potentially fatal 
complication, N-terminal fragments of SAA largely containing residues 1-76, 
termed amyloid A (AA), form extracellular fibrillar deposits in vital organs (kidney, 
liver, spleen) and damage them. AA amyloidosis can be triggered by chronic 
infections, inflammation, rheumatoid arthritis, and certain cancers, and is the 
most prevalent form of human systemic amyloidosis worldwide, which is 
developed by 5-10% of patients with chronic inflammation. Several SAA isoforms 
are found in humans, among which SAA 1.1 is the most amyloidogenic in vivo. 
The reasons for the isoform-specific amyloid formation are unclear and were 
proposed to involve differences in the protein structure, stability and proteolysis 
[Srinivasan et al., 2013; van der Hilst et al., 2008]. It is also unclear whether 
cleavage of the N-terminal AA fragment precedes or follows SAA misfolding in 
AA amyloidosis.  
During inflammation, plasma levels of SAA can increase up to 1000-fold, 
reaching 1-10 mg/ml and making SAA the most abundant protein in plasma 
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[Gillmore et al., 2001]. As a result of mass action, SAA can displace most apoA-I 
from plasma HDL to form of large dense SAA-rich HDL [van der Westhuyzen et 
al., 2007, Eklund et al., 2012, Jayaraman et al., 2015]. In addition, in acute phase 
response, the HDL surface is saturated with SAA and a substantial fraction of 
SAA (up to 25%) circulates in labile free form [van der Westhuyzen et al., 2007]. 
SAA on HDL is predominantly -helical, yet this helical structure is unstable in 
free protein at near-physiologic conditions, which is thought to promote fibril 
formation in vivo [Wang et al., 2005]. This structural instability of SAA has greatly 
complicated its atomic-resolution studies. These studies culminated in 2014 with 
publication of the high-resolution 2.2Å x-ray crystal structure of human SAA1.1 in 
two crystal forms, one of which contains hexamers and probably depicts the 
structure of the hexameric SAA found in solution, while the other contains dimers 
[Lu et al., 2014]. The molecular structure of human SAA1 in hexameric and 
dimeric forms is in excellent agreement with the structure of murine SAA3 that 
was crystallized as a tetramer [Derebe et al., 2014]. The protein fold revealed in 
these crystal structures is thought to be conserved in the SAA family [Derebe et 
al., 2014; Lu et al., 2014]. 
Our analysis of human SAA1.1, in Figure 5.10A, by using AmylPred2 and 
PASTA2 shows that the amyloid-forming propensity is relatively weak and is 
confined largely to the N-terminal ~75 residues, which is consistent with the 
deposition of 1-76 residue fragment in AA amyloidosis. AmylPred2 predicts two 




Figure 5.10 Predicted amyloidogenic profile and the structure of human serum 
amyloid A. 
AmylPred2 (A) and PASTA profiles (B) of SAA1.1 isoform that causes human 
amyloidosis. AmylPred2 predicts amyloidogenic segments in residues 2-9 (blue) 
by six methods, residues 65-70 (green) by five methods and residues 67-70 by 
four methods. PASTA2.0 predicts that the major N-terminal amyloidogenic 
segment can form parallel or antiparallel -sheet with comparable relatively low 
pairing energy. Green bar shows fragment 1-76 that deposits in human AA 
amyloidosis linked to inflammation. Rectangles show helical segments observed 
in the x-ray crystal structure. Amino acid sequence shows predicted 
amyloidogenic segments color-coded. (C) X-ray crystal structure of human 
SAA1.1 monomer determined to 2.2 Å resolution by [Lu et al, 2014]. The 
predicted amyloidogenic segments are mapped on the structure and color-coded. 
Orange dots show positions 52 and 57 of Ala/Val substitutions that distinguish 




minor hot spot in the nearby residues 67-70. Although these consensus 
predictions are not very strong [4-6 out of 11 methods], they are in excellent 
agreement with the sequence analysis by using ZipperDB and TANGO 
algorithms [Lu et al., 2014] as well as with our own analysis by PASTA2 (Figure 
5.10B). The latter shows that the major N-terminal amyloid hot spot has weak 
pairing energy of -2.7 PASTA units, which is comparable for the parallel and 
antiparallel -sheet orientation. Importantly, the predicted hot spots in SAA have 
been verified in experimental studies by using site-directed mutagenesis and 
peptide fragments [Patel et al., 1996; Egashira et al., 2011; Lu et al., 2014].  
Compared to other major HDL proteins, the predicted amyloidogenic 
potential of SAA is comparable to that of apoA-I and is much lower than that of 
apoA-II. This unexpected result suggests that AA amyloidosis is probably driven 
not by the high intrinsic propensity of SAA for -aggregation but by the protein 
overproduction [de Beer et al., 1982] combined with its structural instability and 
solvent exposure of the N-terminal amyloidogenic segment in SAA monomer [Lu 
et al., 2014]. 
In the crystal structure, the major amyloidogenic segment in residues 2-9 
is located at the end of the N-terminal amphipathic -helix (Figure 5.10C, blue). 
This segment is solvent-exposed in free SAA monomer but is sequestered in the 
hexamer, suggesting that hexamer dissociation is prerequisite for SAA misfolding 
[Lu et al., 2014]. Importantly, this amyloidogenic segment overlaps the primary 
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HDL binding site in SAA [Patel et al., 1996, Ohta et al., 2009], suggesting 
strongly that SAA binding via its N-terminal helix to HDL surface protects the 
protein from misfolding [Lu et al., 2014]. The second-major amyloidogenic 
segment is adjacent to residues 52 and 57 that differ among the major human 
isoforms, SAA 1.1 [V52, A57], SAA 1.3 [A52, A57] and SAA 1.5 [A52, V57] 
(Figure 5.10B, C, orange dots). Even though these isoforms are predicted to 
have comparable sequence propensity for -aggregation, one cannot exclude 
that the location of the isoform-specific mutations in the amyloidogenic segment 
contributes to the differences in the amyloid formation by SAA1 isoforms [Takase 
et al., 2014]. Moreover, the second major amyloidogenic segments in residues 
53-55 and 67-70 are located in the proposed HDL binding site of SAA [Frame & 
Gursky, 2016]. Therefore, all amyloidogenic segments in SAA are probably 
protected in the HDL-bound protein. 
In summary, in spite of its name, serum amyloid A has only moderate 
intrinsic sequence propensity to form amyloid, which is comparable to that of 
apoA-I and significantly lower than that of apoA-II. The N-terminal end of SAA is 
predicted and observed to form the major amyloid hot spot that overlaps with the 
primary HDL binding site and forms a native amphipathic -helix on the lipid 
[Ohta et al., 2009]. Therefore, this segment is protected against misfolding by 
binding to lipid surface. Similarly, other predicted amyloidogenic segments in 




Despite structural instability of free SAA under near-physiologic conditions 
and its persistently high plasma concentrations in chronic inflammation, only a 
small percentage of patients develop AA amyloidosis ([Gillmore et al., 2001] and 
references therein). To explain this observation, SAA has been proposed to 
develop protective mechanisms against misfolding, such as the proteolysis of its 
amyloid-forming N-terminal part [Yamada et al., 1995] or hexamer formation [Lu 
et al., 2014]. We hypothesize that the modest intrinsic sequence propensity to 
form amyloid, which was revealed in our comparative studies of exchangeable 
apolipoproteins, is one of such protective mechanisms.  
 
5.8 Apolipoprotein B  
In addition to exchangeable apolipoproteins, we also analyzed the large 
non-exchangeable apolipoprotein B. ApoB is a 550 kDa glycoprotein synthesized 
by the liver. Plasma apoB contains a single chain of 4536 amino acids, which is 
one of the largest known proteins and the largest apolipoprotein. One copy of 
full-length apoB, termed apoB100, is present as the major protein on the surface 
of LDL and VLDL [Segrest et al., 2001]. A shorter variant representing the first 
48% of apoB sequence, termed apoB48, is synthesized in the intestine and 
forms the major protein on chylomicrons [Nakajima et al., 2014]. ApoB forms a 
flexible structural scaffold on the lipoprotein surface and an important functional 
ligand for binding to LDL receptor and heparan sulfate proteoglycans [Goldstein 
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& Brown, 1976, Camejo et al., 1998]. In contrast to other apolipoproteins, apoB is 
non-exchangeable (water-insoluble) and remains associated with its host particle 
during metabolism. Also in contrast with the exchangeable apolipoproteins, apoB 
is predicted and observed to contain both amphipathic -helices and-sheets 
[Segrest et al., 2001].  
The enormous size and insolubility of apoB have precluded its detailed 
structural studies. Amino acid sequence analysis suggests five large structural 
domains [Segrest et al., 2001]. Residue segment 1-1023, termed 1 domain, is 
thought to form an autonomously folded globular domain that protrudes from the 
LDL surface. A homology model of this domain has been proposed based on the 
x-ray crystal structure of a related protein, lamprey lipovitellin [Segrest et al., 
1999]. Epitope labeling combined with cryo-electron microscopy have determined 
the overall arrangement of human apoB on the mid-size LDL and showed that 
the protein fully encircles LDL, with the N- and C-terminal domains located near 
each other to close the circle [Liu & Atkinson, 2011; Kumar et al., 2011].  
The involvement of apoB in amyloid formation has been suggested in 
several in vitro studies of modified LDL, including oxidized and electronegative 
LDL [Stewart et al., 2005; Parasassi et al., 2008; Brunelli et al., 2014]. 
Aggregation of modified LDL was evident in these and other studies [Bancells et 
al., 2010], including work from our laboratory [Jayaraman et al., 2007; Lu et al., 
2012, Lu & Gursky, 2013; Rull et al., 2016]. However, convincing experimental 
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evidence for amyloid formation by apoB, such as the oriented fiber diffraction and 
a large increase in cross--sheet content measured by spectroscopy, is still 
lacking. 
Our amino acid sequence analysis revealed that apoB has unusually high 
amyloid-forming potential, comparable to that of A peptide (Figure 5.9,11, Table 
5.1). Major amyloidogenic segments, which are predicted in all five apoB 
domains, span regions that are thought to form native -helices or -sheets. 
Figure 5.11 shows amyloidogenic profile in three representative portions of apoB 
including residues 300-400 (predicted to form native -helical structure), residues 
780-880 (located in a predicted -sheet region), and residues 2150-2250 from 
the 2 helical domain that was proposed to be involved in -aggregation 
[Parasassi et al., 2008]. Many amyloidogenic segments in these and other parts 
of apoB are predicted strongly by AmylPred2 (8-11 methods) and span 10 or 
more amino acids, longer than those in the exchangeable apolipoproteins (Table 
5.1). Likewise, PASTA2 predicts unusually strong favorable pairing energies 
below -9 units for many apoB segments, which is consistent with their high 
hydrophobicity. In comparison, the lowest (most favorable) PASTA2 energies are 
about -8.4 for A (1-42), -7 for apoA-II and -5.5 or weaker for other exchangeable 
apolipoproteins (Table 5.1). Furthermore, similar to most exchangeable 
apolipoproteins, PASTA predicts parallel in-register -sheet for all major 
amyloidogenic segments in apoB. 
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In summary, of all apolipoproteins explored, apoB has by far the strongest 
sequence propensity to form amyloid, which correlates with high protein 
hydrophobicity. Nevertheless, there is no compelling evidence for amyloid 
formation by apoB in vivo or in vitro. We propose that the reason why apoB does 
not readily form amyloid is due to its extensive protein-lipid and protein-protein 
interactions on LDL and VLDL. These native interactions make this enormous 




The studies outlined in this chapter show that amyloidogenic segments in 
human apolipoproteins i) are largely hydrophobic, ii) are located almost entirely in 
the native amphipathic -helices in the exchangeable apolipoproteins while in the 
non-exchangeable apoB they span both predicted -helices and -sheets, and iii) 
are predicted to preferentially form parallel in-register -sheet in amyloid. These 
amyloidogenic segments are enriched in aromatic residues that often form native 
interactions stabilizing the helix bundle structures of free proteins such as apoA-
IV and apoE. Importantly, the predicted amyloidogenic segments have been 
verified in the experimental studies of apoA-I, apoC-II, apoA-II and SAA [Wilson 
et al., 2007; Sawashita et al., 2009; Adachi et al., 2014; Das et al., 2014; Lu et 





Figure 5.11 Amyloidogenic propensity of selected portions of human apoB. 
AmylPred2 and PASTA2.0 profiles are shown for 100-residue portions that are 
predicted to form various native secondary structures: residues 300-400 (left) 
form mainly -helices that are a part of the so-called A-helix region; residues 
780-880 (middle) form mainly -sheets that are a part of the A-sheet region; 
residues 2150-2250 (right) form mainly -helices that are a part of the 2 region 
(nomenclature according to [Segrest et al., 2001; Wang et al., 2010]). Residue 
numbers in top panels indicate amyloidogenic segments predicted by five or 
more methods in AmylPred2 (at or above the dotted line). Bottom panels show 





Table 5.1. Summary of the amyloid-forming propensity of human apolipoproteins 
discussed in this chapter. 
Parameters for the exchangeable apolipoproteins (top box) and for selected 
regions of the non-exchangeable apoB (lower box) are listed; A(1-42) is 
included for comparison. Numbers in brackets refer to the naturally occurring C-
terminal extension in apoA-II that causes human amyloidosis. Total number of 
residues in each protein or polypeptide and the number of residues predicted to 
be in amyloidogenic segments by five or more AmylPred2 methods (major hot 
spots) are listed. The ratio of these values (hot spot/total) can be used to rank 
amyloidogenic propensity. This propensity of the exchangeable apolipoproteins 
decreases as listed in the top box from 1 to 9. Although other criteria, such as the 
minimal (most favorable) segment pairing energy by PASTA2, yield somewhat 
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different rank order, various prediction methods consistently show that apoB has 
the strongest amyloidogenic potential, followed by apoA-II, apoC-II and other 
apolipoproteins, with SAA in the middle and apoE near the end of the range. 




segments in many other globular proteins share similar characteristics: they tend 
to be hydrophobic (with exception of prions), are enriched in aromatic groups, 
and are often protected from misfolding by forming well-ordered native secondary 
structure such as -helix [Tzotzos and Doig, 2010]. Furthermore, a parallel in-
register -sheet has emerged as the predominant structural motif observed by 
EPR and solid-state NMR in amyloid fibrils formed by many proteins [Tycko, 
2006; Margittai & Langen, 2008; Shewmaker et al., 2011], including those of 
apoC-II and -synuclein [Der-Sarkissian et al., 2003; Teoh et al., 2011; Lv et al., 
2012].  
A surprising conclusion emerging from our studies was that the intrinsic 
sequence propensity to form amyloid decreases in order apoB > apoA-II > apoC-
II ≥ apoA-I, apoC-I, apoC-III, SAA > apoA-IV, apoA-V, apoE (Table 5.1). This 
rank order was unexpected given that apoE and SAA are prominent players in 
human amyloidoses such as Alzheimer’s disease and inflammation-linked AA 
amyloidosis, while apoB and normal human apoA-II are not.  Clearly, intrinsic 
sequence propensity is just one of many factors determining amyloid formation in 
vivo and in vitro. Other important factors include stability of the native protein 
structure, protein concentration, external conditions such as pH, ligand binding, 
proteolytic environment, etc. Moreover, the probability of protein misfolding is 
determined not only by the global stability of its native structure, but also by the 
local conformation and dynamics in sensitive regions [Chiti and Dobson, 2009; 
Das & Gursky, 2015]. We propose that sequestration of such amyloidogenic 
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regions via the native protein-protein and protein-lipid interactions protects 
apolipoproteins against misfolding [Das et al., 2014; Gursky, 2014; Lu et al., 
2014]. Strong apolipoprotein-lipid interactions are expected and observed to be 
particularly protective. One example is apoB, where these strong interactions 
render apoB non-exchangeable and thereby protect it from forming amyloid 
despite its unusually high sequence propensity to do so. Interestingly, human 
apolipoproteins that commonly form amyloid in vivo are consistently predicted to 
be in the middle of the amyloid propensity range (SAA1.1) or near its end (apoE). 
These proteins can readily dissociate from the lipid surface and circulate in labile 
free form. We propose that these proteins have evolved protective strategies 
against misfolding, such as the high structural stability of the N-terminal domain 
of apoE that contains all amyloidogenic hot spot [Chen & Wang, 2011], self-
association of lipid-free apoA-IV [Deng et al., 2012], or sequestration of the major 
amyloidogenic segments in SAA oligomers [Lu et al., 2014]. Finally, rapid 
proteolysis and clearance of free apolipoproteins can serve as important 
protective mechanisms against amyloidosis.  
Overall our analysis suggests that the apolipoproteins’ propensity to bind 
lipid surface and to form amyloid are two sides of the same coin, both rooted in 
the proteins’ hydrophobicity. This suggests that functional constraints on 
apolipoproteins make it difficult to eliminate their pathologic -aggregation. 
Nevertheless, the primary sequences that are optimal for lipid surface binding 
and for amyloid formation are distinctly different, as illustrated in several 
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examples. First, large apolar faces of the amphipathic helices or -sheets 
found in the exchangeable and non-exchangeable apolipoproteins are essential 
for binding to lipid surface but not for amyloid formation. This is exemplified by 
the naturally occurring C-terminal extension in human apoA-II, which is highly 
amyloidogenic but cannot form a lipid-binding amphipathic -helix [Gursky, 
2014]. Other examples include apoA-V and the C-domain of apoE, which are 
highly lipophilic but not highly amyloidogenic (Figure 5.4, 5.7). Furthermore, 
stretches of similarly charged amino acids, such as the receptor and the heparan 
binding sites in apoE, apoA-V and apoB, are well-tolerated in the polar faces of 
the lipid-binding class-A -helices, yet such stretches are expected to disrupt 
amyloid structure due to their intra- and intermolecular electrostatic repulsion in a 
parallel in-register -sheet. These examples illustrate various strategies 
potentially employed during evolution to optimize reversible binding of 
apolipoproteins to lipid surface while reducing the risk of amyloid formation.   
In summary, the reason why apolipoproteins are overrepresented in 
amyloid diseases is not due to their native class-A amphipathic -helices per se. 
Rather, it is rooted in increased apolipoprotein hydrophobicity that is not only 
required for lipid binding but also increases protein propensity for -aggregation. 
In fact, class-A apolipoprotein -helices are not necessarily more amyloidogenic 
than their class-G counterparts, as suggested by the highly amyloidogenic 
hydrophobic C-terminal segment in apoC-II that forms a native class-G helix 
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(Figure 5.5B). Furthermore, the apolipoprotein -helices do not necessarily have 
higher amyloid-forming propensity than their -sheet counterparts. This is evident 
from the amino acid sequence analysis of apoB, the most amyloidogenic of all 
apolipoproteins and the only one with significant -sheet content. Numerous 
amyloidogenic segments span the whole length of apoB including predicted -
helices and -sheets (Figure 5.11). Importantly, the amyloidogenic segments in 
the exchangeable apolipoproteins are located in the amphipathic -helices and 
overlap their apolar lipid-binding faces, which probably protects them from 
misfolding. Likewise, amyloidogenic regions in globular proteins often overlap 
with their functional interfaces, suggesting a competition between normal protein 
function and pathogenic -aggregation [Castillo & Ventura 2009]. 
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Chapter 6 Summary and Future Directions 
 
6.1. Prevailing Ideas in the Field of ApoA-I Amyloidosis and Overall Goals 
of this Thesis Research 
The primary goals of this dissertation were to determine the molecular 
mechanism of apoA-I misfolding in hereditary and in acquired forms of human 
amyloidosis, and to understand why the apolipoprotein family is over-represented 
in amyloid diseases. We believe that the research described in this dissertation 
represents a significant advancement towards these goals.  
Prior to the beginning of our research, the general concept in the field was 
that the misfolding of a globular protein in vivo results mainly from the 
destabilization of its native structure [Chiti & Dobson, 2009]. However, it was 
unclear why some destabilizing mutations in globular proteins such as apoA-I 
caused the misfolding and amyloid formation in vivo while others did not. A 
specific concept in the field of apoA-I amyloidosis was that it resulted from the 
proteolytic cleavage in residue segment 83-100, leading to the release of 
amyloidogenic N-terminal fragments that can misfold and deposit as fibrils [Obici 
et al., 2006; Lagerstedt et al., 2007; Chetty et al., 2012; Gursky et al., 2012]. This 
concept was based upon the proteomic analysis of the patient-derived fibrillar 
deposits that contained residue fragments 1-83 to 1-100 of variant apoA-I in the 
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amyloid core ([Obici et al., 2006, Rowczenio et al., 2011] and references therein). 
The sole HD exchange study of an amyloidogenic mutant of apoA-I, G26R 
(apoA-IIowa) by Phillips, Englander and colleagues supported these ideas [Chetty 
et al., 2012]. This study showed that the G26R mutation not only decreased the 
overall structural stability of apoA-I but also increased local dynamics in several 
regions, including in the vicinity of residue 93 [Chetty et al., 2012]. The authors 
proposed that local destabilization of this region can contribute to its enhanced 
proteolysis with the release of the 1-93 fragment, which was found in cardiac 
amyloid deposits of G26R apoA-I [Chetty et al., 2012]. However, the region 
surrounding residue 93 remained substantially -helical and, hence, relatively 
protected from proteolysis in the full-length lipid-free G26R apoA-I mutant. 
Therefore, there was no solid evidence to support the mechanism whereby 
apoA-I cleavage and release of the N-terminal fragment triggers amyloidosis.  
Other studies suggested that the apoA-I cleavage was perhaps the end 
point rather than the triggering event in the apoA-I misfolding in vivo [Soutar et 
al., 1992; Booth et al., 1996; Wong et al., 2010]. In fact, in acquired amyloidosis, 
it is mainly the full-length apoA-I that is found in the fibrillar deposits in vivo 
[Mucchiano et al., 2001; Howlett & Moore, 2006]. This observation indicates that 
the proteolytic cleavage followed by the release of the N-terminal fragments is 
not necessary for apoA-I amyloid formation in vivo. In essence, there was no 
molecular mechanism that could explain apoA-I misfolding in both hereditary and 
acquired forms of amyloidosis. Furthermore, the role of global and local protein 
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destabilization and proteolysis in these pathogenic processes was unclear. Our 
research has augmented our understanding of these processes and bridged 
some of the existing gaps in the knowledge of apoA-I misfolding. 
 
6.2 Summary of Our Studies of ApoA-I and Its Disease-causing Mutants 
In this dissertation, we studied WT and several naturally occurring 
disease-causing mutants of human apoA-I, which included both amyloidogenic 
(G26R, W50R, F71Y, L170P) and non-amyloidogenic (L159R) variants. We have 
used a wide range of biophysical and biochemical methods, including far- and 
near-UV CD, intrinsic Trp and ANS fluorescence, limited proteolysis, HDX MS 
and other methods (described in chapter 2) to study lipid-free and lipid-bound 
forms of these proteins. We leveraged the recent advances in bioinformatics 
methods to predict amyloidogenic segments in proteins, and mapped the 
predicted segments on the crystal structure of (185-243)apoA-I. The results of 
our multipronged studies have challenged the existing concepts and have 
enabled us to propose the first common molecular mechanism for apoA-I 
misfolding in acquired and in hereditary forms of human amyloidosis. 
First, our biophysical studies showed that a large global destabilization of 
lipid-free or lipid-bound apoA-I is neither necessary nor sufficient for amyloidosis. 
In fact, while some of the amyloidogenic mutants such as F71Y and W50R 
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exhibited minimal global destabilization of the native protein structure, the non-
amyloidogenic L159R along with the amyloidogenic L170P mutant showed the 
greatest destabilization as compared to the WT. These observations highlighted 
the importance of additional factors for protein misfolding in vivo, particularly local 
structural changes in apoA-I.  
To explore these local changes, we established a collaboration with Dr. 
John Engen and his team to harness HDX MS in understanding the effects of the 
mutations on the local conformation and dynamics in apoA-I. Together, we 
analyzed WT and five disease-causing mutants of apoA-I in their lipid-free form. 
The results demonstrated that local destabilization and unfolding of the 83-100 
region was neither necessary nor sufficient for amyloid formation. In fact, the 
amyloidogenic mutants showed variability in the structural protection of this 
region in order L170P<G26R<W50R<F71Y, and L159R showed one of the 
greatest reductions in protection similar to that of L170P, even though L159R 
mutant does not cause amyloidosis in vivo.  
Furthermore, we have identified four short segments in apoA-I, particularly 
in residues 14-22, with a high sequence propensity to trigger amyloid formation. 
Mapping three of these four segments, or amyloid hot spots, on the crystal 
structure of the (184-243)apoA-I showed that these hot spots are located in the 
bottom half of the four-helix bundle, close to most sites of the AApoAI mutations. 
This observation suggested that the mutations perturb the structure in these 
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sensitive regions and thereby trigger protein misfolding.  
The results of our HDX MS studies strongly supported this idea and 
showed that all disease-causing mutations decreased the structural protection in 
amyloid hot spots, particularly in the most amyloidogenic residue segment 14-22. 
Experimental analysis of the non-amyloidogenic L159R (Fin) mutant provided an 
important control that helped explain why this mutant does not form amyloid in 
vivo despite a large decrease in its global thermodynamic stability combined with 
the greatly reduced local protection of the amyloid hot spots, including residues 
14-22. The L159R mutant was previously shown to be cleaved in plasma around 
the mutation site to produce a ~18 kDa N-terminal fragment [McManus et al., 
2001]. Our HDX MS analysis of this mutant showed increased dynamics 
consistent with local unfolding near the L159R site, which can make the protein 
susceptible to proteolysis in this region. Further analysis of the ~18 kDa 
fragment, (1-159)apoA-I, revealed the low thermodynamic stability and a largely 
unfolded structure of this fragment at physiological temperature. These 
observations suggested that this fragment probably gets proteolysed in vivo 
before it can accumulate into amyloid fibers, thereby preventing an 
amyloidogenic outcome. 
Taken together, our studies have enabled us to propose the first common 
molecular mechanism of apoA-I amyloidosis and to postulate a new central 
hypothesis. According to our hypothesis, two factors make the protein 
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amyloidogenic: i) reduced protection of the amyloid hot spots in apoA-I, 
particularly in residues 14-22; ii) sufficient structural integrity of the native four-
helix bundle to promote protein accumulation in amyloid rather than rapid 
degradation. We posit that this concept is not limited to apoA-I but may be 
generalized to other globular proteins that misfold and form amyloid in vivo. If 
confirmed, this idea represents a next frontier that goes beyond global protein 
stability or local hot spots to explain what makes a protein amyloidogenic. 
 
6.3 Role of Proteostasis in Amyloidosis 
The competition between the generation of a protein and its clearance and 
misfolding, termed proteostasis, explains why the extent of overall structural 
destabilization in apoA-I and other amyloidogenic proteins like transthyretin and 
immunoglobulin light chain does not always correlate with amyloid formation in 
vivo [Shnyrov et al., 2000; Del Pozo et al., 2008; Klimtchuk et al., 2010; Das et al. 
2014]. The delicate balance between the protein generation, proteolysis and 
aggregation, which depends, in part, on the local backbone conformation and 
dynamics in the amyloid hot spots versus protease-sensitive regions, is probably 
a key fundamental determinant for globular protein misfolding and amyloid 
deposition in vivo.  
Furthermore, the concept that apoA-I misfolding upon destabilization of 
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specific sensitive regions, and not necessarily proteolytic cleavage, could be the 
primary event in amyloidosis suggests that apoA-I misfolding in hereditary and in 
acquired amyloidosis may proceed via similar molecular mechanisms and, 
hence, could be potentially influenced by similar factors. We hypothesize that 
HDL proteins, lipids and other factors that promote apoA-I dissociation from HDL 
in the lipid-poor/free aggregation-prone state can contribute to apoA-I misfolding 
in amyloid in vivo. Such contributing factors may possibly include: i) serum 
amyloid A protein that can displace apoA-I from HDL during acute inflammation 
[Cabana et al., 1996; van der Westhuyzen et al., 2007]; ii) free fatty acids whose 
increase in HDL promotes apoA-I dissociation and lipoprotein fusion in vitro and, 
probably, in vivo [Rye & Barter, 2004; Jayaraman et al., 2011]; iii) increased HDL 
triglycerides whose lipolysis promotes apoA-I dissociation from HDL in vitro and 
in vivo [Cabana et al., 1996; Lamarche et al., 1999; Jayaraman et al. 2016]. 
These factors are beginning to be explored in the ongoing projects in our 
laboratory. 
 
6.4 Role of Protein-Lipid Interactions in Amyloidoses 
Amyloidosis is not limited to apoA-I but also involves other members of the 
apolipoprotein family (described in chapter 5). In fact, out of approximately 40 
human proteins and peptides that are known to misfold and deposit as amyloid 
fibers in vivo [Sipe et al., 2014], seven belong to the apolipoprotein family (apoA-
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I, apoA-II, apoA-IV, apoC-II, apoC-III and apoE). Structural and sequence-based 
analysis of apoA-I and eight other apolipoproteins (apoA-II, apoA-IV, apoA-V, 
apoC-I, apoC-II, apoC-III, apoE and apoB) along with SAA, suggested that the 
reason behind apolipoproteins’ overrepresentation in amyloid diseases is rooted 
in the apolipoproteins’ enhanced hydrophobicity that is not only required for lipid 
binding but also increases protein propensity for β-aggregation (chapter 5; [Das 
& Gursky, 2015] and references therein). Importantly, the amyloidogenic 
segments in the exchangeable apolipoproteins are largely hydrophobic; these 
segments are often located in the amphipathic α-helices and overlap their apolar 
lipid-binding faces. Such location probably protects these segments from 
initiating protein misfolding in the lipid-bound state. Likewise, amyloidogenic 
regions in globular protein often overlap with their functional interfaces, 
suggesting a competition between normal protein function and pathogenic β-
aggregation [Castillo & Ventura, 2009].  
For apolipoproteins, this competition implies that increased apolipoprotein 
retention on the lipid surface may provide a potential therapeutic strategy against 
amyloidosis. For example, increased levels of plasma triacylglycerol (TG) are 
well-known to promote apoA-I dissociation from the HDL surface upon enzymatic 
lipolysis of core TG [Lamarche et al., 1999]. Recent studies from several groups 
including ours showed that apoA-I is released more readily from the TG-rich HDL 
even in the absence of TG hydrolysis ([Jayaraman et al., 2016] and references 
therein). Consistent with these in vitro observations, clinical studies showed that 
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the amount of apoA-I amyloid deposits found in atherosclerotic arteries correlate 
directly only with patients’ age and with the plasma levels of TG [Röcken et al., 
2006]. We propose that this correlation may reflect causation, as elevated levels 
of TG in HDL induce the release of lipid-poor/free apoA-I that is the protein 
precursor of amyloid. This prompts us to speculate that TG-reducing therapies 
may help protect apoA-I against dissociation from the lipid, and thereby delay 
amyloid formation in vivo [Das et al. 2014; Jayaraman et al. 2016]. These and 
other ideas will be tested in the future studies. 
 
6.5 Future Directions: Experimental and Computational Studies 
6.5.1 Experimental Studies of Additional Naturally Occurring ApoA-I Mutants 
Our future studies aim to extensively test our new central hypothesis and 
to understand additional factors that influence apoA-I misfolding, and thereby 
pave the way to identify therapeutic strategies to decelerate this pathogenic 
process. To this end, we will analyze the structure and stability of other AApoAI 
mutants in lipid-free and lipid-bound states and compare those to the naturally 
occurring non-amyloidogenic controls.  
Among the AApoAI mutants, E34K is particularly interesting [Rowczenio et 
al., 2011]. Figure 6.1 shows E34K, which is the only charge inversion mutation 
and is located at the top of the N-terminal four-helix bundle, unlike all other 
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AApoAI mutants [Gursky et al., 2012]. So far, the expression of this full-length 
mutant has presented significant challenges due to limited solubility. In order to 
tackle challenges with the expression of the full-length E34K apoA-I, we plan to 
study the C-terminally truncated version of this mutant, (184-243)E34K apoA-I, 
by using combined biophysical and computational approaches. We hope that the 
deletion of the flexible hydrophobic C-terminal tail (residues 185-243) will 
improve the protein’s solubility and will enable us to express and purify this 
mutant in quantities sufficient for detailed biophysical and structural studies. 
Previous studies have shown that C-terminally truncated apoA-I has similar 
tertiary structure compared to plasma apoA-I [Rogers et al., 1998; Saito et al., 
2003; Mei & Atkinson, 2015]. Therefore, by using C-terminally truncated forms of 
E34K apoA-I, we hope to obtain important information on the effects of this 
mutation on the four-helix bundle in full-length protein apoA-I, particularly its 
major amyloid hot spot, 14-22. 
Another set of interesting mutants, shown in Figure 6.1, includes R173P 
(AApoAI) and R173C (a non-AApoAI mutant termed apoA-I Milano, which can 
form a disulfide-linked homodimer in humans) [Franceschini et al., 1980, 1982; 
Hamidi Asl et al., 1999]. Thus, the differences in amino acid substitution at 
position 173 of apoA-I can lead to either an amyloidogenic (R173P) or a non-
amyloidogenic outcome (R173C) [Sorci-Thomas & Thomas, 2002; Gursky et al., 
2012, 2013], making these mutants particularly interesting candidates for our 
studies. Notably, similar to AApoAI mutants, carriers of the L173C mutation 
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exhibit low levels of HDL yet lower risk for cardiovascular disease. A similar 
property has previously attracted a lot of attention to the Milano mutant as a 
possible gain-of-function anti-atherogenic variant of apoA-I [Bielicki & Oda, 2002; 
Calabresi et al., 2006; Cimmino et al., 2009; Gursky et al., 2013]. A lot less is 
known about the structural and functional properties of its amyloidogenic 
counterpart, R173P. Our future studies will help to fill in this gap. 
6.5.2 Computational Studies of Lipid-free C-terminally Truncated WT and Mutant 
ApoA-I 
As an additional approach, we will use molecular dynamics (MD) 
simulations of apoA-I mutants. The 2.2Å resolution structure of the globular helix-
bundle domain of (185-243)apoA-I [Mei & Atkinson, 2011] provides a useful 
starting model for MD simulations. To conduct MD simulations, we have 
established a collaboration with Dr. John Straub from the Chemistry Department 
at Boston University. In our preliminary MD studies conducted by Dr. Afra Panahi 
at the Straub laboratory, the C-terminally truncated apoA-I monomer (1-184 
residue fragment) was used as the starting model.  
The lipid-free apoA-I monomer in solution has been proposed to adopt a 
four-helix bundle fold similar to that observed in the crystal structure of (1-
184)apoA-I (PDB ID: 3R2P) ([Mei & Atkinson, 2011] and references therein), but 
with all four helices coming from the same molecule. The monomer used in our 




Figure 6.1 Location of additional mutation sites in the proposed helix bundle 
structure of the C-terminally truncated apoA-I monomer. 
Disease-causing point substitutions to be explored in further studies are 
indicated, including two amyloidogenic (E34K and R173P) and one non-
amyloidogenic (R173C) mutation. The major amyloid hot spot residues 14-22 are 




bundle (residues 143-184) from molecule 2 to molecule 1 via the central repeat 
5. This repeat contains residues 122-143 that are disordered in solution and have 
high main-chain B-factors in the crystal structure; these residues were proposed 
to form a flexible hinge-region mediating domain-swapping during monomer to 
dimer conversion in apoA-I [Mei & Atkinson, 2011]. The conformation in this 
region was manually built as a loop at the top of the helix bundle, which 
connected helices III and IV. This structure was then equilibrated using 
CHARMM force field in explicit solvent for 400 nsec. The helix bundle structure 
remained stable after the equilibration, indicating that this starting model was 
energetically favorable.  
Next, single point mutations F71Y and L159R were introduced, followed 
by 230 nsec simulations repeated three times. F71Y, located in the hydrophobic 
cluster at the bottom of the helix bundle, caused small local perturbations without 
affecting the top of the bundle. However, L159R located near the top of the helix 
bundle caused larger structural perturbations that affected the entire molecule. 
These preliminary results are in excellent agreement with our previous 
biophysical and HDX MS data of full-length mutants (described in chapter 4) 
where F71Y caused minimal global and local perturbations, while L159R resulted 
in significant destabilization of the global protein structure and increased local 
dynamics.  
In the future we plan to conduct more extensive MD simulations of these 
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and other disease-causing mutants of apoA-I. We expect that all AApoAI 
mutations will perturb amyloid hot spots, especially residues 14-22; some 
mutations may also cause local helical unfolding; e.g. we expect that L159R 
causes local helical unfolding near the mutation site which extends towards 
repeat 5. Longer simulation time is required to better understand the implications 
of these mutation-induced structural changes, including local helical unfolding 
near mutation site. To provide the experimental validation for these 
computational studies, the results of the MD simulations will be correlated with 
our biophysical studies of either full-length or C-terminally truncated proteins. 
These combined computational and experimental studies are expected to 
provide a more complete picture of the molecular events leading to protein 
misfolding and/or proteolysis. 
6.5.3 HDX MS Studies of ApoA-I in Model HDL 
We plan to study the apoA-I mutants in their lipid-bound state to 
understand how the disease-causing mutations affect the protein conformation 
on model HDL. Lipid-bound apoA-I undergoes metabolic remodeling in vivo to 
adapt to increasing HDL size during reverse cholesterol transport [Philips, 2013]. 
Nascent HDL are generated through the interactions of lipid-free apoA-I and 
ABCA1 transporter [Oram & Heinecke, 2005] and are suggested to form 
discoidal particles that are ~8 nm in diameter [Sorci-Thomas & Thomas, 2012]. 
These particles are then converted into mature spherical HDL with incremental 
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increase in diameter up to 12 nm [Silva et al., 2008; Rothblat & Phillips, 2010]. 
Previous studies by the team of Englander and Phillips have used HDX MS to 
understand the conformation of lipid-bound apoA-I on reconstituted discoidal 
particles with diameters of 7.8 nm and 9.6 nm, which contained various ratios of 
WT apoA-I and lipids (POPC and cholesterol) [Chetty et al., 2012]. These studies 
showed that the non-helical regions observed by HDX MS in lipid-free apoA-I 
(45-53, 66-69, 116-146, and 179-236) convert to a helical conformation on the 
discs. Further, comparison of the apoA-I conformation on the small (7.8 nm) and 
mid-size particles (9.6 nm) showed that apoA-I adapts to a smaller particle size 
by displacing certain residue segments off the lipoprotein surface in a disordered 
conformation. For example, while lipoprotein particles with a diameter of 9.6 nm 
had residues 125-158 forming a disordered loop, particles with a 7.6 nm diameter 
had residue segments 115-158 and 212-225 in a disordered conformation. The 
team of Phillips and Englander has also used HDX MS to compare the apoA-I 
conformation on discoidal and spherical particles of similar size; they concluded 
that the secondary structure in full-length WT apoA-I remains largely invariant 
upon changes in HDL shape from disc to sphere [Chetty et al., 2013].  
Our research will complement the results of these recent studies by 
establishing the conformation of full-length WT apoA-I on large discoidal particles 
with diameter of ~12 nm, which is the largest diameter found in plasma HDL. We 
expect that residue segments such as 115-158 and 125-158 that were 
disordered in smaller lipoprotein particles of 7.8 and 9.6 nm diameter, 
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respectively, will become more -helical upon association with larger lipoprotein 
particles of 12 nm diameter. Furthermore, by using discoidal particles containing 
the naturally occurring disease-causing mutants of apoA-I, we will determine the 
effects of mutations on the protein conformation on HDL, which, in turn, may 
influence interactions of HDL with its functional ligands in RCT. 
Currently HDX MS studies of apoA-I:DMPC discs comparing full-length 
WT, F71Y, L170P and L159R are ongoing in collaboration with Dr. Engen’s 
team. The preliminary studies have shown promising results with nearly 100% 
coverage and 4-fold redundancy to establish the feasibility. Unexpectedly, 
comparison of similar-size DMPC complexes containing WT and F71Y apoA-I 
show a significant difference in the solvent exposure of the 44-55 segment. This 
strand-like segment, which is equally unprotected on the WT and mutant protein 
in solution, shows an increased protection on the lipid, which is significantly 
higher in the mutant than in the WT apoA-I. This result is particularly interesting 
since the residue segment 44-55 is remote from the F71Y mutation site in the 
double-belt structure of apoA-I that is thought to represent the lipid-bound protein 
conformation, as illustrated in Figure 6.2. Studies such as these will shed light on 






Figure 6.2 Experimental results from HDX MS studies of rHDL particles plotted 
on (1-43)apoA-I structure.  
The crystal structure of (1-43)apoA-I is proposed to represent the lipid-bound 
conformation of apoA-I, with H5/H5 and H10/H10 repeats in registry in the two 
dimer-forming molecules [Borhani et al., 1997]. In our preliminary HDX MS 
studies (carried out by Christopher Wilson at NEU), apoA-I:DMPC particles that 
contained full-length F71Y apoA-I exhibited greater protection of residues 44-55 




6.5.4 Limited Proteolytic Studies to Mimic the Plasma Environment 
In addition to understanding structural determinants of protein misfolding, 
we also seek to better understand the proteolytic behavior of AApoAI mutants. 
Previous studies, including our own limited proteolysis studies using trypsin 
digestion (described in chapter 3), did not provide a conclusive evidence 
regarding the role of the AApoAI mutations in the generation of specific 
fragments, such as the N-terminal fragments containing residues 1-83 to 1-100 
found in fibrillar deposits in vivo [Obici et al., 2006; Petrlova et al., 2011; Ramella 
et al., 2012]. Part of the problem lies in the lack of detailed information on the 
proteases involved in apoA-I cleavage in vivo [Obici et al., 2006]. Broad-
specificity proteases such as matrix metalloproteinases (MMPs), chymotrypsin 
and V8, have been implicated to play a role in the proteolysis of AApoAI mutants 
in vivo [Obici et al., 2006; Lagerstedt et al., 2007; Ramella et al., 2012]. However, 
studies of apoA-I cleavage by these proteases in vitro were inconclusive. 
Proteolytic studies by Ramella and colleagues reported that recombinant WT 
apoA-I and its two AApoAI mutants, G26R and K107, are degraded to a similar 
extent by MMP-12 [Ramella et al., 2012]. Contrary to this observation, it was 
previously reported that G26R mutation promotes processing of the His-tagged 
apoA-I by nonspecific proteases, chymotrypsin and V8, to produce the N-terminal 
fragment [Lagerstedt et al., 2007]. The same group observed similar protease 
sensitivity in an outside AApoAI mutant, L178H [Petrlova et al., 2011]. In our own 
studies using trypsin, AApoAI mutants W50R and G26R did not significantly 
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enhance the rate of apoA-I proteolysis by trypsin [Das et al., 2014]. The 
variability in results from different groups studying various mutants using different 
proteases has limited our understanding of the effects of AApoAI mutants on 
protease sensitivity of apoA-I.  
To circumvent this problem, we will use a protease cocktail that closely 
mimics the proteolytic environment in plasma to assess the kinetics of proteolysis 
and correlate it with the results from HDX MS studies. We expect that apoA-I 
regions showing local helical unfolding by HDX will constitute the initial cleavage 
sites in the protein; such an initial cleavage, in turn, will determine the ultimate 
fate of apoA-I in vivo (aggregation vs. clearance). We expect that, similar to the 
apoA-I Fin mutation, other naturally occurring apoA-I mutations may influence 
this initial cleavage, and thereby potentially contribute to the disease 
development.  
6.5.5 Functional Cell-Based Studies 
To complement our structural studies of the apoA-I mutants with cell-
based functional studies, we are also interested in understanding the effects of 
these mutations on the primary function of apoA-I in reverse cholesterol 
transport. These studies will help us understand why the carriers of AApoAI 
mutations exhibit cardioprotective behavior in spite of having low levels of apoA-I 
and HDL in their plasma. One possibility is that the AApoAI mutations confer gain 
of function to apoA-I at specific steps of reverse cholesterol transport. The early 
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rate-limiting steps in this complex process involve cholesterol efflux from cells to 
lipid-free or lipid-poor forms of apoA-I. These early steps are mediated by ABC 
transporters A1 and G1 that facilitate lipid efflux from cells to lipid-free apoA-I or 
to nascent HDL, respectively ([Phillips, 2014] and references therein). These 
steps lead to HDL biogenesis and formation of nascent cholesterol-containing 
discoidal HDL that are then converted into mature spherical HDL via the action of 
LCAT.  
We will explore the effects of AApoAI mutations on the cholesterol efflux 
from cells at these early steps of the reverse cholesterol transport. As cholesterol 
donors, we will be using macrophages that express ABCA1 on the surface of 
their plasma membrane. WT and mutant apoA-I will be used as cholesterol 
acceptors. The cells will be loaded with fluorescently labelled cholesterol and the 
time course of cholesterol efflux to apoA-I acceptors will be determined following 
published protocols [Wang et al., 2000; Sankarnarayan et al., 2011]. The 
resulting lipoprotein particles will be characterized for their size and biochemical 
composition to determine possible effects of AApoAI mutations on HDL 
biogenesis. Our preliminary data shown in Figure 6.3, which were obtained with 
the help and guidance of Dr. Haya Herscovitz, show that the F71Y mutation has 
no significant effect on the amount of cholesterol efflux from cells, while other 
mutants showed reduced amount of cholesterol efflux (Figure 6.3A). Further 
analysis of the particles formed by these apoA-I variants showed that the particle 
size distribution was different for different variants (Figure 6.3B). These 
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observations suggest that the gain-of-function effects probably involve other 
steps in cholesterol transport. Such steps may include lipid efflux to HDL via 
ABCG1 transporter or HDL maturation via the lecithin:cholesterol acyltransferase 
(LCAT) reaction, which will be explored in the future. Also, the formation of 
different-size particles and possible differences in the lipid composition of these 
particles might influence catabolism of these particles and, therefore, their 
function in reverse cholesterol transport.  
We will complete these studies in the future to confirm our initial findings 
and expand the functional cell-based studies to a wider range of apoA-I mutants 
as well as to additional steps in reverse cholesterol transport. These results will 
complement our HDX MS studies of recombinant lipoproteins containing these 
apoA-I mutants described above. Together, these studies will help in 
understanding the structural and functional changes in the apoA-I during cellular 
cholesterol removal under normal and pathogenic conditions, including 





Figure 6.3 Functional studies of AApoAI mutants using cell cholesterol efflux at 
an early rate-limiting step of reverse cholesterol transport.  
(A) Cell cholesterol efflux to human lipid-free apoA-I variants. J774 macrophages 
were incubated with BODIPY-cholesterol complexed to methyl--cyclodextrin. 
ABCA1 was upregulated with a cAMP analogue. Efflux was measured as % of 
total fluorescence, and is shown in comparison to WT. Error bars show standard 
deviations. (B) Immunoblot for apoA-I showing the resulting reconstituted HDL 
formed upon lipid efflux from cells to apoA-I variants. +/- depicts the presence or 
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absence of ABCA1 upregulation. First column for each mutant shows lipid-free 
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